<SEC-DOCUMENT>0001193125-17-344831.txt : 20171116
<SEC-HEADER>0001193125-17-344831.hdr.sgml : 20171116
<ACCEPTANCE-DATETIME>20171116080629
ACCESSION NUMBER:		0001193125-17-344831
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20171116
DATE AS OF CHANGE:		20171116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TELEFLEX INC
		CENTRAL INDEX KEY:			0000096943
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				231147939
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276
		FILM NUMBER:		171206722

	BUSINESS ADDRESS:	
		STREET 1:		550 E SWEDESFORD RD
		STREET 2:		SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		610-225-6800

	MAIL ADDRESS:	
		STREET 1:		550 E SWEDESFORD RD
		STREET 2:		SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VasoNova Inc
		CENTRAL INDEX KEY:			0001391627
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-03
		FILM NUMBER:		171206738

	BUSINESS ADDRESS:	
		STREET 1:		1364 Bordeaux Dr
		CITY:			Sunnyvale
		STATE:			CA
		ZIP:			94089
		BUSINESS PHONE:		6502698444

	MAIL ADDRESS:	
		STREET 1:		1364 Bordeaux Dr
		CITY:			Sunnyvale
		STATE:			CA
		ZIP:			94089

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROW INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000886046
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				231969991
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1027

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-13
		FILM NUMBER:		171206728

	BUSINESS ADDRESS:	
		STREET 1:		2400 BERNVILLE RD
		STREET 2:		P O BOX 12888
		CITY:			READING
		STATE:			PA
		ZIP:			19612
		BUSINESS PHONE:		6103780131

	MAIL ADDRESS:	
		STREET 1:		2400 BERNVILLE RD
		STREET 2:		P.O. BOX 12888
		CITY:			READING
		STATE:			PA
		ZIP:			19612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teleflex Medical Inc
		CENTRAL INDEX KEY:			0001519267
		IRS NUMBER:				951867330
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-08
		FILM NUMBER:		171206733

	BUSINESS ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468
		BUSINESS PHONE:		(610) 948-5100

	MAIL ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HOTSPUR TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001452138
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-11
		FILM NUMBER:		171206730

	BUSINESS ADDRESS:	
		STREET 1:		880 MAUDE AVENUE, SUITE A
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6508151942

	MAIL ADDRESS:	
		STREET 1:		880 MAUDE AVENUE, SUITE A
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFX North America Inc.
		CENTRAL INDEX KEY:			0001519279
		IRS NUMBER:				020622705
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-04
		FILM NUMBER:		171206737

	BUSINESS ADDRESS:	
		STREET 1:		CONSOLIDATED SERVICES LTD, 3RD FLOOR
		STREET 2:		PAR LA VILLE PLACE, 14 PAR LA VILLE RD
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM08
		BUSINESS PHONE:		(441) 295-8313

	MAIL ADDRESS:	
		STREET 1:		CONSOLIDATED SERVICES LTD, 3RD FLOOR
		STREET 2:		PAR LA VILLE PLACE, 14 PAR LA VILLE RD
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM08

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Technology Holding Co II
		CENTRAL INDEX KEY:			0001519305
		IRS NUMBER:				232365446
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-10
		FILM NUMBER:		171206731

	BUSINESS ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808
		BUSINESS PHONE:		(302) 225-5194

	MAIL ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFX Equities Inc
		CENTRAL INDEX KEY:			0001519258
		IRS NUMBER:				232494396
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-07
		FILM NUMBER:		171206734

	BUSINESS ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808
		BUSINESS PHONE:		(302) 225-5194

	MAIL ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arrow Interventional, Inc.
		CENTRAL INDEX KEY:			0001519290
		IRS NUMBER:				232766329
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-12
		FILM NUMBER:		171206729

	BUSINESS ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468
		BUSINESS PHONE:		(610) 948-5100

	MAIL ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Airfoil Technologies International-Ohio, Inc.
		CENTRAL INDEX KEY:			0001519264
		IRS NUMBER:				341524431
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-15
		FILM NUMBER:		171206726

	BUSINESS ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468
		BUSINESS PHONE:		(610) 948-5100

	MAIL ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFX Medical Wire Products, Inc.
		CENTRAL INDEX KEY:			0001519262
		IRS NUMBER:				411820485
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-05
		FILM NUMBER:		171206736

	BUSINESS ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468
		BUSINESS PHONE:		(610) 948-5100

	MAIL ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFX International Corp
		CENTRAL INDEX KEY:			0001519265
		IRS NUMBER:				510234032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-06
		FILM NUMBER:		171206735

	BUSINESS ADDRESS:	
		STREET 1:		CONSOLIDATED SERVICES LTD, 3RD FLOOR
		STREET 2:		PAR LA VILLE PLACE, 14 PAR LA VILLE RD
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM08
		BUSINESS PHONE:		(441) 295-8313

	MAIL ADDRESS:	
		STREET 1:		CONSOLIDATED SERVICES LTD, 3RD FLOOR
		STREET 2:		PAR LA VILLE PLACE, 14 PAR LA VILLE RD
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM08

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arrow International Investment Corp.
		CENTRAL INDEX KEY:			0001519293
		IRS NUMBER:				510318940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-01
		FILM NUMBER:		171206740

	BUSINESS ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468
		BUSINESS PHONE:		(610) 948-5100

	MAIL ADDRESS:	
		STREET 1:		155 SOUTH LIMERICK ROAD
		CITY:			LIMERICK
		STATE:			PA
		ZIP:			19468

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Technology Holding Co III
		CENTRAL INDEX KEY:			0001519303
		IRS NUMBER:				510375996
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-09
		FILM NUMBER:		171206732

	BUSINESS ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808
		BUSINESS PHONE:		(302) 225-5194

	MAIL ADDRESS:	
		STREET 1:		DELAWARE MANAGEMENT SERVICES
		STREET 2:		2751 CENTERVILLE ROAD, SUITE 310
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vidacare LLC
		CENTRAL INDEX KEY:			0001632830
		IRS NUMBER:				742899035
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-02
		FILM NUMBER:		171206739

	BUSINESS ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD, SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		(610) 225-6800

	MAIL ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD, SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOTRACT INC
		CENTRAL INDEX KEY:			0001356876
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				203275141
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-16
		FILM NUMBER:		171206724

	BUSINESS ADDRESS:	
		STREET 1:		4473 WILLOW ROAD
		STREET 2:		SUITE 100
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588
		BUSINESS PHONE:		925-401-0623

	MAIL ADDRESS:	
		STREET 1:		4473 WILLOW ROAD
		STREET 2:		SUITE 100
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teleflex Urology Ltd
		CENTRAL INDEX KEY:			0001722887
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-18
		FILM NUMBER:		171206725

	BUSINESS ADDRESS:	
		STREET 1:		AF4 ATHLONE BUSINESS & TECHNOLOGY PARK
		STREET 2:		GARRYCASTLE, DUBLIN ROAD
		CITY:			ATHLONE, CO. WESTMEATH
		STATE:			L2
		ZIP:			AF4
		BUSINESS PHONE:		6102256904

	MAIL ADDRESS:	
		STREET 1:		AF4 ATHLONE BUSINESS & TECHNOLOGY PARK
		STREET 2:		GARRYCASTLE, DUBLIN ROAD
		CITY:			ATHLONE, CO. WESTMEATH
		STATE:			L2
		ZIP:			AF4

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VASCULAR SOLUTIONS LLC
		CENTRAL INDEX KEY:			0001030206
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				411859679
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-17
		FILM NUMBER:		171206723

	BUSINESS ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD
		STREET 2:		SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		6102256800

	MAIL ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD
		STREET 2:		SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VASCULAR SOLUTIONS INC
		DATE OF NAME CHANGE:	19990714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wolfe-Tory Medical, Inc.
		CENTRAL INDEX KEY:			0001632832
		IRS NUMBER:				870516090
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211276-14
		FILM NUMBER:		171206727

	BUSINESS ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD, SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		(610) 225-6800

	MAIL ADDRESS:	
		STREET 1:		550 E. SWEDESFORD ROAD, SUITE 400
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d483473d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration Statement No. 333-211276<BR> </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>The information in this prospectus supplement is not complete and
may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
</B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>Subject to completion, dated November 16, 2017
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary prospectus supplement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(To
prospectus dated November&nbsp;16, 2017) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g483473g40e12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="6"><B>Teleflex Incorporated </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>$500,000,000 </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;%&nbsp;Senior Notes due 2027 </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Interest payable May&nbsp;15 and November&nbsp;15 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Issue
price:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are offering $500.0&nbsp;million in aggregate principal amount of our&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% Senior
Notes due 2027 (the &#147;notes&#148;). The notes will mature on November&nbsp;15, 2027. Interest will accrue on the notes
from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, and the first interest payment date will be May&nbsp;15, 2018. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At any time prior November&nbsp;15, 2022, we may, on one or more occasions, redeem all or a part of the notes at 100% of the principal amount thereof plus accrued
and unpaid interest to, but not including, the redemption date plus the applicable &#147;make-whole premium&#148; described under &#147;Description of notes&#151;Optional redemption.&#148; On or after November&nbsp;15, 2022, we may, on one or more
occasions, redeem all or a part of the notes at the applicable redemption prices listed under &#147;Description of notes&#151;Optional redemption.&#148; In addition, at any time prior to November&nbsp;15, 2020, we may, on one or more occasions,
redeem up to 40% of the aggregate principal amount of the notes with the net cash proceeds from certain equity offerings at the applicable redemption price listed under &#147;Description of notes&#151;Optional redemption.&#148; If we undergo a
change of control triggering event (as defined herein), we may be required to offer to repurchase the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The obligations under the notes will be
fully and unconditionally guaranteed, jointly and severally, by each of our existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under our Credit Agreement (as defined herein) and by certain of our other
wholly-owned subsidiaries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes and the guarantees thereof will be our and the guarantors&#146; general unsecured senior obligations and will rank
pari passu in right of payment with all of our and the guarantors&#146; existing and future senior obligations, and senior in right of payment to any of our and the guarantors&#146; future subordinated indebtedness. The notes and the guarantees
thereof will be effectively subordinated to our and the guarantors&#146; existing and future secured indebtedness, including all outstanding term loans and revolver borrowings under our Credit Agreement, to the extent of the value of the assets
securing such indebtedness. The notes and the guarantees will be structurally subordinated to all existing and future indebtedness and other claims and liabilities, including preferred stock, of our subsidiaries that do not guarantee the notes. See
&#147;Description of notes&#151;Note guarantees.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>You should read this prospectus supplement, together with the accompanying prospectus,
carefully before you invest in the notes. Investing in the notes involves risks. See &#147;<A HREF="#supprom483473_9">Risk factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-16</FONT> of this prospectus supplement and page 5 of
the accompanying prospectus for a discussion of certain risks that you should consider in connection with an investment in the notes. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these notes or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary
is a criminal offense. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Price to public(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Underwriting&nbsp;discounts<BR>and&nbsp;commissions(2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Proceeds,&nbsp;before<BR>expenses,&nbsp;to<BR>Teleflex&nbsp;Incorporated</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Per note</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Plus accrued interest, if any, from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We refer you to &#147;Underwriting (conflicts of interest)&#148; beginning on page <FONT STYLE="white-space:nowrap">S-83</FONT> of this prospectus supplement for additional
information regarding underwriter compensation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes will not be listed on any securities exchange. Currently, there is no public
market for the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes will be ready for delivery in book-entry form only through the facilities of The Depository Trust Company for the
accounts of its participants, including Euroclear Bank S.A./N.V., as operator of the Euroclear System, and Clearstream Banking, <I>soci&eacute;t&eacute; anonyme</I>, on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Joint
book-running managers </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="3"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B>BofA Merrill Lynch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="3"><B>PNC Capital Markets LLC</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Senior <FONT STYLE="white-space:nowrap">co-managers</FONT> </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>Citizens Capital Markets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>DNB Markets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>HSBC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>MUFG</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>SMBC Nikko</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Wells Fargo Securities</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">Co-managers</FONT> </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>Capital One Securities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Fifth Third Securities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>US Bancorp</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Guggenheim Securities</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The date of this prospectus
supplement is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, </B>2017 </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Prospectus supplement </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_1">About this prospectus supplement</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_2">Trademarks and trade names</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_3">Industry and market data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_4">Where you can find more information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_5">Incorporation of certain information by reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">iii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_6">Forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">v</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_7"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">vi</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_8">Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_9">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-16</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_10">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-38</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_11">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-39</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_12">Ratio of earnings to fixed charges</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-40</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_13">Description of other indebtedness</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-41</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_14">Description of notes</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_15">Certain United States federal income and estate tax consequences to <FONT STYLE="white-space:nowrap">non-United</FONT> States
 holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-77</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_16">Certain ERISA considerations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-80</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_17">Underwriting (conflicts of interest)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-83</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_18">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-89</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#supprom483473_19">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">S-89</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Prospectus </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">About this prospectus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Where you can find more information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Incorporation of certain information by reference</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forward-looking statements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Our company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ratios of earnings to fixed charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of debt securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of guarantees of certain debt securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of capital stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of depositary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of purchase contracts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Description of units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Plan of distribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Validity of the securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Experts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You should rely only on the information contained in or
incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus filed by us with the Securities and Exchange Commission (the &#147;SEC&#148;). We have not, and the underwriters have not,
authorized anyone to provide you with additional information or information different from that contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus. We are offering
to sell, and seeking offers to buy, the notes only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement, the accompanying prospectus or in any free writing prospectus or any document
incorporated by reference is accurate only as of the date of such document, regardless of the time of delivery of this prospectus supplement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For
investors outside of the United States, we have not done anything that would permit the offering, possession or distribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United
States. You are required to inform yourselves about and to observe any restrictions relating to the offering, possession or the distribution of this prospectus supplement outside of the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">i </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_1"></A>About this prospectus supplement </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As used in this prospectus supplement, unless otherwise specified or unless the context indicates otherwise, the terms the &#147;Company&#148;, &#147;we&#148;,
&#147;us&#148;, &#147;our&#148; and &#147;Teleflex&#148; refer to Teleflex Incorporated, a Delaware corporation, and its consolidated subsidiaries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
document is in two parts. The first part is this prospectus supplement which contains specific information about the terms of this offering. This prospectus supplement also adds and updates information contained in the accompanying prospectus. The
second part, the accompanying prospectus, provides more general information about us and securities we may offer from time to time, some of which may not apply to this offering of securities. If there is any inconsistency between the information in
this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_2">
</A>Trademarks and trade names </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">We own or have rights to use various trademarks, trade names and service marks in conjunction
with the operation of our business, including, but not limited to: Arrow, Deknatel, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Hem-o-lok,</FONT></FONT> Hudson RCI, LMA, Pilling, Rusch, TFX OEM and Weck. Solely for convenience,
trademarks, trade names and service marks referred to in this prospectus supplement or the accompanying prospectus may appear without the
<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, SM or </FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. Use or display by us of other parties&#146; trademarks, trade names or service marks is not intended to and does not imply a
relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_3"></A>Industry
and market data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The industry and market data contained or incorporated by reference in this prospectus supplement and the accompanying prospectus
are based either on our management&#146;s own estimates or on independent industry publications, reports by market research firms or other published independent sources. Although we believe these sources are reliable, we have not independently
verified the information and cannot guarantee its accuracy and completeness, as industry and market data are subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the
voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market shares. Accordingly, you should be aware that the industry and market data contained or incorporated by reference in
this prospectus supplement and the accompanying prospectus, and estimates and beliefs based on such data, may not be reliable. Unless otherwise indicated, all information contained or incorporated by reference in this prospectus supplement and the
accompanying prospectus concerning our industry in general or any segment thereof, including information regarding our general expectations and market opportunity, is based on management&#146;s estimates using internal data, data from industry
related publications, consumer research and marketing studies and other externally obtained data. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_4"></A>Where you can find
more information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;),
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to the notes offered hereby. This prospectus supplement and the accompanying prospectus do not contain all the information set forth in the registration statement and its
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">ii </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
exhibits and schedules, parts of which are omitted in accordance with the rules and regulations of the SEC. For further information about us and the notes offered hereby, reference is made to the
registration statement and to its exhibits. Statements in this prospectus supplement and the accompanying prospectus about the contents of any contract, agreement or other document are not necessarily complete and, in each instance, we refer you to
the copy of such contract, agreement or document filed as an exhibit to the registration statement, with each such statement being qualified in all respects by reference to the document to which it refers. You may inspect the registration statement
and its exhibits and schedules without charge at the public reference facilities the SEC maintains at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of these materials from the SEC upon the payment of certain
fees prescribed by the SEC. You may obtain further information about the operation of the SEC&#146;s Public Reference Room by calling the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> You may also inspect these reports and other information without charge at a website maintained by the SEC. The
address of this site is <I>http://www.sec.gov</I>. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are currently subject to the information requirements of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), and in accordance therewith file periodic reports, proxy statements and other information with the SEC. You may read and copy (at prescribed rates) any such reports, proxy statements and other information at
the SEC&#146;s Public Reference Room as described above. Our SEC filings will also be available to you on the SEC&#146;s website at www.sec.gov. Our filings with the SEC are also available to the public through the New York Stock Exchange, 20 Broad
Street, New York, New York 10005. We make our filings available on the investors section of our website (<I>www.teleflex.com</I>) as soon as reasonably practicable after such material is electronically filed or furnished with the SEC pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act. Our website and the information contained on or accessible through our website are not a part of this prospectus supplement, and you should not rely on any such information in making your decision
whether or not to purchase our securities. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_5"></A>Incorporation of certain information by reference </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus supplement and the accompanying prospectus, which means that we can
disclose important information about us by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus supplement. This prospectus supplement incorporates
by reference the documents and reports listed below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2016 (including the portions of our Proxy
Statement on Schedule&nbsp;14A for our 2017 annual meeting of stockholders filed with the SEC on March&nbsp;31, 2017 that are incorporated by reference therein); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended April&nbsp;2, 2017, July&nbsp;2, 2017 and October&nbsp;1, 2017;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on January&nbsp;5, 2017, January&nbsp;20, 2017, February&nbsp;21, 2017,
February&nbsp;23, 2017 (Item 5.02 only), May&nbsp;11, 2017, September&nbsp;5, 2017 (Item 1.01 only), October&nbsp;2, 2017 and November&nbsp;16, 2017; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K/A</FONT> filed on May&nbsp;4, 2017 and November&nbsp;16, 2017. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also incorporate by reference the information contained in all other documents we file with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act after the date of this prospectus supplement and prior to the termination of this offering. The information contained in any such document will be considered part of this prospectus supplement from the date the document is filed with
the SEC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">iii </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing, we are not incorporating by reference information furnished under Items 2.02 or
7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including any Form <FONT STYLE="white-space:nowrap">8-K</FONT> listed above), including the related exhibits, nor in any documents or other information that is deemed to
have been &#147;furnished&#148; to and not &#147;filed&#148; with the SEC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any statement contained in a document incorporated or deemed to be
incorporated by reference in this prospectus supplement and the accompanying prospectus will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference in this prospectus supplement modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus
supplement and the accompanying prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You can obtain any of the filings incorporated by reference into this prospectus supplement and the
accompanying prospectus through us or from the SEC through the SEC&#146;s website at <I>http://www.sec.gov</I>. We will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus supplement or the
accompanying prospectus is delivered, upon written or oral request of such person, a copy of any or all of the reports and documents referred to above which have been or may be incorporated by reference into this prospectus supplement or the
accompanying prospectus. You should direct requests for those documents to: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Teleflex Incorporated </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Attn: Jake Elguicze, Treasurer and Vice President, Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">550 E. Swedesford Road </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Suite 400 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Wayne, PA 19087 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(610) <FONT
STYLE="white-space:nowrap">225-6800</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">iv </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_6"></A>Forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein may contain forward-looking statements within
the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. All statements made in this prospectus supplement and the accompanying prospectus, other than statements of historical fact, are forward-looking
statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148; &#147;guidance,&#148;
&#147;potential,&#148; &#147;continue,&#148; &#147;project,&#148; &#147;forecast,&#148; &#147;confident,&#148; &#147;prospects,&#148; and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are
based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks,
uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in business relationships with and purchases by or from major customers or suppliers </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">including delays or cancellations in shipments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">demand for and market acceptance of new and existing products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with
expectations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to effectively execute our restructuring programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to realize savings resulting from restructuring plans and programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the impact of healthcare reform legislation and proposals to amend the legislation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in Medicare, Medicaid and third-party coverage and reimbursements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">competitive market conditions and resulting effects on revenues and pricing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increases in raw material costs that cannot be recovered in product pricing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">global economic factors, including currency exchange rates, interest rates, sovereign debt issues and the impact of the United Kingdom&#146;s vote to leave the
European Union; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">difficulties entering new markets; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">general economic conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There may be
other factors that may cause our actual results to differ materially from the forward-looking statements. Our actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking statements.
We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them does, what impact they will have on our results of operation and financial condition. You should carefully read the factors
described in the &#147;Risk Factors&#148; section of this prospectus supplement and the accompanying prospectus and the documents incorporated by reference into this prospectus supplement for a description of certain risks that could, among other
things, cause our actual results to differ from these forward-looking statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All future written and verbal forward-looking statements attributable
to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">v </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You should not place undue reliance on forward-looking
statements. Such statements speak only as to the date on which they are made, and we undertake no obligation to update or revise any forward-looking statement, except as otherwise specifically stated by us or as required by law or regulation.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_7"></A><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We refer to the terms Adjusted EBITDA and Free Cash Flow (as defined in &#147;Summary&#151;Summary financial data&#148;) in various places in this prospectus
supplement. These are supplemental financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;). Any analysis of <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measures should be used only in conjunction with results presented in accordance with GAAP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC has adopted rules to regulate the use in
filings with the SEC and in public disclosures and press releases of <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures,&#148; such as Adjusted EBITDA, Free Cash Flow and the ratios related thereto. These measures are derived
on the basis of methodologies other than in accordance with GAAP. These rules govern the manner in which <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are publicly presented and require, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a presentation with equal or greater prominence of the most comparable financial measure or measures calculated and presented in accordance with GAAP; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a statement disclosing the purposes for which the registrant&#146;s management uses the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The rules prohibit, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the exclusion of charges or liabilities that require, or will require, cash settlement or would have required cash settlement, absent an ability to settle in
another manner, from a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> liquidity measure; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the adjustment of a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> performance measure to eliminate or smooth items identified as <FONT
STYLE="white-space:nowrap">non-recurring,</FONT> infrequent or unusual, when the nature of the charge or gain is such that it has occurred in the past two years or is reasonably likely to recur within the next two years.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our measurements of Adjusted EBITDA and Free Cash Flow may not be comparable to those of other companies. Please see
&#147;Summary&#151;Summary financial data&#148; for a discussion of our use of Adjusted EBITDA and Free Cash Flow in this prospectus supplement, including the reasons that we believe this information is useful to management and to investors and a
reconciliation of Adjusted EBITDA and Free Cash Flow to the most closely comparable financial measures calculated in accordance with GAAP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">vi </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_8"></A>Summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>This summary highlights selected information appearing or incorporated by reference in this prospectus supplement and the accompanying prospectus and may not contain all of the information that is important to
you. This prospectus supplement and the accompanying prospectus includes information about the notes we are offering as well as information regarding our business and financial data. You should read this prospectus supplement, the accompanying
prospectus and the information incorporated by reference into this prospectus supplement and the accompanying prospectus in their entirety, including the sections entitled &#147;Risk factors&#148; of this prospectus supplement and the accompanying
prospectus and the financial statements and related notes incorporated by reference herein, before deciding to invest in the notes. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our company
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total
procedural costs. We primarily design, develop, manufacture and supply <FONT STYLE="white-space:nowrap">single-use</FONT> medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care
and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any
one <FONT STYLE="white-space:nowrap">end-market</FONT> or procedure. As of October&nbsp;2, 2017, we manufactured our products at 36 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and
the United&nbsp;States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are focused on achieving consistent, sustainable and profitable growth and improving our financial performance by increasing
our market share and improving our operating efficiencies through: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">development of new products and product line extensions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">investment in new technologies and broadening their applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expansion of the use of our products in existing markets and introduction of our products into new geographic markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">achievement of economies of scale as we continue to expand by leveraging our direct sales force and distribution network for new products, as well as increasing
efficiencies in our sales and marketing and research and development structures and our manufacturing and distribution facilities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expansion of our product portfolio through select acquisitions, licensing arrangements and business partnerships that enhance, extend or expedite our development
initiatives or our ability to increase our market share. In <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> 2017, we completed several acquisitions of businesses that complement and expand our product
portfolio, as well as expand our business into new markets. See &#147;&#151;Recent acquisitions.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our research and development
capabilities, commitment to engineering excellence and focus on <FONT STYLE="white-space:nowrap">low-cost</FONT> manufacturing enable us to bring cost effective, innovative products to market that improve the safety, efficacy and quality of
healthcare. Our research and development initiatives focus on developing these products for both existing and new therapeutic applications, as well as enhancements to, and line extensions of, existing products. We introduced 25 new products and line
extensions during 2016, and 20 during <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> 2017. Our portfolio of existing products and products under development consists primarily of Class&nbsp;I and
Class&nbsp;II devices, most of which require 510(k) clearance by the United States Food and Drug Administration (&#147;FDA&#148;) for </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
sale in the United States, and some of which are exempt from the requirement to obtain 510(k) clearance. We believe that 510(k) clearance (or 510(k)-exempt status) reduces our research and
development costs and risks, and typically results in a shorter timetable for new product introductions as compared to the premarket approval (&#147;PMA&#148;) process that would be required for Class&nbsp;III devices. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our markets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We generally serve three <FONT
STYLE="white-space:nowrap">end-markets:</FONT> hospitals and healthcare providers, medical device manufacturers and home care. These markets are affected by a number of factors, including demographics, utilization and reimbursement patterns. The
following charts depict the percentage of net revenues for the years ended December&nbsp;31, 2016, 2015 and 2014 derived from each of our end markets. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g483473g12y83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our segments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
reportable segments, other than the Original Equipment Manufacturer and Development Services (&#147;OEM&#148;) segment, design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and
generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty
surgical applications. Our OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
charts depict our net revenues by reportable operating segment as a percentage of our net revenues for the years ended December&nbsp;31, 2016, 2015 and 2014. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g483473g47t88.jpg" ALT="LOGO">
 </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Vascular North America</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our vascular access products facilitate a variety of
critical care therapies, including the administration of intravenous medications and other therapies and the measurement of blood pressure and taking of blood samples through a single puncture site. We believe that our vascular product portfolio
offers the opportunity to reduce injuries to the healthcare provider, expedite placement of a central venous catheter, reduce patient exposure to <FONT STYLE="white-space:nowrap">x-rays,</FONT> expedite infusion of medication and reduce the risk of
catheter related infection and thrombosis for the patient. Moreover, we believe our products can help hospitals achieve reduced costs, improved quality and patient outcomes and increased satisfaction. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our Vascular North America segment represented $278.3&nbsp;million, or approximately 18%, of our net revenues from
external customers. For the year ended December&nbsp;31, 2016, our Vascular North America segment represented $350.5&nbsp;million, or approximately 19%, of our net revenues from external customers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Anesthesia North America</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our anesthesia products include airway and pain management products. Our airway management products,
marketed under the LMA and Rusch brands, are designed to help eliminate airway related complications and improve procedural efficiencies for patients in surgical, critical care and emergency settings. Our portfolio of pain management products are
marketed under the Arrow brand and are designed to provide pain relief during a broad range of surgical and obstetric procedures, thereby helping clinicians better manage each patient&#146;s individual pain while reducing complications and
associated costs. Our pain management products include epidural catheters and trays, spinal needles and trays and peripheral nerve block needles, catheters, trays and ambulatory pain pumps. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our Anesthesia North America segment represented $148.1&nbsp;million, or approximately 10%, of our net revenues from external customers. For the year ended
December&nbsp;31, 2016, our Anesthesia North America segment represented $198.8&nbsp;million, or approximately 11%, of our net revenues from external customers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Surgical North America</I><B>.</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Our surgical products, which consist of both <FONT STYLE="white-space:nowrap">single-use</FONT> and reusable products, include: ligation and
closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; fluid management products used for chest drainage; and a
microlaparoscopic product line, designed to enhance surgeons&#146; ability to perform scarless surgery while producing better patient outcomes. Our surgical products also include reusable hand-held instruments for general and specialty surgical
procedures. We market our surgical products under the Percuvance, <FONT STYLE="white-space:nowrap">Mini-Lap,</FONT> Deknatel, Pilling, Kmedic and Weck brand names. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Hem-o-lok,</FONT></FONT> a significant part of the Weck portfolio, is a unique locking polymer ligation clip that combines the security of a suture
with the speed of a metal clip for open and laparoscopic surgery. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Hem-o-lok</FONT></FONT> clips have special applications in robotic, laparoscopic and cardiovascular surgery.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our Surgical North America segment represented $131.5&nbsp;million, or approximately 8%, of our net
revenues from external customers. For the year ended December&nbsp;31, 2016, our Surgical North America segment represented $172.2&nbsp;million, or approximately 9%, of our net revenues from external customers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Europe, the Middle East and Africa (&#147;EMEA&#148;)</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our EMEA segment designs, manufactures and distributes medical devices
primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The products offered by our EMEA segment are most widely used in the acute care setting for a range of diagnostic and
therapeutic procedures and in general and specialty surgical applications, such as urology. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our EMEA segment represented $394.2&nbsp;million, or
approximately 25%, of our net revenues from external customers. For the year ended December&nbsp;31, 2016, our EMEA segment represented $510.9&nbsp;million, or approximately 27%, of our net revenues from external customers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Asia</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Asia segment, like our EMEA segment, designs, manufactures and distributes medical devices primarily used in critical care,
surgical applications and cardiac care and generally serves hospitals and healthcare providers. The products offered by our Asia segment are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in
general and specialty surgical applications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our Asia segment represented $185.3&nbsp;million, or
approximately 12%, of our net revenues from external customers. For the year ended December&nbsp;31, 2016, our Asia segment represented $249.4&nbsp;million, or approximately 13%, of our net revenues from external customers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>OEM</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Our OEM
division, which includes the TFX OEM and Deknatel OEM brands, provides custom-engineered extrusions, diagnostic and interventional catheters, sheath/dilator sets (introducers) and kits, sutures, performance fibers, and bioresorbable resins and
fibers. We offer an extensive portfolio of integrated capabilities, including engineering, material selection, regulatory affairs, prototyping, testing and validation, manufacturing, assembly and packing. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, our OEM segment represented $137.1&nbsp;million, or approximately 9% of our net revenues from external customers.
For the year ended December&nbsp;31, 2016, our OEM segment represented $161.0&nbsp;million, or approximately 9% of our net revenues from external customers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>All other businesses</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our other operating segments do not meet the threshold for separate disclosure under applicable accounting guidance and are therefore included in the &#147;All
other&#148; line item in tabular presentations of segment information. Products offered by these operating segments include <FONT STYLE="white-space:nowrap">single-use</FONT> interventional cardiology and radiology, respiratory, urology and cardiac
care products, as well as capital equipment, which are provided to hospitals and other alternative channels of care. Also included in the &#147;All other&#148; line item is our Latin American business and the Vascular Solutions business, beginning
in the first quarter of 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the nine months ended October&nbsp;1, 2017, all other businesses represented $276.7&nbsp;million, or 18% of our net
revenues from external customers. For the year ended December&nbsp;31, 2016, all other businesses represented $225.2&nbsp;million, or approximately 12% of our net revenues from external customers. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Competitive strengths </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe the following competitive
strengths differentiate us from our competitors and contribute to our continued success: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Diversified, global medical technology
company</I>.&nbsp;&nbsp;&nbsp;&nbsp;We are a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply <FONT
STYLE="white-space:nowrap">single-use</FONT> medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a
combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one <FONT STYLE="white-space:nowrap">end-market</FONT> or procedure. We are
focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Well-positioned to take advantage of favorable industry dynamics</I>.&nbsp;&nbsp;&nbsp;&nbsp;We believe the
medical markets in which we currently participate represent an aggregate addressable market of approximately $30&nbsp;billion. Growth drivers for our medical markets include favorable market demographics such as the aging population, improving
standard of living in emerging markets and increasing overall demand for medical products, technology advancements, increasing awareness of infection prevention and a general demand for a better quality of life. We believe we are well positioned to
take advantage of the favorable dynamics in our markets due to the breadth and quality of our portfolio, established global brands, global manufacturing and distribution network, broad customer base and focus on
<FONT STYLE="white-space:nowrap">single-use</FONT> products used in <FONT STYLE="white-space:nowrap">non-elective</FONT> procedures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Leading market
positions with established global brands</I>.&nbsp;&nbsp;&nbsp;&nbsp;We believe each of our <FONT STYLE="white-space:nowrap">end-user</FONT> medical product groups has a leading market position with well established, global brands that are
recognized for their consistently high quality and reliability. These brands include Arrow, Deknatel, Hudson RCI, Pilling, Rusch and Weck. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Broad
portfolio of <FONT STYLE="white-space:nowrap">non-elective,</FONT> <FONT STYLE="white-space:nowrap">single-use</FONT> medical products</I>.&nbsp;&nbsp;&nbsp;&nbsp;94% of our net revenues for the year ended December&nbsp;31, 2016 were derived from <FONT
STYLE="white-space:nowrap">single-use,</FONT> disposable products. The majority of our <FONT STYLE="white-space:nowrap">single-use</FONT> medical devices are used in <FONT STYLE="white-space:nowrap">non-elective</FONT> procedures which we believe
provides us with a portfolio of recurring revenue items with minimal exposure to cyclical activity. In addition, our focus on <FONT STYLE="white-space:nowrap">single-use</FONT> medical products reduces our overall capital expenditures, improving our
cash flow generation. Our capital expenditures for the year ended December&nbsp;31, 2016 were approximately $53.1&nbsp;million, or approximately 2.8% of our net revenues for such period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Diversified customer and supplier base</I>.&nbsp;&nbsp;&nbsp;&nbsp;We have a diversified customer base and are not dependent on any single customer for a substantial amount of our revenues. For the year ended
December&nbsp;31, 2016, only five customers individually accounted for more than 1% of our net revenues, the largest of which accounted for approximately 8%, and our top ten customers in aggregate accounted for less than 25% of our net revenues.
Similarly, materials used in the manufacture of our medical products are purchased from a large number of suppliers in diverse geographic locations. For the year ended December&nbsp;31, 2016, no supplier accounted for greater than 4% of our raw
materials, and our top ten suppliers in aggregate accounted for less than 21% of our raw materials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Strong cash flow generation and proven history of
deleveraging</I>.&nbsp;&nbsp;&nbsp;&nbsp;We have demonstrated strong Free Cash Flow generation underpinned by the diversity of our revenue sources and our acute focus on cost management. We generated net cash provided by operating activities from
continuing operations of $410.6&nbsp;million and Free Cash Flow of $357.5&nbsp;million, respectively, during the year ended December&nbsp;31, 2016. Through our strong Free Cash Flow generation from continuing operations and successful integration of
acquisitions, we have a proven track-record of continuing to delever. See &#147;&#151;Summary financial data&#148; for a reconciliation of net cash provided by operating activities from continuing operations to Free Cash Flow. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Experienced management team</I>.&nbsp;&nbsp;&nbsp;&nbsp;We have a senior management team with extensive experience in the medical industry. Benson F. Smith, our
current CEO, has served as our CEO since January&nbsp;30, 2011 and has been a member of our board of directors since 2005. Mr.&nbsp;Smith has over 40 years of experience in the medical device industry. Upon Mr.&nbsp;Smith&#146;s retirement effective
as of December&nbsp;31, 2017, Liam J. Kelly will serve as our President and CEO, and Mr.&nbsp;Smith will continue to serve as <FONT STYLE="white-space:nowrap">non-executive</FONT> Chairman of our board of directors. Mr.&nbsp;Kelly is our current
President and Chief Operating Officer and has over 25 years of experience in the medical device industry, which included senior level positions with <FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc., a medical device company, prior to
joining Teleflex in April 2009. Our CFO, Thomas E. Powell, has over 30 years of professional experience, including, as CFO for Tomotherapy Incorporated, a medical device company, prior to joining Teleflex in August
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
2011. Our senior management team has a proven track record of employing a disciplined portfolio management strategy, including several acquisitions and divestitures, that has enabled Teleflex to
deliver consistent, sustainable and profitable growth. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We plan to continue to grow our business and improve our financial performance by implementing our business strategy, the key elements of which are: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Maintain acute focus on research and development</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our research and development initiatives are focused on developing new, innovative products for existing and new therapeutic
applications as well as enhancements to, and line extensions of, existing products. We introduced 25 new products and line extensions during 2016, and 20 during
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> 2017. Our portfolio of existing products and products under development consists primarily of Class&nbsp;I and Class&nbsp;II devices, most of which require
510(k) clearance by the United States Food and Drug Administration (&#147;FDA&#148;) for sale in the United States, and some of which are exempt from the requirement to obtain 510(k) clearance. We believe that 510(k) clearance (or 510(k)-exempt
status) reduces our research and development costs and risks, and typically results in a shorter timetable for new product introductions as compared to the PMA process that would be required for Class&nbsp;III devices. In addition, from time to
time, we augment development efforts through the acquisition of other technologies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Continue to enhance market leadership
positions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In addition to focusing on research and development and technology, we expect to also enhance our market leadership positions by leveraging our global established brands and distribution network and selectively
pursuing acquisitions, licensing and partnership agreements that may provide us with access to new markets for all of our products. We have well-established, global brands across all of our product groups, which we are able to leverage in our
efforts to commercialize new products and expand the use of existing products into new geographic markets and therapeutic applications. Our existing global sales force and distribution network allow us to rapidly commercialize new products globally
upon obtaining regulatory approvals. We also continually evaluate the composition of the portfolio of our products and businesses to ensure alignment with our overall objectives. We strive to maintain a portfolio of products and businesses that
provide consistency of performance, improved profitability and sustainable growth. In furtherance of these objectives, we may identify opportunities to expand our margins through strategic divestitures of existing businesses and product lines that
do not meet our financial criteria. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Continue to achieve consistent, sustainable and profitable growth</I>.&nbsp;&nbsp;&nbsp;&nbsp;We intend to
continue to achieve consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies. We expect to increase our market share through the development of new products, the expansion of the use of
existing products, the introduction of existing products into new geographic markets and the potential broadening of our product portfolio through selected acquisitions, distributor conversions, licensing agreements and partnerships. Our efforts to
improve our operating efficiencies include leveraging our direct sales force and distribution network with new products, manufacturing and distribution facility rationalization and achieving economies of scale as we continue to expand. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent acquisitions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Vascular
Solutions.&nbsp;&nbsp;&nbsp;&nbsp;</I>On February&nbsp;17, 2017, we completed the acquisition of Vascular Solutions, Inc. (&#147;Vascular Solutions&#148;) for $975.5&nbsp;million net of cash acquired. Vascular Solutions is a medical device company
that develops and markets clinical products for use in minimally invasive coronary and peripheral vascular procedures. Vascular Solutions&#146; product offering consists of over 80 devices and services that are sold to
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
interventional cardiologists, interventional radiologists, electrophysiologists and vein practices worldwide. Its research and corporate development programs focus in three areas: complex
interventions, radial artery catheterization and embolization procedures. The acquisition is expected to meaningfully accelerate the growth of our vascular and interventional access product portfolios by facilitating our further penetration of the
coronary and peripheral vascular market, and by generating increased cross-portfolio selling opportunities to both our and Vascular Solutions&#146; customer bases. We financed the acquisition through a combination of a $750.0&nbsp;million secured
term loan facility and borrowings under our $1.0&nbsp;billion revolving credit facility, both of which were provided under our amended and restated credit agreement, dated January&nbsp;20, 2017 (the &#147;Credit Agreement&#148;). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Vascular Solutions had total revenues of $147.2&nbsp;million and $166.6&nbsp;million for the years ended December&nbsp;31, 2015 and 2016, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial information of Vascular Solutions is presented within the &#147;All Other&#148; category in our presentation of segment information beginning from the
date of its acquisition in the first quarter of 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>NeoTract</I>.&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;2, 2017, we completed the acquisition of
NeoTract, Inc. (&#147;NeoTract&#148;) for a purchase price of $725.0&nbsp;million in cash, subject to customary purchase price adjustments, as well as additional milestone payments by us of up to $375.0&nbsp;million in the aggregate, which milestone
payments are each subject to certain net sales requirements with respect to sales of certain products. Founded in 2004, NeoTract is a medical device company that has developed and commercialized the
<FONT STYLE="white-space:nowrap">FDA-cleared</FONT> UroLift System. The Urolift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH, which is an <FONT
STYLE="white-space:nowrap">age-related</FONT> male condition that results in a larger than usual prostate that squeezes the urethra. The Urolift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction
and open the urethra directly without cutting, heating or removing prostate tissue. The acquisition is expected to expand our existing product portfolio into the benign prostatic hyperplasia market and enhance NeoTract&#146;s revenue growth by
utilizing our international presence and distribution network. We financed the acquisition principally through borrowings under our revolving credit facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">NeoTract had total revenues of $18.2&nbsp;million, $50.5&nbsp;million and $86.6&nbsp;million for the years ended December&nbsp;31, 2015 and 2016 and the nine months ended September&nbsp;30, 2017, respectively.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex Incorporated is a corporation organized under the laws of the State of Delaware. Our principal executive offices are located at 550 East Swedesford Road,
Suite 400, Wayne, PA 19087, and our telephone number at this location is <FONT STYLE="white-space:nowrap">(610)&nbsp;225-6800.</FONT> Our website is <I>www.teleflex.com</I>. Information on our website is not part of this prospectus supplement or the
accompanying prospectus. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Offering summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>The following summary is provided solely for your convenience. The summary is not intended to be complete. You should read the full text and more specific details contained elsewhere in this prospectus
supplement and the accompanying prospectus. For a more detailed description of the notes, see &#147;Description of notes.&#148; </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Issuer </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Teleflex Incorporated, a Delaware corporation. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Notes offered </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">$500.0&nbsp;million aggregate principal amount of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% Senior Notes due 2027. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Maturity </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes will mature on November&nbsp;15, 2027. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Interest rate </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes will bear interest at a rate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% per annum. Interest will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year
comprised of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Interest payment dates </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">May&nbsp;15 and November&nbsp;15 of each year, commencing on May&nbsp;15, 2018. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Guarantees </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The obligations under the notes will be fully and unconditionally guaranteed, jointly and severally, by each of our existing and future wholly-owned subsidiaries that is a guarantor or other obligor under
our Credit Agreement and by certain of our other wholly-owned subsidiaries. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Not all of our subsidiaries will guarantee the notes. Our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries generated approximately 46% of our consolidated net
revenue in the year ended December&nbsp;31, 2016 and held approximately 55% of our consolidated assets as of December&nbsp;31, 2016. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The guarantees will be automatically and permanently released if the notes are rated investment grade by both Moody&#146;s and S&amp;P and in certain other circumstances. See
&#147;Description of notes&#151;Note guarantees.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Ranking </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes and the guarantees thereof will be our and the guarantors&#146; general unsecured senior obligations and will: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">rank senior in right of payment to all of our and the guarantors&#146; future subordinated indebtedness; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">rank <I>pari passu </I>in right of payment with all of our and the guarantors&#146; existing and future senior indebtedness; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be effectively subordinated to all of our and the guarantors&#146; existing and future secured indebtedness, including outstanding term loans and revolver
borrowings under our Credit Agreement, to the extent of the value of the assets securing such indebtedness; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be structurally subordinated to all of the existing and future indebtedness and other claims and liabilities, including preferred stock, of each of our
subsidiaries that do not guarantee the notes. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">As of October&nbsp;1, 2017 (which actual amount includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition
that closed on October&nbsp;2, 2017), on an as adjusted basis to give effect </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%"><FONT STYLE="font-family:arial" SIZE="2">
to this offering and the use of the net proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under our revolving credit facility: </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had approximately $2,270.8&nbsp;million of total indebtedness, including $1,150.0&nbsp;million of senior unsecured indebtedness (which would have
been represented by our 5.25% Senior Notes due 2024 (the &#147;2024 Notes&#148;), our 4.875% Senior Notes due 2026 (the &#147;2026 Notes&#148;) and the notes offered hereby) and no subordinated indebtedness; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">of our total indebtedness, we would have had approximately $1,120.8&nbsp;million of secured indebtedness (comprised of $721.0&nbsp;million of outstanding term
loans, $349.8&nbsp;million of borrowings outstanding under our revolving credit facility and $50.0&nbsp;million of indebtedness under our accounts receivable securitization facility) to which the notes would have been effectively subordinated;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had additional borrowing capacity under our revolving credit facility, after taking into account the limitations under the covenants thereunder, of
$648.0&nbsp;million; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries would have had $262.2&nbsp;million of our consolidated liabilities, all of which would
have been structurally senior to the notes. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Optional redemption </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">At any time on or after November&nbsp;15, 2022, we may redeem all or a part of the notes at the redemption prices set forth under &#147;Description of notes&#151;Optional redemption,&#148; plus accrued
and unpaid interest, if any, to, but not including, the applicable redemption date. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In addition, at any time prior to November&nbsp;15, 2022, we may, on one or more occasions, redeem all or a part of the notes at a redemption price equal to 100% of the principal
amount of the notes redeemed plus a &#147;make-whole&#148; premium plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">At any time prior to November&nbsp;15, 2020, we may also redeem up to 40% of the aggregate principal amount of the notes, using the net cash proceeds of certain qualified equity
offerings, at a redemption price equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount of the notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date.
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">See &#147;Description of notes&#151;Optional redemption.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Change of control </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">If we experience certain change of control events coupled with a downgrade in the ratings of the notes (&#147;change of control triggering event&#148;), we must offer to repurchase the notes at a
repurchase price in cash equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to, but not including, the repurchase date. See &#147;Description of notes&#151;Change of control.&#148;
</FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We may not have sufficient funds available at the time of any change of control triggering event to make any required debt repayment (including repurchases of the notes). See
&#147;Risk factors&#151;Risks related to our indebtedness and this offering&#151;We may not have the ability to raise the funds necessary to finance the change of control offer required by the indenture.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Certain covenants </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The indenture governing the notes will contain covenants that, among other things, will restrict our ability and the ability of our subsidiaries to: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">create certain liens; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enter into sale lease back transactions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">merge, consolidate, sell or otherwise dispose of all or substantially all of our assets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">These covenants are subject to important exceptions and limitations, which are described under &#147;Description of notes&#151;Certain covenants.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Events of default </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Except as described under &#147;Description of notes&#151;Events of default and remedies,&#148; if an event of default with respect to the notes occurs, holders may, upon satisfaction of certain
conditions, accelerate the principal amount of the notes plus accrued and unpaid interest. In addition, the principal amount of the notes plus accrued and unpaid interest will automatically become due and payable in the case of certain types of
bankruptcy or insolvency events of default involving us. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering will be approximately $491.2&nbsp;million, after deducting the underwriters&#146; discount and offering expenses payable by us.
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to use such net proceeds to repay approximately $491.2&nbsp;million of borrowings under our revolving credit facility. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Absence of a public market for the notes </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes will be new securities for which there is currently no market. If no active trading market develops, you may not be able to resell your notes at their fair market value or at all. Future trading
prices of the notes will depend on many factors, including, among other things, prevailing interest rates, our operating results and the market for similar securities. We have been informed by certain of the underwriters that they currently intend
to make a market in the notes after this offering is completed. However, the underwriters are not obligated to do so, and they may cease their market-making at any time and without notice. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Listing </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We do not intend to apply for listing of the notes on any securities exchange. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>United States federal income<BR> and estate tax consequences </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">For certain United States federal income and estate tax consequences of the holding and disposition of the notes, see &#147;Certain United States federal income and estate tax consequences to <FONT
STYLE="white-space:nowrap">non-United</FONT> States holders.&#148; </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>DTC eligibility </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes will be issued in fully registered book-entry form and will be represented by permanent global notes without coupons. Global notes will be deposited with a custodian for and registered in the
name of a nominee of DTC, in New York, New York. Investors may elect to hold interests in the global notes through DTC and its direct or indirect participants. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Denominations </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The notes will be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Conflicts of interest </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Because affiliates of each of J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, PNC Capital Markets LLC, Citizens Capital Markets, Inc., DNB Markets, Inc., HSBC
Securities (USA) Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Capital One Securities, Inc., Citigroup Global Markets Inc., Fifth Third Securities, Inc. and U.S. Bancorp Investments, Inc. are
each lenders under our revolving credit facility and will each receive 5% or more of the net proceeds of this offering due to the repayment of borrowings under our revolving credit facility, J.P. Morgan Securities LLC, Merrill Lynch, Pierce,
Fenner&nbsp;&amp; Smith Incorporated, PNC Capital Markets LLC, Citizens Capital Markets, Inc., DNB Markets, Inc., HSBC Securities (USA) Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Capital
One Securities, Inc., Citigroup Global Markets Inc., Fifth Third Securities, Inc. and U.S. Bancorp Investments, Inc. are each deemed to have a conflict of interest within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc.
(&#147;FINRA&#148;). Accordingly, this offering will be conducted in accordance with Rule 5121, which requires, among other things, that a &#147;qualified independent underwriter&#148; participate in the preparation of, and exercise the usual
standards of &#147;due diligence&#148; with respect to, the registration statement and this prospectus. Guggenheim Securities, LLC has agreed to act as a qualified independent underwriter for this offering and to undertake the legal responsibilities
and liabilities of an underwriter under the Securities Act, specifically including those inherent in Section&nbsp;11 thereof. Guggenheim Securities, LLC will not receive any additional fees for serving as a qualified independent underwriter in
connection with this offering. We have agreed to indemnify Guggenheim Securities, LLC against liabilities incurred in connection with acting as a qualified independent underwriter, including liabilities under the Securities Act. See
&#147;Underwriting (conflicts of interest)&#151;Conflicts of interest.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Investing in the notes involves substantial risks. In evaluating an investment in the notes, prospective investors should carefully consider, along with the other information in this prospectus supplement
and the accompanying prospectus, the specific factors set forth under &#147;Risk factors&#148; in this prospectus supplement and the accompanying prospectus for risks involved with an investment in the notes. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Summary financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The summary financial data presented for the years ended December&nbsp;31, 2016, 2015 and 2014 and as of December&nbsp;31, 2016, 2015 and 2014 has been derived from our audited financial statements incorporated by
reference herein. This summary should be read together with our financial statements and the accompanying notes to those statements incorporated by reference herein. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The summary financial data presented for the nine months ended October&nbsp;1, 2017 and September&nbsp;25, 2016 and as of October&nbsp;1, 2017 and September&nbsp;25, 2016 has been derived from our unaudited
financial statements incorporated by reference herein and has been prepared on the same basis as our audited financial statements and, in management&#146;s opinion, includes all adjustments which we consider necessary for a fair presentation of our
financial position and results of operations for such periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The results of the nine months ended October&nbsp;1, 2017 are not necessarily indicative
of the results to be expected for the year ended December&nbsp;31, 2017 or any future period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial information of Vascular Solutions is included in
our financial information for the nine months ended October&nbsp;1, 2017 from the date of its acquisition. Financial information for NeoTract will be included in future periods. Certain financial information is presented on a rounded basis, and
consequently totals may appear not to sum. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(dollars in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>October&nbsp;1,&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>September&nbsp;25,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Statement of Income Data(1):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,868,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,809,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,839,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,551,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,354,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">871,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">865,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">897,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">710,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">630,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">996,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">944,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">942,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">841,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">723,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">563,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">568,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">578,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">59,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">59,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gain on sale of assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income from continuing operations before interest, loss on extinguishments of debt and taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">315,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">281,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">252,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on extinguishments of debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income from continuing operations before taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">245,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">244,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">220,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">217,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Taxes on income from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">237,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">236,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating loss from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tax (benefit) on loss from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income (loss) from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">237,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">245,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">188,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(dollars in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>October&nbsp;1,&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>September&nbsp;25,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: Income from continuing operations attributable to noncontrolling interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income attributable to Teleflex Incorporated common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">237,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">244,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187,679</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income attributable to Teleflex Incorporated common shareholders from continuing operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">237,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">235,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">190,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance Sheet Data (end of period):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">543,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">338,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">303,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,017,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">499,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,276,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,295,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,323,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,886,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,305,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,091,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,199,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,216,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,606,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,164,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,891,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,871,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,912,431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,680,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,001,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,033,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,059,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,058,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,250,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,031,862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Mezzanine equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,137,517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,011,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,913,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,472,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,169,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Other Financial Data(1):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by (used in):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating activities from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">410,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">303,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">290,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">301,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investing activities from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(154,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(108,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,058,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(40,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Financing activities from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(118,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(85,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(287,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,155,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">532,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">452,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">427,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">446,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">371,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Free cash flow(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">357,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">241,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">222,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">265,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">265,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>As Adjusted Data(4):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total indebtedness</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,270,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total secured indebtedness</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,120,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net secured indebtedness(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">828,177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ratio of total indebtedness to Adjusted EBITDA(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.74x</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ratio of net secured indebtedness to Adjusted EBITDA(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.36x</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Amounts exclude the impact of businesses presented in our consolidated financial results as discontinued operations. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA represents net income before interest expense, provision for income taxes, depreciation and amortization, as further adjusted to exclude unusual items and other
adjustments (including the pro forma effect of certain acquisitions) that are required or permitted in determining our ability to engage in certain activities, such as incurring additional debt and making certain payments under the indenture that
governs the 2024 Notes and the indenture that governs the 2026 Notes and incurring liens and engaging in certain sale and lease back transactions under the indenture that will govern the notes offered hereby. The amounts presented in this prospectus
supplement for Adjusted EBITDA are calculated under the definition of Consolidated EBITDA set forth under &#147;Description of notes&#151;Certain definitions.&#148; The amounts presented in this prospectus supplement for Adjusted EBITDA do not
include any amounts related to future cost savings and operating expenses. The amounts presented in this prospectus supplement for Adjusted EBITDA differ from the amounts calculated under the definition of Consolidated EBITDA used in our Credit
Agreement as a result of differences in certain adjustments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">We believe that the presentation of Adjusted EBITDA is
appropriate to provide additional information to investors about certain <FONT STYLE="white-space:nowrap">non-cash</FONT> items, unusual items that we do not expect to continue at the same level in the future, or other items that we do not believe
to be reflective of our ongoing operating performance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA is not a measurement of operating performance computed in
accordance with GAAP and should not be considered a substitute for income from continuing operations, net income or cash flows from operating activities of continuing operations computed in accordance with GAAP. Adjusted EBITDA has limitations as an
analytical tool. Some of the limitations are: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">although depreciation and amortization are <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, the assets being depreciated and amortized will often have
to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">Because of these limitations, Adjusted EBITDA should not be considered a measure of discretionary cash available to us
to invest in the growth of our business. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally. We further believe that our presentation of these GAAP and <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measurements provide information that is useful to investors because they are important indicators of the strength of our operations and the performance of our core business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:arial" SIZE="1">A reconciliation of net income to Adjusted EBITDA is provided below: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Nine months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>(dollars in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>October&nbsp;1,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2017</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>September&nbsp;25,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">237,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">245,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">188,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">195,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">176,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">(Income) loss from discontinued operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(8,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income (loss) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">237,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">236,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">191,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">198,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">176,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Taxes on income from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">28,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">54,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">61,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">58,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">117,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">108,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">111,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">106,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">87,758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring, restructuring-related charges and asset impairments(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">74,949</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">17,705</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">28,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">26,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="white-space:nowrap">Non-cash</FONT> stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net gain on sales of businesses and assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Foreign currency losses (gains)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> items(b)(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(9,134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">532,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">452,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">427,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">446,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">371,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes employee termination benefits, facility closure and other exit costs, contract termination costs and asset impairments as well as other costs directly related to the
restructuring plans including accelerated depreciation, project management and other regulatory costs. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes loss on extinguishments of debt, acquisition costs and other items. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The year ended December 31, 2016 includes a pro forma adjustment of $12.2 million, representing the Adjusted EBITDA of Vascular Solutions for the three months December 31, 2016.
The nine months ended October 1, 2017 includes a pro forma adjustment of $5.2 million, representing the Adjusted EBITDA of Vascular Solutions from January 1, 2017 to the closing of the acquisition of Vascular Solutions on February 17, 2017. We have
included these adjustments for the purpose of calculating Adjusted EBITDA for the four fiscal quarters ended October 1, 2017 in each of the ratio of total indebtedness to Adjusted EBITDA and the ratio of net secured indebtedness to Adjusted EBITDA,
as further described in footnote (6) below. There can be no assurances that Vascular Solutions would have achieved the same results if we had acquired them at the beginning of each such period. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Free cash flow is calculated by subtracting capital expenditures from cash provided by operating activities from continuing operations. Free cash flow is considered a <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. We use this financial measure for internal managerial purposes, when publicly providing guidance on possible future results, and to evaluate <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons. This financial measure is used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial
measures. Management believes that free cash flow is a useful measure to investors because it facilitates an assessment of funds available to satisfy current and future obligations, pay dividends and fund acquisitions. Free cash flow is not a
measure of cash available for discretionary expenditures since we have certain <FONT STYLE="white-space:nowrap">non-discretionary</FONT> obligations, such as debt service, that are not deducted from the measure. We strongly encourage investors to
review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. The following is a reconciliation of free cash flow to the most comparable GAAP measure. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Nine months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>October&nbsp;1,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>September&nbsp;25,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net cash provided by operating activities from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">410,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">303,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">290,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">319,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">301,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: Capital expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">61,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">67,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">35,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Free cash flow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">357,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">241,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">222,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">265,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">265,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Actual debt amounts outstanding as of October&nbsp;1, 2017 includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund
the NeoTract acquisition that closed on October&nbsp;2, 2017. Total indebtedness and net secured indebtedness are presented on as adjusted </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="1">
basis after giving effect to this offering and the use of proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under our revolving credit facility.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Net secured indebtedness refers to total secured indebtedness less cash and cash equivalents. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Calculated on the basis of Adjusted EBITDA for the four fiscal quarters ended October&nbsp;1, 2017, which has been derived by subtracting Adjusted EBITDA for the nine months
ended September&nbsp;25, 2016 from the Adjusted EBITDA for the year ended December&nbsp;31, 2016 and adding the Adjusted EBITDA for the nine months ended October&nbsp;1, 2017. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_9"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>An investment in our securities involves various risks. Prior to making a decision about investing in our securities, and in consultation with your own financial and legal advisors, you should carefully
consider, among other matters, the risks described below as well as other information and data included in, or incorporated by reference into, this prospectus supplement and accompanying prospectus. If any of the events described in the risk factors
below occur, our business, financial condition, operating results and prospects could be materially adversely affected, which in turn could adversely affect our ability to repay the notes or the trading price of the notes. </I></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We face strong
competition. Our failure to successfully develop and market new products could adversely affect our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The medical device industry is
highly competitive. We compete with many domestic and foreign medical device companies ranging from small <FONT STYLE="white-space:nowrap">start-up</FONT> enterprises that might sell only a single or limited number of competitive products or compete
only in a specific market segment, to companies that are larger and more established than us, have a broad range of competitive products, participate in numerous markets and have access to significantly greater financial and marketing resources than
we do. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the medical device industry is characterized by extensive product research and development and rapid technological advances. The
future success of our business will depend, in part, on our ability to design and manufacture new competitive products and enhance existing products. Our product development efforts may require us to make substantial investments. There can be no
assurance that we will be able to successfully develop new products, enhance existing products or achieve market acceptance of our products due to, among other things, our inability to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">identify viable new products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain adequate intellectual property protection; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">gain market acceptance of new products; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successfully obtain regulatory approvals. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition, our competitors currently may be developing, or may develop in the future, products that provide better features, clinical outcomes or economic value than those that we currently offer or subsequently develop. Our failure to successfully
develop and market new products or enhance existing products could have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our customers depend on third party coverage and reimbursements and the failure of healthcare programs to provide coverage and reimbursement, or the reduction in reimbursement levels, for our medical products
could adversely affect us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ability of our customers to obtain coverage and reimbursement for our products is important to our business.
Demand for many of our existing and new medical products is, and will continue to be, affected by the extent to which government healthcare programs and private health insurers reimburse our customers for patients&#146; medical expenses in the
countries where we do business. Even when we develop or acquire a promising new product, demand for the product may be limited unless reimbursement approval is obtained from private and government third party payors. Internationally, healthcare
reimbursement systems vary significantly. In some countries, medical centers are constrained by fixed budgets, regardless of the volume and nature of their patient treatment. Other countries require application for, and approval of, government or
third party reimbursement. Without both favorable coverage determinations by, and the financial support of, government and third party insurers, the market for many of our medical products would be adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In this regard, we cannot be sure that third party payors will maintain the current level of coverage and
reimbursement to our customers for use of our existing products. Adverse coverage determinations or any reduction in the amount of reimbursement could harm our business by discouraging customers&#146; selection of our products and reducing the
prices they are willing to pay. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, as a result of their purchasing power, third party payors are implementing cost cutting measures such as
seeking discounts, price reductions or other incentives from medical products suppliers and imposing limitations on coverage and reimbursement for medical technologies and procedures. These trends could compel us to reduce prices for our products
and could cause a decrease in the size of the market or a potential increase in competition that could negatively affect our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and may experience business disruptions associated with restructuring, facility
consolidations, realignment, cost reduction and other strategic initiatives. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Over the past several years we have implemented a number of
restructuring, realignment and cost reduction initiatives, including facility consolidations, organizational realignments and reductions in our workforce. While we have realized some efficiencies from these actions, we may not realize the benefits
of these initiatives to the extent we anticipated. Further, such benefits may be realized later than expected, and the ongoing difficulties in implementing these measures may be greater than anticipated, which could cause us to incur additional
costs or result in business disruptions. In addition, if these measures are not successful or sustainable, we may be compelled to undertake additional restructuring, realignment and cost reduction efforts, which could result in significant
additional charges. Moreover, if our restructuring, realignment and cost reduction efforts prove ineffective, our ability to achieve our other strategic and business plan goals may be adversely affected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, as part of our efforts to increase operating efficiencies, we have implemented a number of initiatives over the past several years to consolidate our
enterprise resource planning, or ERP, systems. To date, we have not experienced any significant disruptions to our business or operations in connection with these initiatives. However, as we continue our efforts to further consolidate our ERP
systems, we could experience business disruptions, which could adversely affect customer relationships and divert the attention of management away from daily operations. In addition, any delays in the implementation of these initiatives could cause
us to incur additional unexpected costs. Should we experience such difficulties, our business, cash flows and results of operations could be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>A significant portion of our United States revenues is derived from sales to distributors, and &#147;destocking&#148; activity by these distributors can adversely affect our revenues and results of
operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A significant portion of our revenues in the United States is derived from sales to distributors, who, in turn, sell our products to
hospitals and other health care institutions. From time to time, these distributors may decide to reduce their levels of inventory with regard to certain of our products, which we refer to as &#147;destocking.&#148; A distributor&#146;s decision to
reduce inventory levels with respect to our products may be based on a number of factors, such as distributor expectations regarding demand for a particular product, distributor buying decisions (including with respect to competing products),
changes in distributor policies regarding the maintenance of inventory levels, economic conditions and other factors. For example, during the third quarter of 2016, we experienced a decline in purchases by our United States distributors that
adversely affected our revenues and results of operations. We believe the reduction resulted from the distributors&#146; expectations of a less severe 2016-2017 flu season, which resulted in reduced levels of purchasing with respect to certain of
our products that are used for treatment of hospitalized patients suffering from the flu. Following such instances of reduced purchases, distributors may revert to previous purchasing levels; nevertheless, we cannot assure that distributors will, in
fact, increase purchases of our products in this manner. A decline in the level of product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
purchases by our United States distributors in the future could have a material adverse effect on our revenues and results of operations during a reporting period, and an extended decline in such
product purchases could have a longer term material adverse effect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to extensive government regulation, which may require us to
incur significant expenses to ensure compliance. Our failure to comply with those regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our products are classified as medical devices and are subject to extensive regulation in the United States by the FDA and by comparable government agencies in
other countries. The regulations govern, among other things, the development, design, approval, manufacturing, labeling, importing and exporting and sale and marketing of many of our products. Moreover, these regulations are subject to future
change. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, before we can market a new medical device, or a new use of, or claim for, or significant modification to, an existing
product, we generally must first receive either 510(k) or de novo clearance or approval of a PMA from the FDA. Similarly, most major markets for medical devices outside the United States also require clearance, approval or compliance with certain
standards before a product can be commercially marketed. The process of obtaining regulatory clearances and approvals to market a medical device, particularly from the FDA and certain foreign government authorities, can be costly and time consuming,
and clearances and approvals might not be granted for new products on a timely basis, if at all. In addition, once a device has been cleared or approved, a new clearance or approval may be required before the device may be modified or its labeling
changed. Furthermore, the FDA or a foreign government authority may make its review and clearance or approval process more rigorous, which could require us to generate additional clinical or other data, and expend more time and effort, in obtaining
future product clearances or approvals. The regulatory clearance and approval process may result in, among other things, delayed realization of product revenues, substantial additional costs or limitations on indicated uses of products, any one of
which could have a material adverse effect on our financial condition and results of operations. Even after a product has received marketing approval or clearance, such product approval or clearance can be withdrawn or limited due to unforeseen
problems with the device or issues relating to its application. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Failure to comply with applicable regulations could lead to adverse effects on our
business, which could include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">partial suspension or total shutdown of manufacturing; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product shortages; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delays in product manufacturing; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">warning or untitled letters; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines or civil penalties; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delays in obtaining new regulatory clearances or approvals; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal or suspension of required clearances, approvals or licenses; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product seizures or recalls; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">criminal prosecution; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advisories or other field actions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">operating restrictions; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">prohibitions against exporting of products to, or importing products from, countries outside the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We could be required to expend significant financial and human resources to remediate failures to comply with applicable regulations and quality assurance
guidelines. In addition, civil and criminal penalties, including exclusion under Medicaid or Medicare, could result from regulatory violations. Any one or more of these events could have a material adverse effect on our business, financial condition
and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Medical devices are cleared or approved for one or more specific intended uses and performance claims must be
adequately substantiated. Promoting a device for an <FONT STYLE="white-space:nowrap">off-label</FONT> use or making misleading or unsubstantiated claims could result in government enforcement action. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, our facilities are subject to periodic inspection by the FDA and other federal, state and foreign government authorities, which require manufacturers
of medical devices to adhere to certain regulations, including the FDA&#146;s Quality System Regulation, which requires periodic audits, design controls, quality control testing and documentation procedures, as well as complaint evaluations and
investigation. In addition, any facilities assembling convenience kits that include drug components and are registered as drug repackaging establishments are also subject to current good manufacturing practices requirements for drugs. The FDA also
requires the reporting of certain adverse events and product malfunctions and may require the reporting of recalls or other field safety corrective actions. Issues identified through such inspections and reports may result in FDA enforcement action
through any of the actions discussed above. Moreover, issues identified through such inspections and reports may require significant resources to resolve. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to healthcare fraud and abuse laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on
our results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to healthcare fraud and abuse regulation and enforcement by the federal
government and the governments of those states and foreign countries in which we conduct our business. The laws that may affect our ability to operate include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal healthcare anti-kickback statute, which, among other things, prohibits persons from knowingly and willfully offering or paying remuneration to induce
either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid, or soliciting payment for such referrals,
purchases, orders and recommendations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">federal false claims laws which, among other things, prohibit individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent
claims for payment from the federal government, including Medicare, Medicaid or other third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which prohibits schemes to defraud any healthcare benefit program
and false statements relating to healthcare matters; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any
third-party payor, including commercial insurers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our operations are found to be in violation of any of these laws or any other
government regulations, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and
imprisonment of personnel, any of which could adversely affect our ability to operate our business and our financial results. The risk of our being found to have violated these laws is increased by the fact that many of them have not been fully
interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#147;Affordable Care Act&#148;), imposed annual reporting and disclosure requirements on device manufacturers for any &#147;transfer of
value&#148; made or distributed to physicians or teaching hospitals. Our first report was submitted in 2014, and the reported information was made publicly available in a searchable format in September 2014. In addition, device manufacturers are
required to report and disclose </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
any investment interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties
for each payment, transfer of value or ownership or investment interests not reported in an annual submission, up to an aggregate of $150,000 per year (and up to an aggregate of $1&nbsp;million per year for &#147;knowing failures&#148;). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, there has been a recent trend of increased federal and state regulation of payments made to healthcare providers. Some states, such as California,
Connecticut, Nevada and Massachusetts, mandate implementation of compliance programs that include the tracking and reporting of gifts, compensation for consulting and other services, and other remuneration to healthcare providers. The shifting
commercial compliance environment and the need to build and maintain robust and expandable systems to comply with the different compliance and/or reporting requirements among a number of jurisdictions increases the possibility that we may
inadvertently violate one or more of the requirements, resulting in increased compliance costs that could adversely impact our results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may incur material losses and costs as a result of product liability and warranty claims, as well as product recalls, any of which may adversely affect our
results of operations and financial condition. Furthermore, our reputation as a medical device company may be damaged if one or more of our products are, or are alleged to be, defective. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our businesses expose us to potential product liability risks that are inherent in the design, manufacture and marketing of our products. In particular, our medical
device products are often used in surgical and intensive care settings for procedures involving seriously ill patients. In addition, many of our products are designed to be implanted in the human body for varying periods of time. Product defects or
inadequate disclosure of product-related risks with respect to products we manufacture or sell could result in patient injury or death. In addition, in connection with the divestitures of our former
<FONT STYLE="white-space:nowrap">non-medical</FONT> businesses, we agreed to retain certain liabilities related to those businesses, which include, among other things, liability for products manufactured prior to the date on which we completed the
sale of the business. Product liability and warranty claims often involve very large or indeterminate amounts, including punitive damages. The magnitude of potential losses from product liability lawsuits may remain unknown for substantial periods
of time, and the related legal defense costs may be significant. We could experience material warranty or product liability losses in the future and incur significant costs to defend these claims. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, if any of our products are, or are alleged to be, defective, we may voluntarily participate, or be required by regulatory authorities to participate,
in a recall of that product. In the event of a recall, we may lose sales and be exposed to individual or class-action litigation claims. Moreover, negative publicity regarding a quality or safety issue, whether accurate or inaccurate, could harm our
reputation, decrease demand for our products, lead to product withdrawals or impair our ability to successfully launch and market our products in the future. Product liability, warranty and recall costs may have a material adverse effect on our
business, financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The ongoing volatility in the domestic and global financial markets, combined
with a continuation of constrained global credit markets could adversely impact our results of operations, financial condition and liquidity. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
are subject to risks arising from adverse changes in general domestic and global economic conditions. The economic slowdown and disruption of credit markets that occurred in recent years led to recessionary conditions and depressed levels of
consumer and commercial spending, resulting in reductions, delays or cancellations of purchases of our products and services. Despite some improvements in recent years, economic conditions continue to cause disruption in some financial markets,
resulting in, among other things, diminished liquidity and credit availability. We cannot predict the duration or extent of any economic recovery or the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
extent to which our customers will return to more typical spending behaviors. The continuation of the present broadly applicable economic trends of weak economic growth, constricted credit,
public sector austerity measures in response to public budget deficits and foreign currency volatility, particularly with respect to the euro, could have a material adverse effect on our results of operations, financial condition and liquidity.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, our customers, particularly in Italy, Spain, Portugal and Greece, have extended or delayed payments for products and services already
provided, which has increased our focus on collectability with respect to our accounts receivable from these customers. To date, we have not experienced an inordinate amount of payment defaults by our customers, and we have sufficient lending
commitments in place to enable us to fund our foreseeable additional operating needs. However, the ongoing uncertainty in the European financial markets, combined with a continuation of constrained European credit markets creates a risk that some of
our European customers and suppliers may be unable to access liquidity. As of&nbsp;December&nbsp;31, 2016&nbsp;and&nbsp;2015, our net current and long term trade accounts receivable in Italy, Spain, Portugal and Greece were&nbsp;$51.1
million&nbsp;and&nbsp;$62.3&nbsp;million, respectively. In&nbsp;2016,&nbsp;2015&nbsp;and&nbsp;2014, net revenues from these countries were approximately&nbsp;7%, 7%&nbsp;and&nbsp;8%&nbsp;of total net revenues, respectively, and average days that
accounts receivable from these countries were outstanding were&nbsp;182, 204 and&nbsp;223&nbsp;days, respectively. Although we maintain allowances for doubtful accounts to cover the estimated losses which may occur when customers cannot make their
required payments, we cannot assure that we will continue to experience the same loss rate in the future given the volatility in the worldwide economy. If our allowance for doubtful accounts is insufficient to address receivables we ultimately
determine are uncollectible, we would be required to incur additional charges, which could materially adversely affect our results of operations. Moreover, our inability to collect outstanding receivables could adversely affect our financial
condition and cash flow from operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, adverse economic and financial market conditions may result in future impairment charges with
respect to our goodwill and other intangible assets, which would not directly affect our liquidity but could have a material adverse effect on our reported financial results. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our strategic initiatives, including acquisitions, may not produce the intended growth in revenue and operating income. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our strategic initiatives include making significant investments designed to achieve revenue growth and to enable us to meet or exceed margin improvement targets. If we do not achieve the expected benefits from
these investments or otherwise fail to execute on our strategic initiatives, we may not achieve the growth improvement we are targeting and our results of operations may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, as part of our strategy for growth, we have made, and may continue to make, acquisitions and divestitures and enter into strategic alliances such as joint ventures and joint development agreements.
However, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully, and our joint ventures or strategic alliances may not prove to be successful. In this regard, acquisitions involve
numerous risks, including difficulties in the integration of acquired operations, technologies, services and products and the diversion of management&#146;s attention from other business concerns. Even if we are successful in completing an
acquisition, the products and technologies that we acquire may not be successful or may require significantly greater resources and investments than we anticipated. We could also experience negative effects on our results of operations and financial
condition from acquisition-related charges, amortization of intangible assets and asset impairment charges, and other issues that could arise in connection with the acquisition of a company or business, including issues related to internal control
over financial reporting, regulatory compliance and short-term effects of increased costs on results of operations. Although our management will endeavor to evaluate the risks inherent in any particular transaction, there can be no assurance that we
will identify all such risks or the magnitude of the risks. In addition, prior acquisitions have resulted, and future acquisitions could result, in the incurrence of substantial additional indebtedness and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
expenditures. Future acquisitions may also result in potentially dilutive issuances of equity securities. There can be no assurance that difficulties encountered in connection with acquisitions
will not have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Health care reform may have a material
adverse effect on our industry and our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Political, economic and regulatory developments have effected fundamental changes in the
healthcare industry. The Affordable Care Act substantially changed the way health care is financed by both government and private insurers. It also encourages improvements in the quality of health care products and services and significantly impacts
the United States pharmaceutical and medical device industries. Among other things, the Affordable Care Act: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">established a 2.3% excise tax on sales of medical devices with respect to any entity that manufactures or imports specified medical devices offered for sale in
the United States, although this tax has been suspended for 2016 and 2017 as a result of the enactment of the Consolidated Appropriations Act of 2016; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">implemented payment system reforms, including a national pilot program to encourage hospitals, physicians and other providers to improve the coordination,
quality and efficiency of certain health care services through bundled payment models; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">created an independent payment advisory board that will submit recommendations to reduce Medicare spending if projected Medicare spending exceeds a specified
growth rate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In&nbsp;2015 and&nbsp;2014, we recorded expenses of&nbsp;$10.2&nbsp;million and&nbsp;$12.7&nbsp;million, respectively,
with respect to the medical device excise tax. While the excise tax has been suspended in 2016 and 2017, unless the suspension is extended, we will again be subject to the excise tax in 2018. We cannot predict at this time the full impact of the
Affordable Care Act or other healthcare reform measures that may be adopted in the future on our financial condition, results of operations and cash flows. In this regard, President Trump and several congressional leaders have expressed an intention
to repeal the Affordable Care Act and adopt legislation to replace that act, although more recent statements by President Trump and several members of Congress indicate that some time may elapse before any legislative action with respect to the
Affordable Care Act is effected. Therefore, the continued viability of, or the nature of any modification of, or legislative substitution for, the Affordable Care Act is highly uncertain, and we cannot predict the effect that any of these events
would have on our financial condition, results of operations or cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to risks associated with our <FONT
STYLE="white-space:nowrap">non-United</FONT> States operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have significant manufacturing and distribution facilities, research and
development facilities, sales personnel and customer support operations in a number of countries outside the United States, including Belgium, the Czech Republic, Germany, Ireland, Malaysia and Mexico. In addition, a significant portion of our <FONT
STYLE="white-space:nowrap">non-United</FONT> States revenues are derived from sales to third party distributors. As of December&nbsp;31, 2016,&nbsp;77%&nbsp;of our full-time and temporary employees were employed in countries outside of the United
States. As of&nbsp;December 31, 2016 and 2015, approximately&nbsp;45% and 43%, respectively, of our net property, plant and equipment was located outside the United States. In addition, for the years ended December&nbsp;31, 2016, 2015 and 2014
approximately 46%, 47% and 50%, respectively, of our net revenues (based on the Teleflex entity generating the sale) were derived from operations outside the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our international operations are subject to risks inherent in doing business outside the United States, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exchange controls, currency restrictions and fluctuations in currency values; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">trade protection measures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potentially costly and burdensome import or export requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">laws and business practices that favor local companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in foreign medical reimbursement policies and procedures; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">subsidies or increased access to capital for firms that currently are or may emerge as competitors in countries in which we have operations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">substantial foreign tax liabilities, including potentially negative consequences resulting from changes in tax laws; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions and taxes related to the repatriation of foreign earnings; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">differing labor regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">additional United States and foreign government controls or regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">difficulties in the protection of intellectual property; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unsettled political and economic conditions and possible terrorist attacks against American interests. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the United States&nbsp;Foreign Corrupt Practices Act (the &#147;FCPA&#148;) and similar worldwide anti-bribery laws in
<FONT STYLE="white-space:nowrap">non-United</FONT> States&nbsp;jurisdictions generally prohibit companies and their intermediaries from making improper payments to <FONT STYLE="white-space:nowrap">non-United</FONT> States&nbsp;officials for the
purpose of obtaining or retaining business. The FCPA also imposes accounting standards and requirements on publicly traded United States&nbsp;corporations and their foreign affiliates, which, among other things, are intended to prevent the diversion
of corporate funds to the payment of bribes and other improper payments to government officials, and to prevent the establishment of &#147;off the books&#148; slush funds from which such improper payments can be made. Because of the predominance of
government-sponsored health care systems around the world, many of our customer relationships outside of the United States are with government entities and are therefore subject to such anti-bribery laws. Our policies mandate compliance with these
anti-bribery laws. However, we operate in many parts of the world that have experienced government corruption to some degree.&nbsp;Despite meaningful measures that we undertake to facilitate lawful conduct, which include training and compliance
programs and internal control policies and procedures, we may not always prevent reckless or criminal acts by our employees, distributors or other agents. In addition, we may be exposed to liability due to
<FONT STYLE="white-space:nowrap">pre-acquisition</FONT> conduct of employees, distributors or other agents of businesses or operations we acquire. Violations of anti-bribery laws, or allegations of such violations, could disrupt our operations,
involve significant management distraction and have a material adverse effect on our business, financial condition, results of operations and cash flows. We also could be subject to severe penalties and other adverse consequences, including criminal
and civil penalties, disgorgement, substantial expenditures related to further enhancements to our procedures, policies and controls, personnel changes and other remedial actions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, we are subject to the export controls and economic embargo rules and regulations of the United&nbsp;States, including the Export Administration Regulations and trade sanctions against embargoed
countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as other laws and regulations administered by the Department of Commerce. These regulations limit our ability to market, sell,
distribute or otherwise transfer our products or technology to prohibited countries or persons. While we train our employees and contractually obligate our distributors to comply with these regulations, we cannot assure that a violation will not
occur, whether knowingly or inadvertently. Failure to comply with these rules and regulations may result in substantial civil and criminal </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
penalties, including fines and the disgorgement of profits, the imposition of a court-appointed monitor, the denial of export privileges and debarment from participation in United
States&nbsp;government contracts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The risks relating to our foreign operations may have a material adverse effect on our international operations or on
our business, results of operations, financial condition and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Foreign currency exchange rate, commodity price and interest rate
fluctuations may adversely affect our results. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are exposed to a variety of market risks, including the effects of changes in foreign currency
exchange rates, commodity prices and interest rates. Products manufactured in, and sold into, foreign markets represent a significant portion of our operations. Our consolidated financial statements reflect translation of financial statements
denominated in <FONT STYLE="white-space:nowrap">non-United</FONT> States&nbsp;currencies to United States&nbsp;dollars, our reporting currency, as well as the foreign currency exchange gains and losses resulting from the remeasurement of assets and
liabilities as well as transactions denominated in currencies other than the primary currency of the country in which the entity operates, which we refer to as <FONT STYLE="white-space:nowrap">&#147;non-functional</FONT> currencies.&#148; A
strengthening or weakening of the United States&nbsp;dollar in relation to the foreign currencies of the countries in which we sell or manufacture our products, such as the euro, will affect our United States&nbsp;dollar-reported revenue and income.
Although we have entered into forward contracts with several major financial institutions to hedge a portion of our monetary assets and liabilities and projected cash flows denominated in <FONT STYLE="white-space:nowrap">non-functional</FONT>
currencies in order to reduce the effects of currency rate fluctuations, changes in the relative values of currencies may, in some instances, have a significant effect on our results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our products have significant plastic resin content. We also use quantities of other commodities, such as aluminum and steel. Increases in the prices of
these commodities could increase the costs of our products and services. We may not be able to pass on these costs to our customers, particularly with respect to those products we sell under group purchase agreements, which could have a material
adverse effect on our results of operations and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Increases in interest rates may adversely affect the financial health of our customers and
suppliers, thereby adversely affecting their ability to buy our products and supply the components or raw materials we need. In addition, our borrowing costs could be adversely affected if interest rates increase. Any of these events could have a
material adverse effect on our financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fluctuations in our effective tax rate and changes to
tax laws may adversely affect our results. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a global company, we are subject to taxation in numerous countries, states and other
jurisdictions. Our effective tax rate is derived from a combination of applicable tax rates in the various countries, states and other jurisdictions in which we operate. In preparing our financial statements, we estimate the amount of tax that will
become payable in each of these jurisdictions. Our effective tax rate may, however, differ from the estimated amount due to numerous factors, including a change in the mix of our profitability from country to country and changes in tax laws. Any of
these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, financial condition and results of operations and cash
flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>An interruption in our manufacturing or distribution operations or our supply of raw materials may adversely affect our business.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our key products are manufactured at or distributed from single locations, and the availability of alternate facilities is limited. If
operations at one or more of our facilities is suspended due to natural disasters or other events, we may not be able to timely manufacture or distribute one or more of our products at </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
previous levels or at all. Furthermore, our ability to establish replacement facilities or to substitute suppliers may be delayed due to regulations and requirements of the FDA and other
regulatory authorities regarding the manufacture of our products. In addition, in the event of delays or cancellations in shipments of raw materials by our suppliers, we may not be able to timely manufacture or supply the affected products at
previous levels or at all. The manufacture of our products is highly exacting and complex, due in part to strict regulatory requirements. Problems in the manufacturing process, including equipment malfunction, failure to follow specific protocols
and procedures, defective raw materials and environmental factors, could lead to launch delays, product shortages, unanticipated costs, lost revenues and damage to our reputation. A failure to identify and address manufacturing problems prior to the
release of products to our customers may also result in quality or safety issues.&nbsp;A reduction or interruption in manufacturing or distribution, or our inability to secure suitable alternative sources of raw materials or components, could have a
material adverse effect on our business, results of operations, financial condition and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our ability to attract, train, develop and
retain key employees is important to our success. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends, in part, on our ability to continue to retain our key personnel,
including our executive officers and other members of our senior management team. Our success also depends, in part, on our ability to attract, train, develop and retain other key employees, including research and development, sales, marketing and
operations personnel. We may experience difficulties in retaining executives and other employees due to many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the intense competition for skilled personnel in our industry; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fluctuations in global economic and industry conditions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in our organizational structure; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our restructuring initiatives; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">competitors&#146; hiring practices; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the effectiveness of our compensation programs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our inability to attract, train, develop and retain such personnel could have an adverse effect on our business, results of operations, financial condition and cash
flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We depend upon relationships with physicians and other health care professionals. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development for some of our products is dependent on our maintaining strong working relationships with physicians and other healthcare professionals.
We rely on these professionals to provide us with considerable knowledge and advice regarding the development and use of our products. Physicians assist us as researchers, product consultants, inventors and public speakers. If we fail to maintain
our working relationships with physicians and, as a result, no longer have the benefit of their knowledge and advice, our products may not be developed in a manner that is responsive to the needs and expectations of the professionals who use and
support our products, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our
technology is important to our success, and our failure to protect our intellectual property rights could put us at a competitive disadvantage. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely on the patent, trademark, copyright and trade secret laws of the United States and other countries to protect our proprietary rights. Although we own
numerous United States and foreign patents and have submitted numerous patent applications, we cannot be assured that any pending patent applications will issue, or that any patents, issued or pending, will provide us with any competitive advantage
or will not be challenged, invalidated or circumvented by third parties. In addition, we rely on confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements with employees and take other measures to protect our <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets. The steps we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
have taken may not prevent unauthorized use of our technology by competitors or other persons who may copy or otherwise obtain and use these products or technology, particularly in foreign
countries where the laws may not protect our proprietary rights to the same extent as in the United States. We cannot assure that current and former employees, contractors and other parties will not breach their confidentiality agreements with us,
misappropriate proprietary information, copy or otherwise obtain and use our information and proprietary technology without authorization or otherwise infringe on our intellectual property rights. Our inability to protect our proprietary technology
could adversely affect our business, financial condition, results of operations and cash flows. Moreover, there can be no assurance that others will not independently develop <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets
comparable to ours or develop better technology than our own, which could reduce or eliminate any competitive advantage we have developed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our
products or processes may infringe the intellectual property rights of others, which may cause us to pay unexpected litigation costs or damages or prevent us from selling our products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We cannot be certain that our products do not and will not infringe issued patents or other intellectual property rights of third parties. We may be subject to legal proceedings and claims in the ordinary course of
our business, including claims of alleged infringement of the intellectual property rights of third parties. Any such claims, whether or not meritorious, could result in litigation and divert the efforts of our personnel. If we are found liable for
infringement, we may be required to enter into licensing agreements (which may not be available on acceptable terms or at all) or to pay damages or cease making or selling certain products. We may need to redesign some of our products or processes
to avoid future infringement liability. Any of the foregoing events could be detrimental to our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other pending and future litigation may
involve significant costs and adversely affect our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are party to various lawsuits and claims arising in the normal course of
business involving, among other things, contracts, intellectual property, import and export regulations, employment and environmental matters. The defense of these lawsuits may divert our management&#146;s attention, and we may incur significant
expenses in defending these lawsuits. In addition, we may be required to pay damage awards or settlements, or become subject to injunctions or other equitable remedies, that could have a material adverse effect on our financial condition and results
of operations. While we do not believe that any litigation in which we are currently engaged would have such an adverse effect, the outcome of litigation, including regulatory matters, is often difficult to predict, and we cannot assure that the
outcome of pending or future litigation will not have a material adverse effect on our business, financial condition, results of operations or cash flows. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Disruption of critical information systems or material breaches in the security of our systems may adversely affect our business and customer relationships.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely on information technology systems to process, transmit, and store electronic information in our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. We also rely on our technology infrastructure, among other functions, to enable us to interact with customers and suppliers, fulfill orders, generate invoices, collect and make
payments, ship products, provide support to customers, fulfill contractual obligations and otherwise conduct business. Our internal information technology systems, as well as those systems maintained by third-party providers, may be subjected to
computer viruses or other malicious codes, unauthorized access attempts, and cyber-attacks, any of which could result in data leaks or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are
becoming more sophisticated and frequent, and in some cases have caused significant harm. Although we have taken numerous measures to protect our information systems and enhance data security, we cannot assure that these measures will prevent
security breaches that could have a significant impact on our business, reputation and financial results. If we fail to monitor, maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or
manage </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-26 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
significant disruptions to these systems, we could, among other things, lose customers, have difficulty preventing fraud, have disputes with customers, physicians and other health care
professionals, be subject to regulatory sanctions or penalties, incur expenses or lose revenues or suffer other adverse consequences.&nbsp;Any of these events could have a material adverse effect on our business, results of operations, financial
condition or cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Regulations related to conflict minerals may increase our costs and adversely affect our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2012, the SEC promulgated rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act regarding disclosure of the use of tin, tantalum, tungsten
and gold, known as &#147;conflict minerals,&#148; included in components of products either manufactured by public companies or for which public companies have contracted to manufacture. These rules require that we undertake due diligence efforts to
determine whether such minerals originated from the Democratic Republic of Congo (the &#147;DRC&#148;) or an adjoining country and, if so, whether such minerals helped finance armed conflict in the DRC or an adjoining country. In accordance with
applicable regulations, we filed conflict minerals reports in 2014, 2015 and 2016. As discussed in these reports, we have determined that certain of our products contain the specified minerals, and we have undertaken, and continue to undertake,
efforts to identify where such minerals originated.&nbsp;We have incurred, and expect to continue to incur, costs associated with complying with these disclosure requirements, including costs related to determining the sources of the specified
minerals used in our products. These rules could adversely affect the sourcing, supply and pricing of materials used in our products. Our customers may require that our products be free of conflict minerals, and our revenues and margins may be
adversely affected if we are unable to provide assurances to our customers that our products are &#147;DRC conflict free&#148; (generally, the product does not contain conflict minerals originating in the DRC or an adjoining country that directly or
indirectly finance or benefit specified armed groups) due to, among other things, our inability to procure conflict free minerals at a reasonable price, or at all. Moreover, we may be adversely affected if we are unable to pass through any increased
costs associated with meeting customer demands that we provide products that are DRC conflict free.&nbsp;We also may face reputational challenges if our due diligence efforts do not enable us to verify the origins of all conflict minerals or to
determine that any conflict minerals used in products we manufacture or in products manufactured by others for us are DRC conflict-free. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our
operations expose us to the risk of material environmental liabilities. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to numerous foreign, federal, state and local
environmental protection and health and safety laws governing, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the generation, storage, use and transportation of hazardous materials; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">emissions or discharges of substances into the environment; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the health and safety of our employees. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These
laws and regulations are complex, change frequently and have tended to become more stringent over time. We cannot provide assurance that our costs of complying with current or future environmental protection and health and safety laws, or our
liabilities arising from past or future releases of, or exposures to, hazardous substances, which may include claims for personal injury or cleanup, will not exceed our estimates or will not adversely affect our financial condition and results of
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our workforce covered by collective bargaining and similar agreements could cause interruptions in our provision of products and
services. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016, approximately 12% of our employees in the United States and in other countries were covered by union
contracts or collective bargaining arrangements. It is likely that a portion of our workforce will remain covered by collective bargaining and similar agreements for the foreseeable future. Strikes or work
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-27 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
stoppages could occur that would adversely impact our relationships with our customers and our ability to conduct our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Certain provisions of our corporate governing documents and Delaware law could discourage, delay, or prevent a merger or acquisition. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Provisions of our certificate of incorporation and bylaws could impede a merger, takeover or other business combination involving us or discourage a potential acquirer from making a tender offer for our common
stock. For example, our certificate of incorporation authorizes our board of directors to determine the number of shares in a series, the consideration, dividend rights, liquidation preferences, terms of redemption, conversion or exchange rights and
voting rights, if any, of unissued series of preferred stock, without any vote or action by our stockholders. Thus, our board of directors can authorize and issue shares of preferred stock with voting or conversion rights that could adversely affect
the voting or other rights of holders of our common stock. We are also subject to Section&nbsp;203 of the Delaware General Corporation Law, which imposes restrictions on mergers and other business combinations between us and any holder of 15% or
more of our common stock. These provisions could have the effect of delaying or deterring a third party from acquiring us even if an acquisition might be in the best interest of our stockholders, and accordingly could reduce the market price of our
common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain provisions in the indentures governing the 2024 Notes, the 2026 Notes and the notes offered hereby could make it more difficult or
more expensive for a third party to acquire us. For example, if an acquisition event constitutes a &#147;change of control&#148; as defined in the indentures governing the 2024 Notes and the 2026 Notes or &#147;change of control triggering
event&#148; in the indenture governing the notes offered hereby, holders of such notes will have the right to require us to purchase their notes in cash. In such case, and in other cases, our obligations under the 2024 Notes, the 2026 Notes and the
notes offered hereby could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, and accordingly could reduce the market price of our common stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our indebtedness and this offering </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our substantial indebtedness could adversely affect our business, financial condition or results of operations and prevent us from fulfilling our obligations
under the notes. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have and, after this offering, will continue to have a significant amount of indebtedness. As of October&nbsp;1, 2017 (which
actual amount includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017), on an as adjusted basis after giving effect to this offering and the
use of the net proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under our revolving credit facility: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had approximately $2,270.8&nbsp;million of total indebtedness, including $1,150.0&nbsp;million of senior unsecured indebtedness (which would have
been represented by the 2024 Notes, the 2026 Notes and the notes offered hereby) and no subordinated indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">of our total indebtedness, we would have had approximately $1,120.8&nbsp;million of secured indebtedness (comprised of $721.0&nbsp;million of outstanding term
loans, $349.8&nbsp;million of borrowings outstanding under our revolving credit facility and $50.0&nbsp;million of indebtedness under our accounts receivable securitization facility) to which the notes would have been effectively subordinated;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had additional borrowing capacity under our revolving credit facility, after taking into account the limitations under the covenants thereunder, of
$648.0&nbsp;million; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-28 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries would have had $262.2&nbsp;million of our consolidated liabilities, all of which would
have been structurally senior to the notes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our substantial level of indebtedness increases the risk that we may be unable to generate
cash sufficient to pay amounts due in respect of our indebtedness, including the notes. It could also have significant effects on our business. For example, it could: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">make it more difficult for us to satisfy our obligations with respect to the notes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increase our vulnerability to general adverse economic and industry conditions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow
to fund working capital, capital expenditures, research and development efforts and other general corporate purposes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limit our ability to borrow additional funds for such general corporate purposes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrict us from exploiting business opportunities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">place us at a competitive disadvantage compared to our competitors that have less indebtedness. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Certain of our debt agreements impose restrictions on our business, which could prevent us from capitalizing on business opportunities and taking some
corporate actions and may adversely affect our ability to respond to changes in our business and manage our operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Credit Agreement and
the indentures governing the 2024 Notes and the 2026 Notes contain covenants that, among other things, impose significant restrictions on our business. The restrictions that these covenants place on us and our restricted subsidiaries include
limitations on our and their ability to, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">incur additional indebtedness or issue disqualified stock or preferred stock; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">create liens; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pay dividends, make investments or make other restricted payments; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sell assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">use the proceeds of permitted sales of our assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enter into transactions with our affiliates; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">designate subsidiaries as unrestricted. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition, our Credit Agreement also contains financial covenants, including covenants requiring maintenance of a consolidated total leverage ratio, a secured leverage ratio and a consolidated interest coverage ratio, calculated in accordance with
the terms of the Credit Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indenture that will govern the notes offered hereby will contain limited covenants that restrict our ability and
the ability of our subsidiaries to, among other things, create certain liens, enter into certain sale and lease-back transactions and consolidate or merge with or into, or sell substantially all of our assets to, another person. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A breach of any covenants under any one or more of these debt agreements could result in a default, which if not cured or waived, could result in the acceleration
of all our debts. In addition, any debt agreements we enter into in the future may further limit our ability to enter into certain types of transactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-29 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The indenture governing the notes offered hereby contains negative covenants that may have a limited
effect. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indenture that will govern the notes offered hereby will contain limited covenants that restrict our ability and the ability of our
subsidiaries to create certain liens, enter into certain sale and lease-back transactions and consolidate or merge with or into, or sell substantially all of our assets to, another person. These limited covenants contain exceptions that allow us and
our subsidiaries to incur liens with respect to material assets and additional subsidiary debt. See &#147;Description of notes&#151;Certain covenants.&#148; In light of these exceptions, holders of the notes may be structurally or effectively
subordinated to new lenders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Despite current substantial indebtedness levels, we and our subsidiaries may still be able to incur substantially
more indebtedness. This could further exacerbate the risks associated with our substantial leverage. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and our subsidiaries may be able to
incur substantial additional indebtedness in the future, including secured indebtedness. As of October&nbsp;1, 2017 (which actual amount includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund the
NeoTract acquisition that closed on October&nbsp;2, 2017), on an as adjusted basis after giving effect to this offering and the use of the net proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under our revolving credit
facility, we would have had additional borrowing capacity under our revolving credit facility, after taking into account the limitations under the covenants thereunder, of $648.0&nbsp;million. Adding new indebtedness to current debt levels could
make it more difficult for us to satisfy our obligations with respect to the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we default on our obligations to pay our other
indebtedness, we may not be able to make payments on the notes. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If there were an event of default under any of the agreements relating to our
outstanding indebtedness, the holders of the defaulted debt could cause all amounts outstanding with respect to that debt to be due and payable immediately. Upon acceleration of our other material indebtedness, holders of the notes could declare all
amounts outstanding under the notes immediately due and payable. We cannot assure you that our assets or cash flow would be sufficient to fully repay borrowings under our outstanding debt instruments if accelerated upon an event of default. Further,
if we are unable to repay, refinance or restructure our indebtedness under our secured indebtedness, the holders of such debt could proceed against the collateral securing that indebtedness. In addition, any event of default or declaration of
acceleration under one debt instrument could also result in an event of default under one or more of our other debt instruments. In addition, counterparties to some of our long term customer contracts may have the right to amend or terminate those
contracts if we have an event of default or a declaration of acceleration under certain of our indebtedness, which could adversely affect our business, financial condition or results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Term loans and borrowings under our Credit Agreement and our accounts receivable securitization facility are at variable rates of interest and
expose us to interest rate risk. If interest rates were to increase, our debt service obligations on the variable rate indebtedness would increase even though the amount borrowed remained the same, and our net income and cash flows, including cash
available for servicing our indebtedness, will correspondingly decrease. Assuming all term loans are outstanding and all revolving loans are fully drawn to the extent of borrowing capacity, each quarter point change in interest rates would result in
a $4.5&nbsp;million change in annual interest expense on our variable rate indebtedness. In the future, we may enter into interest rate swaps that involve the exchange of floating for fixed rate interest payments in order to reduce interest rate
volatility. However, we may not maintain interest rate swaps with respect to all of our variable rate indebtedness, and any swaps we enter into may not fully mitigate our interest rate risk. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-30 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be able to generate sufficient cash to service all of our indebtedness, including the notes. Our
ability to generate cash depends on many factors beyond our control. We may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to make payments on, and to refinance, our indebtedness, including the notes, and to fund planned capital expenditures, research and development
efforts, working capital, acquisitions and other general corporate purposes depends on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other
factors, some of which are beyond our control. In addition, the indenture governing the notes offered hereby will allow us to make an unlimited amount of dividends, which may also limit our ability to pay interest or principal on the notes. If we do
not generate sufficient cash flow from operations or if future borrowings are not available to us in an amount sufficient to pay our indebtedness or to fund our other liquidity needs, we may be forced to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refinance all or a portion of our indebtedness on or before it matures; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sell assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduce or delay capital expenditures; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek to raise additional capital. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may not
be able to effect any of these actions on commercially reasonable terms or at all. Our ability to refinance our indebtedness will depend on our financial condition at the time, the restrictions in the instruments governing our outstanding
indebtedness and other factors, including market conditions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our inability to generate sufficient cash flow to satisfy our debt service obligations, or
to refinance or restructure our obligations on commercially reasonable terms or at all, could have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>The notes will be effectively subordinated to our indebtedness under our Credit Agreement and any of our other existing and future secured indebtedness, to the extent of the value of the collateral securing
such indebtedness. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes will not be secured by any of our or our guarantors&#146; assets. As a result, the notes and the guarantees of our
guarantors will be effectively subordinated to our indebtedness under our Credit Agreement and any of our other existing and future secured indebtedness. As of October&nbsp;1, 2017 (which actual amount includes $725.0&nbsp;million in revolving
credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017), on an as adjusted basis after giving effect to this offering and the use of the net proceeds therefrom to repay
$491.2&nbsp;million of outstanding borrowings under our revolving credit facility: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had approximately $1,120.8&nbsp;million of secured indebtedness (comprised of $721.0&nbsp;million of outstanding term loans, $349.8&nbsp;million of
borrowings outstanding under our revolving credit facility and $50.0&nbsp;million of indebtedness under our accounts receivable securitization facility) to which the notes would have been effectively subordinated; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we would have had additional borrowing capacity under our revolving credit facility, after taking into account the limitations under the covenants thereunder, of
$648.0&nbsp;million. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accordingly, upon a default in payment on, or the acceleration of, any of our secured indebtedness, or in the
event of bankruptcy, insolvency, liquidation, dissolution, examinership or reorganization of the company or the guarantors, the proceeds from the sale of assets securing our secured indebtedness will be available to pay obligations on the notes only
after all indebtedness under our Credit Agreement and any other secured indebtedness has been paid in full. As a result, the holders of the notes may receive less, ratably, than the holders of secured debt in the event of our or our guarantors&#146;
bankruptcy, insolvency, liquidation, dissolution or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-31 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
reorganization. Additionally, the indenture governing the notes offered hereby permit us, subject to specified limitations, to incur further secured indebtedness in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are a holding company. Substantially all of our business is conducted through our subsidiaries. Our ability to repay our debt, including the notes, depends
on the performance of our subsidiaries and their ability to make distributions to us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a holding company. Substantially all of our
business is conducted through our subsidiaries, which are separate and distinct legal entities. Therefore, our ability to service our indebtedness, including the notes, is dependent on the earnings and the distribution of funds (whether by dividend,
distribution or loan) from our subsidiaries. None of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries are obligated to make funds available to us for payment on the notes. In addition, we cannot assure you that the agreements
governing the existing and future indebtedness of our subsidiaries will permit our subsidiaries to provide us with sufficient dividends, distributions or loans to fund payments on the notes when due. In addition, any payment of dividends,
distributions or loans to us by our subsidiaries could be subject to restrictions on dividends or repatriation of earnings under applicable local law and monetary transfer restrictions in the jurisdictions in which our subsidiaries operate.
Furthermore, payments to us by our subsidiaries will be contingent upon our subsidiaries&#146; earnings. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Claims of noteholders will be
structurally subordinated to claims of creditors of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Not all of our
subsidiaries will guarantee the notes. Our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries include substantially all of our foreign subsidiaries as well as our captive insurance subsidiaries and securitization subsidiaries. None
of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries are obligated to pay any amounts due pursuant to the notes, or to make any funds available therefor, whether by dividends, loans, distributions of other payments.
Consequently, claims of holders of the notes will be structurally subordinated to the claims of creditors of these subsidiaries, including trade creditors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event of a bankruptcy, liquidation or reorganization of any of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries, such subsidiaries will pay the holders of their debt and the trade
creditors before they will be able to distribute any of their assets to us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of October&nbsp;1, 2017 (which actual amount includes $725.0&nbsp;million
in revolving credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017), our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries had $262.2&nbsp;million of our consolidated
liabilities, all of which would have been structurally senior to the notes. Our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries generated approximately 46% of our consolidated net revenues in the year ended December&nbsp;31, 2016
and held approximately 55% of our consolidated assets as of December&nbsp;31, 2016. For additional information about the division of our consolidated net revenues and assets between our guarantors and our
<FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries, please refer to Note 17 to the consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016 filed on February&nbsp;23, 2017 incorporated by reference herein, and Note 15 to the interim unaudited condensed consolidated financial statements included in our Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended October&nbsp;1, 2017 filed on November&nbsp;2, 2017 incorporated by reference herein. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The guarantees of our guarantors may be released under certain circumstances. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A guarantor will be automatically released from its guarantees under certain circumstances, including if: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the guarantor is released from its guarantee of our Credit Agreement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we sell or dispose of all the assets of a subsidiary such that, subject to certain conditions, it ceases to be a subsidiary; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-32 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we sell capital stock in a subsidiary such that, subject to certain conditions, it ceases to be a subsidiary; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the notes are rated investment grade by both Moody&#146;s and S&amp;P (for the avoidance of doubt, the guarantees will never be reinstated thereafter, even if
the credit ratings assigned to the notes later fall below investment grade). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the guarantees of a subsidiary are released, the
noteholders will be structurally subordinated to the claims of creditors of such subsidiary. See &#147;Risk factors&#151;Risks related to our indebtedness and this offering&#151;Claims of noteholders will be structurally subordinated to claims of
creditors of our <FONT STYLE="white-space:nowrap">non-guarantor</FONT> subsidiaries.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Federal and state statutes allow courts, under specific
circumstances, to void guarantees and require note holders to return payments received from guarantors. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the federal bankruptcy law and
comparable provisions of state fraudulent transfer laws, a guarantee could be voided, or claims in respect of a guarantee could be subordinated to all other debts of that guarantor if (i)&nbsp;such guarantor issued the notes or incurred the
guarantees with the intent of hindering, delaying or defrauding creditors or (ii)&nbsp;such guarantor received less than the reasonable equivalent or fair consideration in return for incurring the guarantees and, in the case of (ii)&nbsp;only, one
of the following is also true of such guarantor at the time thereof: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">was insolvent or rendered insolvent by reason of such incurrence; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">was engaged in a business or transaction for which the guarantor&#146;s remaining assets constituted unreasonably small capital; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">was a defendant in an action for money damages, or had a judgment for money damages docked against such guarantor if, in either case, after final judgment, the
judgment is unsatisfied. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, any payment by that guarantor pursuant to its guarantee could be voided and required to be
returned to the guarantor, or to a fund for the benefit of the creditors of the guarantor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The measures of &#147;insolvency&#148; for purposes of these
fraudulent transfer laws will vary depending upon the law applied in any proceeding to determine whether a fraudulent transfer has occurred. We cannot be certain what standard a court would apply to determine whether a guarantor of the notes was
&#147;insolvent&#148; as of date the notes were issued, and we cannot assure you that, regardless of the method of valuation, a court would not determine that a guarantor of the notes was insolvent on that date. Different jurisdictions define
&#147;insolvency&#148; differently, however, a guarantor generally would be considered insolvent if: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sum of its debts, including contingent liabilities, was greater than the fair saleable value of all of its assets; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">if the present fair saleable value of its assets was less than the amount that would be required to pay its probable liability on its existing debts, including
contingent liabilities, as they become absolute and mature; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it could not pay its debts as they become due. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On the basis of historical financial information, recent operating history and other factors, we believe that each guarantor, after giving effect to its guarantee
of the notes, will not be insolvent, will not have unreasonably small capital for the business in which it is engaged and will not have incurred debts beyond its ability to pay such debts as they mature. We cannot assure you, however, as to what
standard a court would apply in making these determinations or that a court would agree with our conclusions in this regard. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-33 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>As a limited liability company incorporated under the laws of Ireland, Teleflex Urology Limited
(&#147;Teleflex Urology&#148;) is subject to Irish insolvency law under which certain categories of preferential debts could be paid in priority to the claims of holders of the notes upon liquidation. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an Irish incorporated company, Teleflex Urology may be wound up under Irish law. On a liquidation of an Irish company, the claims of those holding certain
categories of preferential debts will take priority over the claims of both secured and unsecured creditors; the claims of secured creditors will rank in priority after the claims of those categories of preferential creditors but before the claims
of unsecured creditors. Such preferential debts would comprise, among other things, any amounts owed in respect of local rates and certain amounts owed to the Irish Revenue Commissioners for income/corporation/capital gains/property tax, value added
tax, employee taxes, social security and pension scheme contributions and remuneration, salary and wages of employees and certain contractors and the expenses of liquidation and examinership (if any). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The holders of the notes would be unsecured creditors of Teleflex Urology and would rank in priority after the claims of preferential creditors and secured
creditors, if any, and on a pari passu basis with other unsecured creditors of Teleflex Urology. As a consequence, the holders&#146; return on their notes may be delayed or reduced and they may suffer a loss on their investment in the event of a
default or insolvency of Teleflex Urology. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Section&nbsp;604 of the Irish Companies Act, 2014 (as amended). </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under Irish company law, a liquidator of Teleflex Urology could apply to court to have set aside certain transactions entered into by Teleflex Urology before the
commencement of liquidation. Section&nbsp;604 of the Irish Companies Act, 2014 (as amended) provides that any conveyance, mortgage, delivery of goods, payment, execution or other act relating to property made or done by or against a company which is
unable to pay its debts as they become due, in favor of any creditor or any person on trust for any creditor, within six months of the commencement of a winding up of the company, with a view to giving such creditor (or any surety or guarantor of
the debt due to such creditor) a preference over its other creditors shall, if the company is at the time of the commencement of the <FONT STYLE="white-space:nowrap">winding-up</FONT> unable to pay its debts (taking into account the continent and
prospective liabilities), be deemed unfair preference of its creditors and be invalid accordingly. Where the conveyance, mortgage, delivery of goods, payment, execution or other action is in favor of a connected person the six month period is
extended to two years. In addition, any such act in favor of a connected person is deemed to be a fraudulent preference and invalid accordingly, unless the contrary is shown. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Section&nbsp;608 of the Irish Companies Act, 2014 (as amended) </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under section 608 of the Irish Companies Act,
2014 (as amended), if it can be shown on the application of a liquidator, creditor or contributory of a company which is being wound up to the satisfaction of the relevant Irish court that any property of such company was disposed of and the effect
of such a disposal was to &#147;perpetrate a fraud&#148; on the company, its creditors or members, the relevant Irish court may, if it deems it just and equitable, order any person who appears to have &#147;use, control or possession&#148; of such
property or the proceeds of the sale or development thereof to deliver it or pay a sum in respect of it to the liquidator on such terms as the relevant Irish court sees fit. In deciding whether it is just and equitable to make an order under section
608, the relevant Irish court must have regard to the rights of persons who have bona fide and for value acquired an interest in the property the subject of the application. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Examinership </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Examinership is a court procedure available under the Irish Companies Act, 2014 (as amended) to
facilitate the survival of Irish companies in financial difficulties. An Irish company which is in financial difficulties, its </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-34 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
directors, its shareholders holding, at the date of presentation of the petition, not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of its voting share capital, or a contingent,
prospective or actual creditor, are each entitled to petition the relevant Irish court for the appointment of an examiner. During the period of examinership, the relevant company is under court protection and rights of creditors are suspended so
that no enforcement action or other legal proceedings can be commenced against such company without the approval of the examiner or the relevant Irish court, as the case may be. Furthermore, the subject company cannot make any payment by way of
satisfaction or discharge of the whole or a part of any liability incurred by it before presentation of a petition except in certain strictly defined circumstances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As per the above the guarantee of the notes by Teleflex Urology may be subject to review under Irish law in the following circumstances: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Teleflex Urology, having become the subject of liquidation proceedings within six months (or two years if the guarantee is given in favor of anyone who is, in
relation to Teleflex Urology, a connected person) of issuing the guarantee, is made the subject of an application by the liquidator, on behalf of Teleflex Urology, to the Irish courts to void the guarantee on the grounds that the issuance of the
guarantee constituted a preference over other creditors at a time when Teleflex Urology was insolvent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">if Teleflex Urology were wound up, the Irish courts, on the application of a liquidator or creditor, may, if it can be shown that the guarantee or any payments
made thereunder constituted a fraud on Teleflex Urology, order a return of payments made by Teleflex Urology under the guarantee; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">if the guarantee is challenged on the grounds that there was no corporate benefit to Teleflex Urology in entering into the guarantee; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Teleflex Urology having become insolvent, or deemed likely to become insolvent, is made the subject of court protection under the examinership procedure (as
discussed more fully above) and the court approves a scheme for the compromise of debts of Teleflex Urology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the laws of
Ireland, a guarantee may only be issued where the entity issuing the guarantee receives sufficient commercial benefit for doing so. If there is insufficient commercial benefit, the beneficiary of the guarantee may not be able to rely on the
authority of the directors of that entity to grant the guarantee and accordingly a court may set aside the guarantee at the request of the entity&#146;s shareholders or a liquidator. In addition, in an insolvency of an Irish company, the claims of
certain preferential creditors (including the Irish Revenue Commissioners for certain unpaid taxes) will rank in priority to claims of unsecured creditors. If Teleflex Urology becomes subject to an insolvency proceeding and Teleflex Urology has
obligations to creditors that are treated under Irish law as creditors that are senior relative to the holders of the notes, the holders of the notes may suffer losses as a result of their subordinated status during such insolvency proceeding.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a court voided the guarantee or any payment under the guarantee of the notes as a result of a fraudulent transfer or held it unenforceable for any
other reason, the rights of holders of the notes under the guarantee would be undermined and such holders could cease to have any claim against Teleflex Urology under its guarantee of the notes. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Enforceability of U.S. judgments in Ireland </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As
Teleflex Urology is incorporated under the laws of Ireland and substantially all of its assets may be located outside the United States. Although it has appointed an agent for service of process in the United States, it may not be possible to
enforce court judgments obtained in the United States in Ireland, based on the civil liability provisions of the U.S. federal or state securities laws. There is some uncertainty as to whether the courts of Ireland would recognize or enforce
judgments of U.S. courts based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions based on those laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-35 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have been advised that the United States currently does not have a treaty with Ireland providing for the
reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S.
federal or state securities laws, would not automatically be enforceable in Ireland. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A judgment of the U.S. courts will be enforced by the Irish courts
if the following general requirements are met: (i) the procedural rules of the U.S. court must have been observed and the U.S. court must have had jurisdiction in relation to the particular defendant according to Irish conflict of law rules (the
submission to jurisdiction by the defendant would satisfy this rule); and (ii) the judgment must be final and conclusive and the decree must be final and unalterable in the court which pronounces it. A judgment can be final and conclusive even if it
is subject to appeal or even if an appeal is pending. Where however, the effect of lodging an appeal under the applicable law is to stay execution of the judgment, it is possible that, in the meantime, the judgment should not be actionable in
Ireland. It remains to be determined whether final judgment given in default of appearance is final and conclusive. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">However, the Irish courts may refuse
to enforce a judgment of the U.S. courts which meets the above requirements for one of the following reasons: (a) if the judgment is not for a definite sum of money; (b) if the judgment was obtained by fraud; (c) if the enforcement of the judgment
in Ireland would be contrary to natural or constitutional justice; (d) if the judgment is contrary to Irish public policy or involves certain United States laws which will not be enforced in Ireland; or (e) if jurisdiction cannot be obtained by the
Irish courts over the judgment debtors in the enforcement proceedings by personal service in Ireland or outside Ireland under Order&nbsp;11 of the Superior Courts Rules. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We may not have the ability to raise the funds necessary to finance the change of control offer required by the indenture. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon the occurrence of a change of control triggering event, we will be required to offer to repurchase all outstanding notes at 101% of the principal amount thereof plus accrued and unpaid interest if any, to, but
not including, the date of repurchase. However, it is possible that we will not have sufficient funds at the time of the change of control triggering event to make the required repurchase of notes or that restrictions in other debt instruments will
not allow such repurchases. We cannot assure that there will be sufficient funds available for us to make any required repurchases of the notes upon a change of control triggering event. In addition, our Credit Agreement and the indentures governing
our 2024 Notes and the 2026 Notes may prohibit or limit us from repurchasing any notes as a result of a change of control triggering event. Because the definition of change of control under our Credit Agreement and the indentures governing our 2024
and the 2026 Notes will differ from that under the indenture that governs the notes, there may be a change of control and resulting default under our Credit Agreement and the indentures governing our 2024 and the 2026 Notes at a time when no change
of control has occurred under the indenture. See &#147;Description of notes&#151;Change of control.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Investors may not be able to determine
when a change of control triggering event giving rise to their right to have the notes repurchased by us has occurred following a sale of &#147;substantially all&#148; of our assets. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A change of control triggering event, as defined in the indenture governing the notes offered hereby, will require us to make an offer to repurchase all outstanding notes. The definition of change of control
includes a phrase relating to the sale, lease or transfer of &#147;all or substantially all&#148; of our assets. There is no precisely established definition of the phrase &#147;substantially all&#148; under applicable law. Accordingly, the ability
of a holder of notes to require us to repurchase their notes as a result of a change of control triggering event may be uncertain. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-36 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Some significant restructuring transactions that may adversely affect you may not constitute a change of
control triggering event, in which case we would not be obligated to offer to repurchase the notes. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the occurrence of a change of control
triggering event (as defined under &#147;Description of notes&#151;Change of control&#148;), you will have the right, at your option, to require us to repurchase your notes for cash. However, the indenture will not afford protection to holders of
notes in the event of other transactions that could adversely affect the notes. Moreover, even if a change of control occurs, if it is not coupled with a ratings decline, holders will not have the right to have their notes repurchased. Transactions
such as leveraged recapitalizations, refinancings, restructurings or acquisitions initiated by us may not constitute a change of control triggering event requiring us to repurchase the notes. In the event of any such transaction, holders of the
notes would not have the right to require us to repurchase their notes, even though each of these transactions could increase the amount of our indebtedness, or otherwise adversely affect our capital structure or any credit ratings, thereby
adversely affecting the holders of notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Any decline in the ratings of our corporate credit could adversely affect the value of the notes.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any decline in the ratings of our corporate credit or any indications from the rating agencies that their ratings on our corporate credit are
under surveillance or review with possible negative implications could adversely affect the value of the notes. In addition, a ratings downgrade could adversely affect our ability to access capital. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>An active trading market for the notes may not develop or be sustained, and the market price for the notes (if any) may be volatile. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes will be new issues of securities for which there is no established trading market. We do not intend to list the notes on any national securities exchange
or include the notes in any automated quotation system. Certain of the underwriters of the notes have advised us that they intend to make a market in the notes, as permitted by applicable laws and regulations. However, such underwriters are not
obligated to make a market in the notes and, if commenced, they may discontinue their market-making activities at any time without notice. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Therefore, an
active market for the notes may not develop or be maintained, which would adversely affect the market price and liquidity of the notes. In that case, the holders of the notes may not be able to sell their notes at a particular time or at a favorable
price. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if an active trading market for the notes does develop, there is no guarantee that it will continue. Historically, the market for <FONT
STYLE="white-space:nowrap">non-investment</FONT> grade debt has been subject to severe disruptions that have caused substantial volatility in the prices of securities similar to the notes. The market, if any, for the notes may experience similar
disruptions and any such disruptions may adversely affect the liquidity in that market or the prices at which you may sell your notes. In addition, subsequent to their initial issuance, the notes may trade at a discount from their initial offering
price, depending upon prevailing interest rates, the market for similar notes, our performance and other factors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-37 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_10"></A>Use of proceeds </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering will be approximately $491.2&nbsp;million, after deducting the underwriters&#146; discount and offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to use such net proceeds to repay approximately $491.2&nbsp;million of borrowings under our revolving credit facility. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of October&nbsp;1, 2017, we had $841.0&nbsp;million of borrowings outstanding under our revolving credit facility, which amount includes $725.0&nbsp;million in
borrowings drawn in September 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017. The final scheduled maturity of our borrowings under our revolving credit facility is January&nbsp;20, 2022, and the borrowings thereunder had
an interest rate of 3.24% as of October&nbsp;1, 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Affiliates of substantially all of the underwriters serve as agents and/or lenders under our
revolving credit facility, and will receive a portion of the net proceeds of this offering in connection with the repayment a portion of the outstanding indebtedness under our revolving credit facility. Accordingly, this offering is being made in
compliance with FINRA Rule 5121. See &#147;Underwriting (conflicts of interest)&#148;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-38 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_11"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth our cash and cash equivalents and capitalization as of October&nbsp;1, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an adjusted basis after giving effect to this offering and the use of the net proceeds therefrom to repay $491.2&nbsp;million of borrowings under our
revolving credit facility. See &#147;Use of proceeds.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This table should be read in conjunction with the information set forth
under the &#147;Use of proceeds&#148; section and the &#147;Description of other indebtedness&#148; section included in this prospectus supplement and our consolidated financial statements and the notes thereto incorporated by reference in this
prospectus supplement and the accompanying prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of October&nbsp;1, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollars in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As adjusted</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">292,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">292,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current borrowings:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable securitization facility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current portion of term loan facility due 2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term borrowings:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revolving credit facility due 2022(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">841,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">349,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Term loan facility due 2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">693,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">693,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">5.25% Senior Notes due 2024</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">4.875%&nbsp;Senior Notes due 2026</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;% Senior Notes due 2027 offered hereby</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total long-term borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,184,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,193,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total indebtedness</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,262,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,270,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,472,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,472,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,734,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,743,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Actual and as adjusted cash and cash equivalents excludes $725.0&nbsp;million that was borrowed under the revolving credit facility in September 2017 and held as cash on our
balance sheet as of October&nbsp;1, 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Actual amount outstanding as of October&nbsp;1, 2017 includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition
that closed on October&nbsp;2, 2017. As of October&nbsp;1, 2017, on an as adjusted basis after giving effect to this offering and the use of the net proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under our revolving credit
facility, we would have had additional borrowing capacity under our revolving credit facility, after taking into account the limitations under the covenants thereunder, of $648.0&nbsp;million. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-39 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_12"></A>Ratio of earnings to fixed charges </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth our historical and pro forma ratios of earnings to fixed charges for the periods indicated. This information should be read in
conjunction with the consolidated financial statements and the accompanying notes incorporated by reference in this prospectus supplement and the accompanying prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Earnings available for fixed charges consist of <FONT STYLE="white-space:nowrap">pre-tax</FONT> earnings from continuing operations before income or loss from equity investees, fixed charges, distributed earnings
of equity investees and amortization of capitalized interest, reduced by <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest income or loss. Fixed charges consist of interest expense, amortization of debt discount and expenses and the
portion of rental expense estimated to be the equivalent of interest. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro forma(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2012</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>October&nbsp;1, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine&nbsp;months&nbsp;ended<BR>October&nbsp;1, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,&nbsp;2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ratio of earnings to fixed charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="32" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The pro forma ratio of earnings gives effect to this offering and the use of the net proceeds therefrom to repay $491.2&nbsp;million of outstanding borrowings under the revolving
credit facility as if such transactions were completed as of January&nbsp;1, 2016. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Due to our loss from continuing operations before taxes for the year ended December&nbsp;31, 2012, the ratio coverage was less than 1:1. We would have needed to generate
additional earnings of $166.7&nbsp;million to achieve a coverage of 1:1. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-40 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_13"></A>Description of other indebtedness </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Amended and restated senior credit facility </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On
January&nbsp;20, 2017, we amended and restated our then-existing senior credit agreement by entering into an Amended and Restated Credit Agreement (the &#147;Credit Agreement&#148;). The Credit Agreement provides for a five-year revolving credit
facility of $1.0&nbsp;billion and a term loan facility of $750.0&nbsp;million. The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of our material domestic subsidiaries and
Teleflex Urology Limited and are secured by a lien on substantially all of the assets owned by us and each guarantor. The maturity date of the revolving credit facility under the credit agreement is January&nbsp;20, 2022 and the term loan facility
will mature on February&nbsp;17, 2022. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At our option, loans under the Credit Agreement bear interest at a rate equal to adjusted LIBOR plus an
applicable margin ranging from 1.25% to 2.50% or at an alternate base rate, which is defined as the highest of (i)&nbsp;the publicly announced prime rate of JPMorgan Chase Bank, N.A., the administrative agent under the Credit Agreement, (ii) 0.5%
above the federal funds rate and (iii) 1% above adjusted LIBOR for a one month interest period on such day, plus an applicable margin ranging from 0.25% to 1.50%, in each case subject to adjustment based on our consolidated total leverage ratio
(generally, the ratio of consolidated total funded indebtedness to consolidated adjusted EBITDA for the four most recent fiscal quarters preceding the date of determination). Overdue loans will bear interest at the rate otherwise applicable to such
loans plus 2.00%. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Credit Agreement contains customary representations and warranties and covenants that, among other things and subject to certain
exceptions, qualifications and thresholds, place limitations on us and our subsidiaries regarding our ability, and the ability of our subsidiaries, to incur additional indebtedness, create additional liens, enter into a merger, consolidation or
amalgamation, dispose of certain assets, make certain investments or acquisitions, pay dividends on, repurchase or make distributions in respect of capital stock and enter into swap agreements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are required to maintain a maximum total consolidated leverage ratio of 4.50 to 1.00 and a maximum consolidated senior secured leverage ratio (generally,
consolidated senior secured funded indebtedness on the date of determination to adjusted consolidated EBITDA for the four most recent quarters preceding the date of determination) of&nbsp;3.50&nbsp;to&nbsp;1.00. We are further required to maintain a
consolidated interest coverage ratio (generally, consolidated adjusted EBITDA for the four most recent fiscal quarters preceding the date of determination to consolidated interest expense paid in cash for such period) of not less
than&nbsp;3.50&nbsp;to&nbsp;1.00. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We capitalized $12.0&nbsp;million related to transaction fees, including underwriters&#146; discounts and commissions,
incurred in connection with the Credit Agreement. In addition, because our entry into the Credit Agreement was considered a partial extinguishment of the indebtedness under our previously outstanding credit agreement, we recognized a loss on
extinguishment of debt of $0.4&nbsp;million during the first quarter 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The term loan facility and borrowings under the revolving credit facility
were used to finance the acquisition of Vascular Solutions. Borrowings under the revolving credit facility were also used to principally finance the acquisition of NeoTract. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of October&nbsp;1, 2017, we were in compliance with all terms of our Credit Agreement and we expect to continue to be in compliance with the terms of this agreement, including the leverage ratio and interest
coverage ratios, throughout 2017. Notwithstanding these restrictions, we believe that the Credit Agreement provides us with significant flexibility to meet our foreseeable working capital needs. As of October&nbsp;1, 2017, we had $721.0&nbsp;million
of term loans outstanding. As of October&nbsp;1, 2017 (which actual amount includes $725.0&nbsp;million in revolving credit facility borrowings drawn in September 2017 to fund the NeoTract acquisition that closed on October&nbsp;2, 2017), after
giving effect to this offering and the use of the net proceeds therefrom, we would have </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-41 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
had $349.8&nbsp;million of outstanding revolving borrowings and an additional $648.0&nbsp;million of borrowing capacity, after taking into account the limitations under the covenants thereunder.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4.875% Senior Notes due 2026 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May&nbsp;16,
2016, we issued $400.0&nbsp;million of 4.875% Senior Notes due 2026. We pay interest on the 2026 Notes semi-annually on June&nbsp;1 and December&nbsp;1, at a rate of 4.875% per year. The 2026 Notes will mature on June&nbsp;1, 2026, unless earlier
redeemed by us at our option, as described below, or purchased by us at the holder&#146;s option under specified circumstances following a change of control or asset sale. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The obligations under the 2026 Notes are guaranteed, jointly and severally, by each of our existing and future subsidiaries that is a guarantor or other obligor under our Credit Agreement and by certain of our
other subsidiaries. The guarantees are full and unconditional, subject to certain customary automatic release provisions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At any time on or after
June&nbsp;1, 2021, we may, on one or more occasions, redeem some or all of the 2026 Notes at a redemption price of 102.438% of the principal amount of the 2026 Notes subject to redemption, declining, in annual increments of 0.813%, to 100% of the
principal amount on June&nbsp;1, 2024, plus accrued and unpaid interest. In addition, at any time prior to June&nbsp;1, 2021, we may, on one or more occasions, redeem some or all of the 2026 Notes at a redemption price equal to 100% of the principal
amount of the 2026 Notes redeemed, plus a &#147;make-whole&#148; premium and any accrued and unpaid interest. The &#147;make-whole&#148; premium is the greater of (a) 1.0% of the principal amount of the 2026 Notes subject to redemption or
(b)&nbsp;the excess, if any, over the principal amount of the 2026 Notes of the present value, on the redemption date of the sum of (i)&nbsp;the June&nbsp;1, 2021 optional redemption price plus (ii)&nbsp;all required interest payments on the 2026
Notes through June&nbsp;1, 2021 (other than accrued and unpaid interest to the redemption date), generally computed using a discount rate equal to the yield to maturity of U.S. Treasury securities with a constant maturity for the period most nearly
equal to the period from the redemption date to June&nbsp;1, 2021, plus 50 basis points. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, at any time prior to June&nbsp;1, 2019, we may, on
one or more occasions, redeem up to 40% of the aggregate principal amount of the 2026 Notes, using the proceeds of specified types of our equity offerings and subject to specified conditions, at a redemption price equal to 104.875% of the principal
amount of the 2026 Notes redeemed, plus accrued and unpaid interest. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indenture relating to the 2026 Notes contains covenants that, among other
things, limit or restrict our ability, and the ability of our subsidiaries, to incur debt, create liens, consolidate, merge or dispose of certain assets, make certain investments, engage in acquisitions, and pay dividends on, repurchase or make
distributions in respect of capital stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5.25% senior notes due 2024 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On May&nbsp;21, 2014, we issued $250.0&nbsp;million of 5.25% Senior Notes due 2024. We pay interest on the 2024 Notes semi-annually on June&nbsp;15 and December&nbsp;15, at a rate of 5.25%&nbsp;per year. The 2024
Notes will mature on June&nbsp;15, 2024, unless earlier redeemed by us at our option, as described below, or purchased by us at the holder&#146;s option under specified circumstances following a change of control or asset sale. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The obligations under the 2024 Notes are guaranteed, jointly and severally, by each of our existing and future subsidiaries that is a guarantor or other obligor
under our Credit Agreement and by certain of our other subsidiaries. The guarantees are full and unconditional, subject to certain customary automatic release provisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-42 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At any time on or after June&nbsp;15, 2019, we may, on one or more occasions, redeem some or all of the 2024
Notes at a redemption price of 102.625% of the principal amount of the 2024 Notes subject to redemption, declining, in annual increments of 0.875%, to 100% of the principal amount on June&nbsp;15, 2022, plus accrued and unpaid interest. In addition,
at any time prior to June&nbsp;15, 2019, we may, on one or more occasions, redeem some or all of the 2024 Notes at a redemption price equal to 100% of the principal amount of the 2024 Notes redeemed plus a &#147;make-whole&#148; premium and any
accrued and unpaid interest. The &#147;make-whole&#148; premium is the greater of (i)&nbsp;1.0% of the principal amount of the 2024 Notes subject to redemption or (ii)&nbsp;the excess, if any, over the principal amount of the 2024 Notes of the
present value, on the redemption date, of the sum of (a)&nbsp;the June&nbsp;15, 2019 optional redemption price, plus (b)&nbsp;all required interest payments on the 2024 Notes through June&nbsp;15, 2019 (other than accrued and unpaid interest to the
redemption date), generally computed using a discount rate equal to the yield to maturity of U.S. Treasury securities with a constant maturity for the period most nearly equal to the period from the redemption date to June&nbsp;15, 2019, plus 50
basis points. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, at any time prior to June&nbsp;15, 2017, we may, on one or more occasions, redeem up to 35% of the aggregate principal amount
of the 2024 Notes, using the proceeds of specified types of our equity offerings and subject to specified conditions, at a redemption price equal to 105.25% of the principal amount of the 2024 Notes redeemed, plus accrued and unpaid interest.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indenture relating to the 2024 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our
subsidiaries, to incur debt, create liens, consolidate, merge or dispose of certain assets, make certain investments, engage in acquisitions, and pay dividends on, repurchase or make distributions in respect of capital stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On March&nbsp;30, 2015, we commenced an exchange offer with respect to the 5.25% Senior Notes due 2024 that initially were issued in May 2014 (the &#147;Old 2024
Notes&#148;), under which the holders of the Old 2024 Notes, which were issued in a private placement, were provided an opportunity to exchange the Old 2024 Notes for new notes (the &#147;New 2024 Notes&#148;) issued pursuant to a registration
statement under the Securities Act. Other than the absence of registration rights for the holders of the New 2024 Notes, the terms of the New 2024 Notes are essentially identical to the terms of the Old 2024 Notes. The exchange offer was completed
on April&nbsp;24, 2015; all of the holders of the Old 2024 Notes exchanged their Old 2024 Notes for New 2024 Notes. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other borrowings </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we have an accounts receivable securitization facility under which accounts receivable of certain domestic subsidiaries are sold on a <FONT
STYLE="white-space:nowrap">non-recourse</FONT> basis to a special purpose entity (&#147;SPE&#148;), which is a bankruptcy-remote consolidated subsidiary of ours. Accordingly, the assets of the SPE are not available to satisfy our obligations or the
obligations of any of our subsidiaries. The SPE sells undivided interests in those receivables to an asset backed commercial paper conduit for consideration of up to $50.0&nbsp;million. This facility is utilized from time to time to provide
increased flexibility in funding short term working capital requirements. The agreement governing the accounts receivable securitization facility contains certain covenants and termination events. An occurrence of an event of default or a
termination event under this facility may give rise to the right of our counterparty to terminate this facility. As of October&nbsp;1, 2017, we were in compliance with the covenants, and none of the termination events had occurred. As of
October&nbsp;1, 2017, we had $50.0&nbsp;million of outstanding borrowings under our accounts receivable securitization facility. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-43 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_14"></A>Description of notes </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You can find the definitions of certain terms used in this description under the subheading &#147;Certain Definitions.&#148; In this description, the word
&#147;Teleflex&#148; refers only to Teleflex Incorporated and not to any of its Subsidiaries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex will issue the notes under an indenture, dated as
of May&nbsp;16, 2016, by and between Teleflex and Wells Fargo Bank, National Association, as trustee. The indenture will be supplemented by a supplemental indenture to be entered into concurrently with the delivery of the notes (as so supplemented,
the &#147;indenture&#148;) The terms of the notes will include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as amended. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following description is a summary of material provisions of the indenture. It does not restate that agreement in its entirety. We urge you to read the indenture because it, and not this description, defines
your rights as a holder of the notes. A copy of the indenture is available as set forth below under &#147;&#151;Additional Information.&#148; Certain defined terms used in this description but not defined below under &#147;&#151;Certain
Definitions&#148; have the meanings assigned to them in the indenture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The registered holder of a note will be treated as the owner of it for all
purposes. Only registered holders will have rights under the indenture. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Brief description of the notes and the note guarantees </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The notes </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be general unsecured obligations of Teleflex; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be <I>pari passu </I>in right of payment with all existing and future senior Indebtedness of Teleflex, including the 2024 Senior Notes and the 2026 Senior
Notes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be senior in right of payment to all future subordinated Indebtedness of Teleflex; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be effectively subordinated to all existing and future secured Indebtedness of Teleflex (including all outstanding term loans and revolver borrowings under
the Credit Agreement) to the extent of the value of the assets securing such Indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be structurally subordinated to all existing and future Indebtedness and other claims and liabilities, including preferred stock, of Subsidiaries of
Teleflex that are not Guarantors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be fully and unconditionally guaranteed by the Guarantors on a senior unsecured basis; <I>provided</I>, <I>however</I>, that all of the guarantees will be
automatically released if the notes are rated Investment Grade by both Moody&#146;s and S&amp;P. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The note guarantees
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes and the indenture will initially be guaranteed on a senior unsecured basis by each of Teleflex&#146;s Domestic Subsidiaries that is a
Wholly-Owned Subsidiary and that is a guarantor or other obligor under a Credit Facility, certain other Domestic Subsidiaries of Teleflex that are Immaterial Subsidiaries and Teleflex Urology Limited. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-44 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each guarantee of the notes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be a general unsecured obligation of the Guarantor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be <I>pari passu </I>in right of payment with all existing and future senior Indebtedness of that Guarantor, including the obligations under its guarantee
of the 2024 Senior Notes and the 2026 Senior Notes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be senior in right of payment to any future subordinated Indebtedness of that Guarantor; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">will be effectively subordinated to all existing and future secured Indebtedness of that Guarantor (including its obligations under any guarantee of, or term
loans and revolver borrowings under, the Credit Agreement) to the extent of the value of the assets securing such Indebtedness. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Not
all of our Subsidiaries will guarantee the notes. In the event of a bankruptcy, liquidation or reorganization of any of these <FONT STYLE="white-space:nowrap">non-guarantor</FONT> Subsidiaries, the
<FONT STYLE="white-space:nowrap">non-guarantor</FONT> Subsidiaries will pay the holders of their debt and other liabilities (including trade payables) before they will be able to distribute any of their assets to us. The <FONT
STYLE="white-space:nowrap">non-guarantor</FONT> Subsidiaries generated approximately 46% of our consolidated net revenue in the year ended December&nbsp;31, 2016, and held approximately 55% of Teleflex&#146;s consolidated assets as of
December&nbsp;31, 2016. See note 17 to our audited consolidated financial statements for the year ended December&nbsp;31, 2016 included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;23, 2017, which
is incorporated by reference herein, for additional information about the division of our consolidated revenues and assets between our guarantor and <FONT STYLE="white-space:nowrap">non-guarantor</FONT> Subsidiaries. For information about the nine
months ended October&nbsp;1, 2017, see note 15 to our interim unaudited consolidated financial statements for the fiscal quarter ended October&nbsp;1, 2017 included in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed
on November&nbsp;2, 2017, which is incorporated by reference herein. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>The indenture will not limit us or our subsidiaries from incurring additional
indebtedness (other than secured Indebtedness) under the indenture, the Credit Facility or any other financing agreement that we may enter in the future. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Principal, maturity and interest </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex will issue $500.0&nbsp;million in aggregate principal amount of
notes in this offering. Teleflex may issue additional notes under the indenture from time to time after this offering. The notes and any additional notes subsequently issued under the indenture will be treated as a single class for all purposes
under the indenture, including, without limitation, waivers, amendments, redemptions and offers to purchase. Unless the context requires otherwise, references to &#147;notes&#148; for all purposes of the indenture and this &#147;Description of
Notes&#148; include any additional notes that are actually issued; <I>provided </I>that additional notes will not be issued with the same CUSIP, if any, as existing notes unless such additional notes are fungible with existing notes for U.S. federal
income tax purposes. Teleflex will issue notes in denominations of $2,000 and integral multiples of $1,000 in excess of $2,000. The notes will mature on November&nbsp;15, 2027. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Interest on the notes will accrue at the rate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% per annum and will be payable semi-annually in arrears on May&nbsp;15 and November&nbsp;15, commencing on
May&nbsp;15, 2018. Teleflex will make each interest payment to the holders of record as of 5:00 p.m., New York City time, on the immediately preceding May&nbsp;1 and November 1. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Interest on the notes will accrue from the date of original issuance or, if interest has already been paid, from the date it was most recently paid. Interest will be computed on the basis of a <FONT
STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. If any interest payment date, the maturity date, any redemption date, or any earlier required repurchase date of a note falls
on a day that is not a business day, the required payment will be made on the next succeeding business day and no interest on such payment will accrue in respect of the delay. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-45 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Methods of receiving payments on the notes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As long as the notes are represented by the global notes, we will pay principal of and interest on those notes to or as directed by The Depository Trust Company (&#147;DTC&#148;) as the registered holder of the
global notes. See &#147;Book-Entry, Delivery and Form.&#148; All other payments on the notes will be made at the office or agency of the paying agent and registrar unless Teleflex elects to direct the paying agent to make interest payments by check
mailed to the noteholders at their address set forth in the register of holders. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Paying agent and registrar for the notes </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The trustee will initially act as paying agent and registrar. Teleflex may change the paying agent or registrar without prior notice to the holders of the notes,
and Teleflex or any of its Subsidiaries may act as paying agent or registrar. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer and exchange </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A holder may transfer or exchange notes in accordance with the provisions of the indenture. The indenture will require holders, among other things, to furnish
appropriate endorsements and transfer documents in connection with a transfer of notes to the registrar and trustee. Holders will be required to pay all taxes due on transfer. Teleflex will not be required to transfer or exchange any note selected
for redemption. Also, Teleflex will not be required to transfer or exchange any note for a period of 15 days before the provision of a notice of redemption of notes to be redeemed. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Note guarantees </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as provided below, the notes and the indenture will be guaranteed on a senior unsecured
basis by each of Teleflex&#146;s Domestic Subsidiaries that is a Wholly-Owned Subsidiary and that is a guarantor or other obligor under a Credit Facility, certain other Domestic Subsidiaries of Teleflex that are Immaterial Subsidiaries and Teleflex
Urology Limited. The Note Guarantees will be joint and several obligations of the Guarantors. The obligations of each Guarantor under its Note Guarantee will be limited as necessary to prevent that Note Guarantee from constituting a fraudulent
conveyance under applicable law. See &#147;Risk factors&#151;Risk related to our indebtedness and this offering&#151;Federal and state statutes allow courts, under specific circumstances, to void guarantees and require note holders to return
payments received from guarantors.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A Guarantor may not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with
or merge with or into (whether or not such Guarantor is the surviving Person) another Person, other than Teleflex or another Guarantor, unless, immediately after giving effect to such transaction, no Default or Event of Default exists. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing, any Guarantor may (i)&nbsp;merge into or transfer all or part of its properties and assets to another Guarantor or Teleflex,
(ii)&nbsp;merge with an Affiliate of Teleflex solely for the purpose of reincorporating or reorganizing the Guarantor in the United States, any state thereof, the District of Columbia or any territory thereof so long as the amount of Indebtedness of
Teleflex and its Subsidiaries is not increased thereby or (iii)&nbsp;convert into a Person organized or existing under the laws of a jurisdiction in the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Note Guarantee of a Guarantor will be automatically and unconditionally released and discharged: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in connection with any sale or other disposition of all or substantially all of the assets of that Guarantor, by way of merger, consolidation or otherwise, to a Person that is
not (either before or after giving effect to such transaction) Teleflex or a Subsidiary of Teleflex; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-46 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in connection with any sale or other disposition of Capital Stock of that Guarantor to a Person that is not (either before or after giving effect to such transaction) Teleflex or
a Subsidiary of Teleflex, if the Guarantor ceases to be a Subsidiary of Teleflex as a result of the sale or other disposition; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to any Guarantor that, as of the date of the indenture, is a guarantor or other obligor with respect to any Indebtedness under any Credit Facility, if that Guarantor
ceases to be a guarantor or other obligor with respect to any such Indebtedness; <I>provided</I>, <I>however</I>, that if, at any time following such release, that Guarantor subsequently guarantees or otherwise becomes an obligor with respect to any
Indebtedness under a Credit Facility, then that Guarantor will be required to provide a Note Guarantee in accordance with the covenant described below under &#147;&#151;Additional Note Guarantees;&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to any Guarantor that, as of the date of the indenture, is not a guarantor or other obligor with respect to any Indebtedness under any Credit Facility, in connection
with any sale or other disposition of all or substantially all of the assets of that Guarantor, by way of merger, consolidation or otherwise, in accordance with the indenture, to any Subsidiary that is not a Guarantor; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">upon legal defeasance, covenant defeasance or satisfaction and discharge of the indenture as provided below under the captions &#147;&#151;Legal Defeasance and Covenant
Defeasance&#148; and &#147;&#151;Satisfaction and Discharge;&#148; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">on the Fall Away Date. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any such release and discharge shall occur
automatically upon the consummation of any such transaction without any further action required of Teleflex, the applicable Guarantor or the trustee; <I>provided </I>that the trustee shall receive an Officer&#146;s Certificate and an Opinion of
Counsel, each stating that all conditions precedent provided for in the indenture relating to such transaction have been complied with. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If on any date
following the date of the indenture: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the notes are rated Investment Grade by both Rating Agencies; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">no Default or Event of Default shall have occurred and be continuing, </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">then, beginning on that day (the &#147;Fall Away Date&#148;) and continuing at all times thereafter regardless of any subsequent changes in the rating of the notes,
the Note Guarantees of each of the Guarantors will be automatically released and the covenant described below under &#147;Additional Note Guarantees&#148; shall cease to apply to the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">There can be no assurance that the notes will ever achieve or maintain an Investment Grade rating. All determinations of the Fall Away Date shall be made by Teleflex and the trustee shall have no obligation to
verify that the Fall Away Date has occurred. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-47 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Optional redemption </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">At any time prior to November&nbsp;15, 2020, Teleflex may on any one or more occasions redeem up to 40% of the aggregate principal amount of notes issued under the indenture (including any additional notes), upon
not less than 15 nor more than 60 days&#146; notice, at a redemption price equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount of the notes redeemed, plus accrued and unpaid interest, if any, to, but not
including, the date of redemption (subject to the rights of holders of notes on the relevant record date to receive interest on the relevant interest payment date), with the net cash proceeds of an Equity Offering; <I>provided </I>that: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">at least 60% of the aggregate principal amount of notes originally issued under the indenture (excluding notes held by Teleflex and its Subsidiaries) remains outstanding
immediately after the occurrence of such redemption; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the redemption occurs within 120 days of the date of the closing of such Equity Offering. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">At any time prior to November&nbsp;15, 2022, Teleflex may on any one or more occasions redeem all or a part of the notes, upon not less than 15 nor more than 60 days&#146; notice, at a redemption price equal to
100% of the principal amount of the notes redeemed, plus the Applicable Premium as of, and accrued and unpaid interest, if any, to, but not including, the date of redemption, subject to the rights of holders of notes on the relevant record date to
receive interest due on the relevant interest payment date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except pursuant to the preceding paragraphs, the notes will not be redeemable at
Teleflex&#146;s option prior to November&nbsp;15, 2022. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On or after November&nbsp;15, 2022, Teleflex may on any one or more occasions redeem all or a
part of the notes, upon not less than 15 nor more than 60 days&#146; notice, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest, if any, on the notes redeemed, to, but not
including, the applicable date of redemption, if redeemed during the twelve-month period beginning on November&nbsp;15 of the years indicated below, subject to the rights of holders of notes on the relevant record date to receive interest on the
relevant interest payment date: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2023</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2024</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2025 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.000%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless Teleflex defaults in the payment of the redemption price, interest will cease to accrue on the notes or portions thereof
called for redemption on the applicable redemption date. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Selection and notice </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If less than all of the notes are to be redeemed at any time, the trustee will select notes for redemption on a <I>pro rata </I>basis (or, in the case of notes issued in global form as discussed under
&#147;Book-Entry, Delivery and Form,&#148; based on a method that most nearly approximates a <I>pro rata </I>selection as the trustee deems fair and appropriate and in accordance with the applicable procedures of the depositary) unless otherwise
required by law or applicable stock exchange or depositary requirements. No notes of $2,000 or less can be redeemed in part. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notices of redemption will
be delivered electronically in portable document format (&#147;pdf&#148;) or mailed by first class mail at least 15 but not more than 60 days before the redemption date to each holder of notes to be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-48 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
redeemed at its registered address or otherwise in accordance with the procedures of DTC, except that redemption notices may be mailed more than 60 days prior to a redemption date if the notice
is issued in connection with a defeasance of the notes or a satisfaction and discharge of the indenture. Any notice of any redemption may, at Teleflex&#146;s discretion, be subject to one or more conditions precedent, including, but not limited to,
availability of borrowings under any Credit Facility, completion of a sale of common stock or other securities offering or corporate transaction. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing, in connection with any tender offer for the notes, including a Change of Control Offer, if Holders of not less than 90% in aggregate
principal amount of the outstanding notes validly tender and do not withdraw such notes in such tender offer and Teleflex or any third party making such tender offer in lieu of Teleflex, purchases all of the notes validly tendered and not withdrawn
by such holders, Teleflex or such third party will have the right upon not less than 15 nor more than 60 days&#146; prior notice, given not more than 15 days following such purchase date, to redeem all notes that remain outstanding following such
purchase at a redemption price equal to the price offered to each other holder in such tender offer plus, to the extent not included in the tender offer payment, accrued and unpaid interest, if any, thereon, to, but not including, the date of such
redemption; <I>provided</I>, that such redemption price shall not be less than 100% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, thereon, to, but not including, the date of such redemption.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If such notice of redemption is subject to satisfaction of one or more conditions precedent, such notice shall state that, in Teleflex&#146;s
discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied (which, for the avoidance of doubt, may be later than 60 days from the date such notice was delivered or mailed), or such redemption may
not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the redemption date, or by the redemption date so delayed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If any note is to be redeemed in part only, the notice of redemption that relates to that note will state the portion of the principal amount of that note that is to be redeemed. A new note in principal amount
equal to the unredeemed portion of the original note will be issued in the name of the holder of notes upon cancellation of the original note. Notes called for redemption become due on the date fixed for redemption, unless such redemption is
conditioned on the happening of a future event. On the redemption date, interest ceases to accrue on notes or portions of notes redeemed unless Teleflex defaults in paying the applicable redemption price. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Mandatory redemption; open market purchases </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex is not
required to make mandatory redemption or sinking fund payments with respect to the notes. Teleflex may at any time and from time acquire notes by tender offer, open market purchases, negotiated transactions or otherwise. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Change of control </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a Change of Control occurs and is
accompanied by a Ratings Event (together, a &#147;Change of Control Triggering Event&#148;), each holder of notes will have the right to require Teleflex to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess
thereof) of that holder&#146;s notes pursuant to an offer by Teleflex (a &#147;Change of Control Offer&#148;) on the terms set forth in the indenture. In the Change of Control Offer, Teleflex will offer a payment in cash equal to 101% of the
aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to, but not including, the date of purchase (the &#147;Change of Control Payment&#148;), subject to the rights of holders of notes on
the relevant record date to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-49 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
receive interest due on the relevant interest payment date. Within thirty days following any Change of Control Triggering Event, Teleflex will deliver electronically in pdf format or mail a
notice to each holder with a copy to the trustee or otherwise in accordance with the procedures of DTC describing the transaction or transactions that constitute the Change of Control Triggering Event and offering to repurchase notes on the date
specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed or otherwise delivered (a &#147;Change of Control Payment Date&#148;), pursuant to the procedures required by the
indenture and described in such notice. Teleflex will comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14e-1</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and any other securities
laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a Change of Control Offer. To the extent that the provisions of any securities laws or regulations
conflict with the Change of Control Offer provisions of the indenture, Teleflex will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control Offer provisions of
the indenture by virtue of such compliance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On the Change of Control Payment Date, Teleflex will, to the extent lawful: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or portions of notes properly tendered; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">deliver or cause to be delivered to the trustee the notes properly accepted together with an officer&#146;s certificate stating the aggregate principal amount of notes or
portions of notes being repurchased by Teleflex. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The paying agent will promptly send to each holder of notes properly tendered the Change
of Control Payment for such notes, and the trustee will promptly authenticate and mail (or cause to be transferred by book entry in accordance with the applicable procedures of DTC) to each holder a new note equal in principal amount to any
unpurchased portion of the notes surrendered, if any. Teleflex will publicly announce the results of the Change of Control Offer on or as soon as practicable after the Change of Control Payment Date. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The provisions described above that require Teleflex to make a Change of Control Offer following a Change of Control Triggering Event will be applicable whether or
not any other provisions of the indenture are applicable. Except as described above with respect to a Change of Control Triggering Event, the indenture does not contain provisions that permit the holders of the notes to require that Teleflex
repurchase or redeem the notes in the event of a takeover, recapitalization or similar transaction. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex will not be required to make a Change of
Control Offer upon a Change of Control Triggering Event if: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in the indenture applicable to a Change of
Control Offer made by Teleflex and purchases all notes properly tendered and not withdrawn under the Change of Control Offer; <I>provided</I>, <I>however</I>, in the event that such third party terminates, or defaults under, its offer, Teleflex will
be required to make a Change of Control Offer treating the date of such termination or default as though it were the date of the Change of Control Triggering Event; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">notice of redemption has been given pursuant to the indenture as described above under the caption &#147;&#151;Optional Redemption,&#148; unless and until there is a default in
payment of the applicable redemption price. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding anything to the contrary contained herein, a Change of Control Offer may be
made in advance of a Change of Control Triggering Event, conditioned upon the consummation of such Change of Control </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-50 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Triggering Event, if a definitive agreement is in place for the Change of Control at the time the Change of Control Offer is made. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To the extent Teleflex is required to offer to repurchase the notes upon the occurrence of a Change of Control, Teleflex may not have sufficient funds to repurchase the notes in cash at such time. In addition,
Teleflex&#146;s ability to repurchase the notes for cash may be limited by law or the terms of other agreements relating to Teleflex&#146;s indebtedness outstanding at the time. The failure to make such repurchase would result in a default under the
indenture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Credit Agreement limits, and future credit agreements or other agreements relating to Indebtedness to which Teleflex becomes a party may
prohibit or limit, Teleflex from repurchasing any notes as a result of a Change of Control Triggering Event. In the event a Change of Control Triggering Event occurs at a time when Teleflex is prohibited from repurchasing the notes, Teleflex could
seek the consent of the holders of such Indebtedness to permit the repurchase of the notes or could attempt to refinance such Indebtedness that contains such prohibition. If Teleflex does not obtain such consent or repay such Indebtedness, Teleflex
will remain prohibited from repurchasing the notes. In such case, Teleflex&#146;s failure to repurchase tendered notes would constitute an Event of Default under the indenture. In addition, the Credit Agreement provides that certain change of
control events with respect to Teleflex constitute a default thereunder. If Teleflex experiences a change of control that triggers a default under the Credit Agreement, Teleflex could seek a waiver of such default or seek to refinance the Credit
Agreement. In the event Teleflex does not obtain such a waiver or refinance the Credit Agreement, such default could result in amounts outstanding under the Credit Agreement being declared due and payable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The definition of Change of Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance or other disposition of &#147;all or
substantially all&#148; of the properties or assets of Teleflex and its Subsidiaries taken as a whole. Although there is a limited body of case law interpreting the phrase &#147;substantially all,&#148; there is no precise established definition of
the phrase under applicable law. Accordingly, the ability of a holder of notes to require Teleflex to repurchase its notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of the assets of Teleflex and its
Subsidiaries taken as a whole to another Person or group may be uncertain. See &#147;Risk factors&#151;Risks related to our indebtedness and this offering&#151;Investors may not be able to determine when a change of control triggering event giving
rise to their right to have the notes repurchased by us has occurred following a sale of &#147;substantially all&#148; of our assets.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Certain
covenants </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Liens </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as described
under &#147;&#151;Exceptions to Limitations&#148; below, Teleflex will not and will not permit any of its Subsidiaries to, create, incur, assume or otherwise cause or suffer to exist or become effective any Lien of any kind (other than Permitted
Liens) securing Indebtedness upon any of their property or assets, now owned or hereafter acquired, unless (1)&nbsp;in the case of any Lien securing <I>pari passu </I>Indebtedness, the notes are secured by a Lien that is senior in priority to or
<I>pari passu </I>with such Lien and (2)&nbsp;in the case of any Lien securing subordinated Indebtedness, the notes are secured by a Lien that is senior in priority to such Lien. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Any Lien created for the benefit of the holders of the notes pursuant to the preceding paragraph will provide by its terms that any such Lien shall be automatically and unconditionally released and discharged upon
the release and discharge of the Lien on such other Indebtedness, without any further action required of Teleflex, any Subsidiary or the trustee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
expansion of Liens by virtue of accrual of interest, the accretion of accreted value, the payment of interest or dividends in the form of additional Indebtedness, amortization of original issue discount and increases in the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-51 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
amount of Indebtedness outstanding solely as a result of fluctuations in the exchange rate of currencies or increases in the value of property securing Indebtedness will not be deemed to be an
incurrence of Liens for purposes of this covenant. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining compliance with this covenant, (x)&nbsp;a Lien need not be incurred
solely by reference to one category of Permitted Liens but may be incurred under any combination of such categories (including in part under one such category and in part under any other such category) and (y)&nbsp;in the event that a Lien (or any
portion thereof) meets the criteria of one or more of such categories of Permitted Liens or may be incurred in compliance with the terms described under &#147;&#151;Exceptions to Limitations&#148; below, the Teleflex shall, in its sole discretion,
classify or may subsequently reclassify at any time such Lien (or any portion thereof) in any manner that complies with this covenant (including by complying with the terms described under &#147;Exceptions to Limitations&#148; below) and the
definition of Permitted Liens. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sale and lease back transactions </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Except as described under &#147;&#151;Exceptions to Limitations&#148; below, Teleflex will not, and will not permit any of its Subsidiaries to, engage in the sale or transfer by Teleflex or any Subsidiary of any
property to a Person (other than Teleflex or a Subsidiary) and the taking back by Teleflex or such Subsidiary, as the case may be, of a lease of such property (a &#147;Sale and Leaseback Transaction&#148;) unless: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex or such Subsidiary could incur Indebtedness secured by a Lien on the property to be leased without equally and ratably securing the notes; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the property leased pursuant to such arrangement is sold for a price at least equal to such property&#146;s fair value (as determined by Teleflex in good faith); or
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">within 365 days of the effective date of any such Sale and Lease Back Transaction, Teleflex applies the Net Proceeds of the sale of the leased property, less the amount of Net
Proceeds used to prepay, redeem or purchase the notes, (i)&nbsp;to the prepayment or retirement of Indebtedness of Teleflex and its Subsidiaries (which may include the notes) and/or (ii)&nbsp;the acquisition, construction or improvement of any
property or assets. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exceptions to limitations </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing covenant provisions described above under &#147;&#151;Liens&#148; and &#147;&#151;Sale and Lease Back Transactions,&#148; Teleflex and any Subsidiary may (1)&nbsp;create, incur or
assume any Lien upon any property or assets, or (2)&nbsp;consummate any Sale and Lease Back Transaction if: (i)&nbsp;the aggregate outstanding principal amount of all secured Indebtedness for borrowed money of Teleflex and its Subsidiaries that is
secured by Liens on any of their property or assets, now owned or hereafter acquired, plus (ii)&nbsp;the aggregate Attributable Indebtedness in respect of Sale and Lease Back Transactions that is subject to the restriction on Sale and Lease Back
Transactions described above does not exceed an amount that would cause the Consolidated Net Secured Leverage Ratio for the period immediately preceding the creation, incurrence or assumption of such a Lien or consummation of such Sale and Lease
Back Transaction, as applicable, to be greater than 3.50 to 1.00, calculated on a <I>pro forma </I>basis after giving effect to the creation, incurrence or assumption of such Lien described above and/or such Attributable Indebtedness in respect of
Sale and Lease Back Transactions that is subject to the restriction on Sale and Lease Back Transactions described above. Teleflex and any Subsidiary may guarantee any Lien created, incurred or assumed and any Sale and Lease Back Transaction
consummated, in each case, in compliance with the terms described in this paragraph. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event any Lien is created, incurred or assumed or any Sale
and Lease Back Transaction is consummated, in each case, in reliance upon compliance with the Consolidated Net Secured Leverage Ratio described above, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-52 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
concurrently with creation, incurrence or assumption of any Permitted Lien, then solely for purposes of calculating the Consolidated Net Secured Leverage Ratio at such time (but, for the
avoidance of doubt, not in any subsequent calculation of the Consolidated Net Secured Leverage Ratio at a subsequent time), the Consolidated Net Secured Leverage Ratio will be calculated without regard to the creation, incurrence or assumption of
any such Permitted Lien. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Merger, consolidation or sale of assets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Teleflex will not, directly or indirectly: (1)&nbsp;consolidate or merge with or into another Person (whether or not Teleflex is the surviving corporation), or (2)&nbsp;sell, assign, transfer, lease, convey or
otherwise dispose of all or substantially all of the properties or assets of Teleflex and its Subsidiaries taken as a whole, in one or more related transactions, to another Person, unless: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">either: (a)&nbsp;Teleflex is the surviving corporation; or (b)&nbsp;the Person formed by or surviving any such consolidation or merger (if other than Teleflex) or to which such
sale, assignment, transfer, lease, conveyance or other disposition has been made (the &#147;Successor Company&#148;) is an entity organized or existing under the laws of the United States, any state of the United States or the District of Columbia;
and, if such entity is not a corporation, a <FONT STYLE="white-space:nowrap">co-obligor</FONT> of the notes is a corporation organized or existing under any such laws; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Successor Company (if other than Teleflex) assumes all the obligations of Teleflex under the notes and the indenture pursuant to a supplemental indenture substantially in the
form attached to the indenture or pursuant to other documents or instruments reasonably satisfactory to the trustee; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">immediately after such transaction, no Default or Event of Default exists. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Successor Company will succeed to, and be substituted for, Teleflex under the indenture and the notes and Teleflex will automatically be released and discharged from its obligations under the indenture and the
notes, but in the case of a lease of all or substantially all of the properties and assets of Teleflex and its Subsidiaries taken as a whole, Teleflex will not be released from the obligation to pay the principal of and interest on the notes.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the immediately preceding clause (3)&nbsp;of the first paragraph of this covenant, </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(1) Teleflex or any Subsidiary may consolidate or amalgamate with or merge with or into or transfer all or part of its properties and assets to Teleflex or another
Subsidiary, and </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(2) Teleflex may merge with or into an Affiliate solely for the purpose of reincorporating Teleflex in another jurisdiction. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Additional note guarantees </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If Teleflex or any of its
Subsidiaries acquires or creates another Domestic Subsidiary that is a Wholly-Owned Subsidiary after the date of the indenture that guarantees or otherwise becomes an obligor with respect to any Indebtedness of Teleflex or any of its Subsidiaries
under a Credit Facility, then such Domestic Subsidiary will become a Guarantor and execute a supplemental indenture and deliver an opinion of counsel to the trustee within 45 business days of the date such Domestic Subsidiary guarantees or otherwise
becomes an obligor with respect to any Indebtedness of Teleflex or any of its Subsidiaries under a Credit Facility; <I>provided </I>that any such Domestic Subsidiary that constitutes an Immaterial Subsidiary, a Captive Insurance Subsidiary or a
Securitization Subsidiary, as the case may be, need not become a Guarantor until such time as it ceases to be an Immaterial Subsidiary, a Captive Insurance Subsidiary or a Securitization Subsidiary, as the case may be. Each
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-53 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Note Guarantee of a Domestic Subsidiary that is a Wholly-Owned Subsidiary will provide by its terms that it will be automatically released under the circumstances described above under the
caption &#147;&#151;Note Guarantees.&#148; Beginning on the Fall Away Date and continuing at all times thereafter regardless of any subsequent changes in the rating of the notes, this covenant will permanently cease to be in effect with respect to
the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex may elect, in its sole discretion, to cause any Subsidiary that is not otherwise required to be a Guarantor to become a Guarantor,
in which case such Subsidiary shall not be required to comply with the 45 business day period described above. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Reports </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whether or not required by the rules and regulations of the SEC, so long as any notes are outstanding, Teleflex will furnish to the holders of notes or cause the
trustee to furnish to the holders of notes, within the time periods specified in the SEC&#146;s rules and regulations (giving effect to any grace period provided by Rule <FONT STYLE="white-space:nowrap">12b-25</FONT> under the Exchange Act):
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all quarterly and annual reports that would be required to be filed with the SEC on Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> and
<FONT STYLE="white-space:nowrap">10-K</FONT> if Teleflex were required to file such reports, including a &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and, with respect to the annual
information only, a report thereon by Teleflex&#146;s certified independent accountants; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all current reports that would be required to be filed with the SEC on Form <FONT STYLE="white-space:nowrap">8-K</FONT> if Teleflex were required to file such reports.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All such reports will be prepared in all material respects in accordance with all of the rules and regulations applicable to such reports.
In addition, Teleflex will file a copy of each of the reports referred to in clauses (1)&nbsp;and (2) above with the SEC for public availability within the time periods specified in the rules and regulations (giving effect to any grace period
provided by Rule <FONT STYLE="white-space:nowrap">12b-25</FONT> under the Exchange Act) applicable to such reports (unless the SEC will not accept such a filing) and will post the reports on its website within those time periods. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of this covenant, reports filed by us with the SEC via the EDGAR system or any successor system will be deemed to be furnished to the holders of the
notes as of the time such reports are filed with EDGAR or such successor system. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Trustee shall have no responsibility whatsoever to monitor whether
such filing or posting referred to in the immediately preceding two paragraphs has occurred. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Delivery of such reports, information and documents to the
Trustee is for informational purposes only and the Trustee&#146;s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including Teleflex&#146;s compliance
with any of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on officer&#146;s certificates). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If, at any time, Teleflex
is no longer subject to the periodic reporting requirements of the Exchange Act for any reason, Teleflex will nevertheless continue filing the reports specified in the preceding paragraphs of this covenant with the SEC within the time periods
specified above unless the SEC will not accept such a filing. Teleflex will not take any action for the purpose of causing the SEC not to accept any such filings. If, notwithstanding the foregoing, the SEC will not accept Teleflex&#146;s filings for
any reason, Teleflex will post the reports referred to in the preceding paragraphs on its website within the time periods that would apply if Teleflex were required to file those reports with the SEC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-54 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any direct or indirect parent company of Teleflex becomes a Guarantor, the indenture will permit Teleflex to
satisfy its obligations in this covenant with respect to financial information relating to Teleflex by furnishing financial information relating to such other parent Guarantor; <I>provided </I>that if and so long as such parent Guarantor shall have
Independent Assets or Operations (as defined below), the same is accompanied by consolidating information that explains in reasonable detail the differences between the information relating to such parent Guarantor, on the one hand, and the
information relating to Teleflex and its Subsidiaries on a standalone basis, on the other hand. &#147;Independent Assets or Operations&#148; means, with respect to any such parent Guarantor, that such parent Guarantor&#146;s total assets or
revenues, determined in accordance with GAAP and as shown on the most recent financial statements of such parent Guarantor, is more than 3.0% of such parent Guarantor&#146;s corresponding consolidated amount. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Events of default and remedies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each of the following is an
&#147;Event of Default&#148; under the indenture: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">default for 30 days in the payment when due of interest on the notes; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">default in the payment when due (at maturity, upon redemption or otherwise) of the principal of, or premium, if any, on, the notes; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">failure by Teleflex or any of its Subsidiaries to comply with the provisions described under the caption &#147;&#151;Certain Covenants&#151;Merger, Consolidation or Sale of
Assets&#148; for 30 days after notice to Teleflex by the trustee or the holders of at least 25% in aggregate principal amount of the notes then outstanding; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">failure by Teleflex or any of its Subsidiaries for 60 days after notice to Teleflex by the trustee or the holders of at least 25% in aggregate principal amount of the notes then
outstanding to comply with any of the other agreements in the indenture; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">default with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which may be secured or evidenced any Indebtedness for money
borrowed in excess of $100.0&nbsp;million in the aggregate by Teleflex or any of its Subsidiaries, whether such Indebtedness or Guarantee now exists or is created after the date of the indenture, if that default: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">constitutes a failure to pay the principal or interest of any such Indebtedness or Guarantee when due and payable at its stated maturity, upon required repurchase, upon
declaration or otherwise (a &#147;Payment Default&#148;); or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">results in such Indebtedness becoming or being declared due and payable; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">failure by Teleflex or any of its Subsidiaries to pay final judgments entered by a court or courts of competent jurisdiction aggregating in excess of $100.0&nbsp;million, which
judgments are not paid, discharged or stayed, for a period of 60 days; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">prior to the Fall Away Date, except as permitted by the indenture, any Note Guarantee of any Guarantor that is a Significant Subsidiary, or any group of Guarantors that, taken
together, would constitute a Significant Subsidiary, is held in any judicial proceeding to be unenforceable or invalid or ceases for any reason to be in full force and effect, or any Guarantor that is a Significant Subsidiary, or any group of
Guarantors that, taken together, would constitute a Significant Subsidiary, or any Person acting on behalf of any such Guarantor or group of Guarantors, denies or disaffirms its obligations under its Note Guarantee; and </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-55 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">certain events of bankruptcy or insolvency described in the indenture with respect to Teleflex or any of its Subsidiaries that is a Significant Subsidiary or any group of its
Subsidiaries that, taken together, would constitute a Significant Subsidiary. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the case of an Event of Default arising from certain
events of bankruptcy or insolvency, with respect to Teleflex, any Subsidiary of Teleflex that is a Significant Subsidiary or any group of Subsidiaries of Teleflex that, taken together, would constitute a Significant Subsidiary, all outstanding notes
will become due and payable immediately without further action or notice. If any other Event of Default occurs and is continuing, the trustee or the holders of at least 25% in aggregate principal amount of the then outstanding notes may declare all
the notes to be due and payable immediately. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to certain limitations, holders of a majority in aggregate principal amount of the then outstanding
notes may direct the trustee in its exercise of any trust or power. The trustee may withhold from holders of the notes notice of any continuing Default or Event of Default if it determines that withholding notice is in their interest, except a
Default or Event of Default relating to the payment of principal of, premium on, if any, and interest. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In case an Event of Default occurs and is
continuing, the trustee will be under no obligation to exercise any of the rights or powers under the indenture at the request or direction of any holders of notes unless such holders have offered to the trustee indemnity or security satisfactory to
the trustee against any loss, liability or expense. Except to enforce the right to receive payment of principal, premium, if any, or interest when due, no holder of a note may pursue any remedy with respect to the indenture or the notes unless:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">such holder has previously given the trustee written notice that an Event of Default is continuing; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">holders of at least 25% in aggregate principal amount of the then outstanding notes make a written request to the trustee to pursue the remedy; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">such holder or holders offer and, if requested, provide to the trustee security or indemnity satisfactory to the trustee against any loss, liability or expense;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the trustee does not comply with such request within 60 days after receipt of the request and the offer of security or indemnity; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">during such <FONT STYLE="white-space:nowrap">60-day</FONT> period, holders of a majority in aggregate principal amount of the then outstanding notes do not give the trustee a
direction inconsistent with such request. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The holders of a majority in aggregate principal amount of the then outstanding notes by written
notice to the trustee may, on behalf of the holders of all of the notes, rescind an acceleration or waive any existing Default or Event of Default and its consequences under the indenture, if the rescission would not conflict with any judgment or
decree, except a continuing Default or Event of Default in the payment of principal of, premium on, if any, or interest on, the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of
any Event of Default specified in clause (6)&nbsp;in the first paragraph under the heading &#147;Events of Default and Remedies&#148; above, such Event of Default and all consequences thereof (excluding any resulting payment default, other than as a
result of acceleration of the notes) shall be annulled, waived and rescinded, automatically and without any action by the Trustee or the holders, if within 20 days after such Event of Default arose: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Indebtedness or Guarantee that is the basis for such Event of Default has been discharged; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">holders thereof have rescinded or waived the acceleration, notice or action (as the case may be) giving rise to such Event of Default; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the default that is the basis for such Event of Default has been cured. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-56 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to certain restrictions, the holders of a majority in principal amount of the total outstanding notes are
given the right to direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee or of exercising any trust or power conferred on the trustee. The trustee, however, may refuse to follow any
direction that conflicts with law or the indenture or that the trustee determines is unduly prejudicial to the rights of any other holder of a note or that could result in personal liability for the trustee. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex is required to deliver to the trustee annually a statement regarding compliance with the indenture. Within 30 days of becoming aware of any Default or
Event of Default that is continuing, Teleflex is required to deliver to the trustee a statement specifying such Default or Event of Default and how Teleflex plans to resolve such Default or Event of Default. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>No personal liability of directors, officers, employees and stockholders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">No director, officer, employee, incorporator or stockholder of Teleflex or any Guarantor, as such, will have any liability for any obligations of Teleflex or the Guarantors under the notes, the indenture, the Note
Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each holder of notes by accepting a note waives and releases all such liability. The waiver and release are part of the consideration for
issuance of the notes. The waiver may not be effective to waive liabilities under the federal securities laws and it is the view of the SEC that such a waiver is against public policy. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Legal defeasance and covenant defeasance </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Teleflex may, at its option and at any time, elect to have all of its
obligations discharged with respect to the outstanding notes and all obligations of the Guarantors discharged with respect to their Note Guarantees (&#147;Legal Defeasance&#148;) except for: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the rights of holders of outstanding notes to receive payments in respect of the principal of, premium on, if any, or interest on, such notes when such payments are due from the
trust referred to below; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex&#146;s obligations with respect to the notes concerning issuing temporary notes, registration of notes, mutilated, destroyed, lost or stolen notes and the maintenance of
an office or agency for payment and money for security payments held in trust; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the rights, powers, trusts, duties and immunities of the trustee under the indenture, and Teleflex&#146;s and the Guarantors&#146; obligations in connection therewith; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Legal Defeasance and Covenant Defeasance provisions of the indenture. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, Teleflex may, at its option and at any time, elect to have the obligations of Teleflex and the Guarantors released with respect to certain covenants (including its obligation to make Change of Control
Offers) that are described in the indenture (&#147;Covenant Defeasance&#148;) and thereafter any omission to comply with those covenants will not constitute a Default or Event of Default with respect to the notes. In the event Covenant Defeasance
occurs, all Events of Default described under &#147;&#151;Events of Default and Remedies&#148; (except those relating to payments on the notes or bankruptcy, receivership, rehabilitation or insolvency events) will no longer constitute an Event of
Default with respect to the notes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In order to exercise either Legal Defeasance or Covenant Defeasance: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Teleflex must irrevocably deposit with the trustee, in trust, for the benefit of the holders of the notes, cash in U.S. dollars,
<FONT STYLE="white-space:nowrap">non-callable</FONT> Government Securities, or a combination thereof, in amounts as will be sufficient, in the opinion of a nationally recognized investment bank, appraisal firm or firm of independent
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-57 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
public accountants, to pay the principal of, premium on, if any, and interest on, the outstanding notes on the stated date for payment thereof or on the applicable redemption date, as the case
may be, and Teleflex must specify whether the notes are being defeased to such stated date for payment or to a particular redemption date; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in the case of Legal Defeasance, Teleflex must deliver to the trustee an opinion of counsel confirming that (a)&nbsp;Teleflex has received from, or there has been published by,
the Internal Revenue Service a ruling or (b)&nbsp;since the date of the indenture, there has been a change in the applicable federal income tax law (or official interpretation thereof), in either case to the effect that, and based thereon such
opinion of counsel will confirm that, the holders of the outstanding notes will not recognize income, gain or loss for federal income tax purposes as a result of such Legal Defeasance and will be subject to federal income tax on the same amounts, in
the same manner and at the same times as would have been the case if such Legal Defeasance had not occurred; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in the case of Covenant Defeasance, Teleflex must deliver to the trustee an opinion of counsel confirming that the holders of the outstanding notes will not recognize income,
gain or loss for federal income tax purposes as a result of such Covenant Defeasance and will be subject to federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such Covenant Defeasance had
not occurred; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">no Default or Event of Default has occurred and is continuing on the date of such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be
applied to such deposit (and any similar concurrent deposit relating to other Indebtedness), and the granting of Liens to secure such borrowings); </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">such Legal Defeasance or Covenant Defeasance will not result in a breach or violation of, or constitute a default under, any material agreement or instrument (other than the
indenture and the agreements governing any other Indebtedness being defeased, discharged or replaced) to which Teleflex or any of the Guarantors is a party or by which Teleflex or any of the Guarantors is bound (other than a Default or Event of
Default resulting from the borrowing of funds to be applied to such deposit (and any similar concurrent deposit relating to other Indebtedness) and the granting of Liens to secure such borrowings); </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex must deliver to the trustee an officer&#146;s certificate stating that the deposit was not made by Teleflex with the intent of preferring the holders of notes over the
other creditors of Teleflex with the intent of defeating, hindering, delaying or defrauding any creditors of Teleflex or others; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex must deliver to the trustee an officer&#146;s certificate and an opinion of counsel, each stating that all conditions precedent relating to the Legal Defeasance or the
Covenant Defeasance have been complied with. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Amendment, supplement and waiver </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as provided in the next three succeeding paragraphs, the indenture or the notes or the Note Guarantees may be amended or supplemented with the consent of the
holders of at least a majority in aggregate principal amount of the then outstanding notes (including, without limitation, additional notes, if any) voting as a single class (including, without limitation, consents obtained in connection with a
tender offer or exchange offer for, or purchase of, the notes), and any existing Default or Event of Default (other than a Default or Event of Default in the payment of the principal of, premium on, if any, or interest on, the notes, except a
payment default resulting from an acceleration that has been rescinded) or compliance with any provision of the indenture or the notes or the Note Guarantees may be waived with the consent of the holders of a majority in aggregate
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-58 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
principal amount of the then outstanding notes (including, without limitation, additional notes, if any) voting as a single class (including, without limitation, consents obtained in connection
with a purchase of, or tender offer or exchange offer for, notes). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Without the consent of each holder of notes affected, an amendment, supplement or
waiver may not (with respect to any notes held by a <FONT STYLE="white-space:nowrap">non-consenting</FONT> holder): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">reduce the principal amount of notes whose holders must consent to an amendment, supplement or waiver; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">reduce the principal of or change the fixed maturity of any note or alter or waive any of the provisions with respect to the redemption of the notes (for the avoidance of doubt,
the provisions with respect to the redemption of the notes referred to in this clause (2)&nbsp;do not include the provisions relating to the covenants described above under the caption &#147;&#151;Change of Control&#148;); </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">reduce the rate of or change the time for payment of interest on any note; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">waive a Default or Event of Default in the payment of principal of, premium on, if any, or interest on, the notes (except a rescission of acceleration of the notes by the holders
of at least a majority in aggregate principal amount of the then outstanding notes and a waiver of the payment default that resulted from such acceleration); </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">make any note payable in money other than that stated in the notes; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">make any change in the provisions of the indenture relating to waivers of past Defaults; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">amend the contractual right expressly set forth in the indenture or notes of holders to receive payments of principal of, premium on, if any, or interest on, the notes on or
after the due dates therefor or to institute suit to enforce such payment; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">waive a redemption payment with respect to any note (other than a payment required by the covenant described above under the caption &#147;&#151;Change of Control&#148;);
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">prior to the Fall Away Date, release any Guarantor that is a Significant Subsidiary (or any group of Guarantors that, taken together, as of the latest audited consolidated
financial statements for Teleflex would constitute a Significant Subsidiary) from any of its obligations under its Note Guarantee or the indenture, except in accordance with the terms of the indenture; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">make any change in the preceding amendment and waiver provisions. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the preceding, without the consent of any holder of notes, Teleflex, the Guarantors and the trustee may amend or supplement the indenture, the notes
or the Note Guarantees: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to cure any ambiguity, defect or inconsistency; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to provide for uncertificated notes in addition to or in place of certificated notes; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to provide for the assumption of Teleflex&#146;s obligations to holders of notes in the case of a merger or consolidation or sale of all or substantially all of Teleflex&#146;s
assets; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to make any change that would provide any additional rights or benefits to the holders of notes or that does not adversely affect the legal rights under the indenture of any
holder; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-59 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to conform the text of the indenture, the notes, the Note Guarantees to any provision of this Description of Notes to the extent that such provision in this Description of Notes
was intended to be a verbatim recitation of a provision of the indenture, the notes, the Note Guarantees, which intent will be evidenced by an officer&#146;s certificate provided to the trustee to that effect; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to provide for the issuance of additional notes in accordance with the limitations set forth in the indenture as of the date of the indenture; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to release a Guarantor from its Guarantee pursuant to the terms of the indenture when permitted or required pursuant to the terms of the indenture; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to secure the notes and the related Note Guarantees or add covenants for the benefit of the holders of notes or to surrender any right or power conferred upon Teleflex or any
Guarantor; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to add additional Note Guarantees; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to evidence and provide for the acceptance and appointment under the indenture of a successor trustee pursuant to the requirements thereof; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to make any amendment to the provisions of the indenture relating to the transfer or legending of the notes; <I>provided</I>, <I>however</I>, that (i)&nbsp;compliance with the
indenture as so amended would not result in notes being transferred in violation of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or any applicable securities law and (ii)&nbsp;such amendment does not materially and
adversely affect the rights of holders to transfer notes. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consent of the holders is not necessary under the indenture to approve the
particular form of any proposed amendment. It is sufficient if such consent approves the substance of the proposed amendment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Satisfaction and
discharge </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indenture will be discharged and will cease to be of further effect as to all notes issued thereunder, when: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">either: </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all notes that have been authenticated, except lost, stolen or destroyed notes that have been replaced or paid and notes for whose payment money has been deposited in trust and
thereafter repaid to Teleflex, have been delivered to the trustee for cancellation; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all notes that have not been delivered to the trustee for cancellation have become due and payable by reason of the mailing of a notice of redemption or otherwise or will become
due and payable within one year or are to be called for redemption within one year and Teleflex or any Guarantor has irrevocably deposited or caused to be deposited with the trustee as trust funds in trust solely for the benefit of the holders, cash
in U.S. dollars, <FONT STYLE="white-space:nowrap">non-callable</FONT> Government Securities, or a combination thereof, in amounts as will be sufficient, in the opinion of a nationally recognized investment bank, appraisal firm or firm of independent
public accountants, without consideration of any reinvestment of interest, to pay and discharge the entire Indebtedness on the notes not delivered to the trustee for cancellation for principal of, premium on, if any, and interest on, the notes to
the date of maturity or redemption; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in respect of clause 1(b), no Default or Event of Default has occurred and is continuing on the date of the deposit (other than a Default or Event of Default
resulting from the borrowing of funds to be applied to such deposit and any similar deposit relating to other Indebtedness and, in each case, the granting of Liens </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-60 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
to secure such borrowings) and the deposit will not result in a breach or violation of, or constitute a default under, any other material instrument to which Teleflex or any Guarantor is a party
or by which Teleflex or any Guarantor is bound (other than with respect to the borrowing of funds to be applied concurrently to make the deposit required to effect such satisfaction and discharge and any similar concurrent deposit relating to other
Indebtedness, and in each case the granting of Liens to secure such borrowings); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex or any Guarantor has paid or caused to be paid all sums payable by it under the indenture; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex has delivered irrevocable instructions to the trustee under the indenture to apply the deposited money toward the payment of the notes at maturity or on the redemption
date, as the case may be. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, Teleflex must deliver an officer&#146;s certificate and an opinion of counsel to the trustee
stating that all conditions precedent to satisfaction and discharge have been satisfied. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Concerning the trustee </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Wells Fargo Bank, National Association will act as trustee under the indenture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If the trustee becomes a creditor of Teleflex or any Guarantor, the indenture limits the right of the trustee to obtain payment of claims in certain cases, or to realize on certain property received in respect of
any such claim as security or otherwise. The trustee will be permitted to engage in other transactions; however, if it acquires any conflicting interest it must eliminate such conflict within 90 days, apply to the SEC for permission to continue as
trustee (if the indenture has been qualified under the Trust Indenture Act) or resign. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The holders of a majority in aggregate principal amount of the
then outstanding notes will have the right to direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee, subject to certain exceptions. The indenture provides that in case an Event of Default
has occurred and is continuing, the trustee will be required, in the exercise of its power, to use the degree of care of a prudent person in the conduct of such person&#146;s own affairs. The trustee will be under no obligation to exercise any of
its rights or powers under the indenture at the request of any holder of notes, unless such holder has offered to the trustee indemnity or security satisfactory to it against any loss, liability or expense. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Anyone who receives this offering
memorandum may obtain a copy of the indenture without charge by writing to Teleflex Incorporated, 550 East Swedesford Road, Suite 400, Wayne, Pennsylvania 19087, Attention: Jake Elguicze, Treasurer and Vice President, Investor Relations. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Certain definitions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Set forth below are certain defined
terms used in the indenture. Reference is made to the indenture for a full disclosure of all defined terms used therein, as well as any other capitalized terms used herein for which no definition is provided. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;2024 Senior Notes&#148; means Teleflex&#146;s 5.25% Senior Notes due 2024 outstanding on the date of the indenture. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;2026 Senior Notes&#148; means Teleflex&#146;s 4.875% Senior Notes due 2026 outstanding on the date of the indenture. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Affiliate&#148; of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control
with such specified Person. For purposes of this definition, &#147;control,&#148; as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such
Person, whether through the ownership of voting </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-61 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
securities, by agreement or otherwise. For purposes of this definition, the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control with&#148; have correlative
meanings. No Person (other than Teleflex or any Subsidiary of Teleflex) in whom a Securitization Subsidiary makes an Investment in connection with a Qualified Securitization Facility will be deemed to be an Affiliate of Teleflex or any of its
Subsidiaries solely by reason of such Investment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Applicable Premium&#148; means, with respect to any note on any redemption date, the greater of:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% of the principal amount of the note; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the excess, if any, of: </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the present value at such redemption date of (i)&nbsp;the redemption price of the note at November&nbsp;15, 2022 (such redemption price being set forth in the table appearing
above under the caption &#147;&#151;Optional Redemption&#148;) plus (ii)&nbsp;all required interest payments due on the note through November&nbsp;15, 2022, (excluding accrued but unpaid interest to the redemption date), computed using a discount
rate equal to the Treasury Rate as of such redemption date plus 50 basis points; over </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the principal amount of the note. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Attributable
Indebtedness&#148; means, with respect to any Sale and Lease Back Transaction, at the time of determination, the lesser of (1)&nbsp;the sale price of the property so leased multiplied by a fraction the numerator of which is the remaining portion of
the base term of the lease included in such transaction and the denominator of which is the base term of such lease, and (2)&nbsp;the total obligation (discounted to the present value at the implicit interest factor, determined in accordance with
GAAP, included in the rental payments) of the lessee for rental payments (other than amounts required to be paid on account of property taxes as well as maintenance, repairs, insurance, water rates and other items which do not constitute payments
for property rights) during the remaining portion of the base term of the lease included in such transaction. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Beneficial Owner&#148; has the
meaning assigned to such term in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> and Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act, except that in calculating the beneficial ownership of any particular
&#147;person&#148; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act), such &#147;person&#148; will be deemed to have beneficial ownership of all securities that such &#147;person&#148; has the right to acquire by conversion or
exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms &#147;Beneficially Owns&#148; and &#147;Beneficially Owned&#148; have a corresponding meaning. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Board of Directors&#148; means: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to a corporation, the board of directors of the corporation or any committee thereof duly authorized to act on behalf of such board; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to a partnership, the Board of Directors of the general partner of the partnership; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to a limited liability company, the managing member or members or any controlling committee of managing members thereof; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">with respect to any other Person, the board or committee of such Person serving a similar function. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Capital Lease Obligation&#148; of any Person means the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property,
or a combination thereof, which obligations are required to be classified and accounted for as capital leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in
accordance with GAAP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-62 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Capital Stock&#148; means: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in the case of a corporation, corporate stock; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in the case of a partnership or limited liability company, partnership interests (whether general or limited) or membership interests; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person,
</FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">but excluding from all of the foregoing any debt securities exchangeable or convertible into Capital Stock, whether or not
such debt securities include any right of participation with Capital Stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Captive Insurance Subsidiary&#148; means any captive insurance company
that is a Subsidiary of Teleflex or any of its Subsidiaries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Cash Equivalents&#148; means: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">United States dollars, Canadian dollars, pounds sterling, euros or yen (or any other currency held temporarily to manage the exposure to such other currency);
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(a) in the case of any Foreign Subsidiary that is a Subsidiary, such local currencies held by it from time to time in the ordinary course of business; and (c)&nbsp;the currency
of any country that is a member of the Organization for Economic Cooperation and Development; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">securities issued or directly and fully guaranteed or insured by the United States government or any agency or instrumentality of the United States government (<I>provided
</I>that the full faith and credit of the United States is pledged in support of those securities) having maturities of not more than 24 months from the date of acquisition; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">certificates of deposit and eurodollar time deposits with maturities of one year or less from the date of acquisition, bankers&#146; acceptances with maturities not exceeding one
year and overnight bank deposits, in each case, with any lender party to a Credit Facility or with any commercial bank having capital and surplus in excess of $500.0&nbsp;million; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">repurchase obligations with a term of not more than seven days for underlying securities of the types described in clauses (3)&nbsp;and (4) above entered into with any financial
institution meeting the qualifications specified in clause (4)&nbsp;above; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">commercial paper having one of the two highest ratings obtainable from Moody&#146;s or S&amp;P and, in each case, maturing within 12 months after the date of acquisition;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">marketable short-term money market and similar securities having a rating of at least <FONT STYLE="white-space:nowrap">P-2</FONT> or <FONT STYLE="white-space:nowrap">A-2</FONT>
from either Moody&#146;s or S&amp;P, respectively (or, if at any time neither Moody&#146;s nor S&amp;P shall be rating such obligations, an equivalent rating from another &#147;nationally recognized statistical rating organization&#148; within the
meaning of Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act selected by Teleflex as a replacement agency) and in each case maturing within 24 months after the date of creation or acquisition thereof;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">readily marketable direct obligations issued by any state, commonwealth or territory of the United States or any political subdivision or taxing authority thereof having an
Investment Grade rating from either Moody&#146;s or S&amp;P with maturities of 12 months or less from the date of acquisition; and </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-63 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">money market funds at least 95% of the assets of which constitute Cash Equivalents of the kinds described in clauses (1)&nbsp;through (8) of this definition.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Change of Control&#148; means the occurrence of any of the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all
or substantially all of the properties or assets of Teleflex and its Subsidiaries taken as a whole to any Person (including any &#147;person&#148; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act)) other than to Teleflex or one of
its Subsidiaries; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the consummation of any transaction (including, without limitation, any merger or consolidation), the result of which is that any Person (including any &#147;person&#148; (as
defined above)) becomes the Beneficial Owner, directly or indirectly, of more than 50% of the Voting Stock of Teleflex, measured by voting power rather than number of shares; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Teleflex consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, Teleflex, in any such event pursuant to a transaction in
which any of the outstanding Voting Stock of Teleflex is converted into or exchanged for cash, securities or other property, other than any such transaction where: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Voting Stock of Teleflex outstanding immediately prior to such transaction is converted into or exchanged for the Voting Stock of such surviving or transferee Person (or any
direct or indirect parent thereof) immediately after giving effect to such transaction; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the holders of the Voting Stock of Teleflex immediately prior to such transaction own, directly or indirectly, not less than a majority of the Voting Stock of Teleflex or such
surviving or transferee Person (or any direct or indirect parent thereof) immediately after giving effect to such transaction. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Consolidated EBITDA&#148; means, with respect to any specified Person for any period, the Consolidated Net Income of such Person for such period plus, without
duplication, in each case to the extent taken into account in computing such Consolidated Net Income: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">provision for taxes based on income, profits or capital, including, without limitation, state, franchise and similar taxes (such as the Pennsylvania capital tax) and foreign
withholding taxes of such Person and its Subsidiaries for such period; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Fixed Charges of such Person and its Subsidiaries for such period; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any foreign currency translation losses (including losses related to currency remeasurements of Indebtedness) of such Person and its Subsidiaries for such period; <I>plus</I>
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">depreciation, amortization (including amortization of intangibles and other assets but excluding amortization of prepaid cash expenses that were paid in a prior period), and any
other <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, including any expenses or losses related to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> charges related to pension and post-retirement
plans, <FONT STYLE="white-space:nowrap">non-cash</FONT> costs associated with inventory purchase price adjustments and in process research and development, any write offs, write downs, losses or items and expenses, in each case, to the extent that
such depreciation, amortization and other <FONT STYLE="white-space:nowrap">non-cash</FONT> charges or expenses were deducted in computing Consolidated Net Income, but excluding any such <FONT STYLE="white-space:nowrap">non-cash</FONT> charge or
expense to the extent that it represents an accrual of or reserve for cash charges or expenses in any future period or amortization of a prepaid cash charge or expense that was paid in a prior period; <I>plus</I> </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-64 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to the extent actually reimbursed, expenses incurred to the extent covered by indemnification provisions in any agreement in connection with any acquisition permitted under the
indenture; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any contingent or deferred payments (including <FONT STYLE="white-space:nowrap">earn-out</FONT> payments, <FONT STYLE="white-space:nowrap">non-compete</FONT> payments and
consulting payments but excluding ongoing royalty payments) made in connection with any acquisition permitted under the indenture; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">deferred financing fees and milestone payments in connection with any Investment or series of related Investments permitted under the indenture; <I>plus</I>
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">costs of surety bonds in connection with financing activities; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the amount of factually supportable and identifiable cost savings related to operational efficiencies, expense reductions, strategic initiatives or improvements or other
synergies, in each case, projected by Teleflex in good faith to be realized based upon actions taken, committed to be taken or reasonably expected to be taken within 18 months of the date of determination (calculated on a pro forma basis as though
such cost savings, improvements and synergies had been realized on the first day of such period) (without duplication of the amount of actual benefit realized during such period from such actions), which cost savings, improvements and synergies can
be reasonably computed, as certified in writing by a responsible financial or accounting officer of Teleflex; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any loss from discontinued operations and any loss on disposal of discontinued operations; <I>minus</I> </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any foreign currency translation gains (including gains related to currency remeasurements of Indebtedness) of such Person and its Subsidiaries for such period; <I>minus</I>
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(13)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">non-cash</FONT> gains, including any gains related to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains related to pension and post-retirement plans, other than the accrual of revenue in the ordinary course of business and excluding any <FONT
STYLE="white-space:nowrap">non-cash</FONT> gains which represent the reversal of any accrual of, or reserve for, anticipated cash charges that reduced Consolidated EBITDA in any prior period; <I>minus</I> </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(14)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> gains for such period; <I>minus</I> </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(15)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any income from discontinued operations and any gain on disposal of discontinued operations, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">in each case, on a consolidated basis and determined in accordance with GAAP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Consolidated Net Income&#148;
means, with respect to any specified Person for any period, the aggregate of the net income (loss) of such Person and its Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP and without any reduction in respect
of preferred stock dividends; <I>provided </I>that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any <FONT STYLE="white-space:nowrap">after-tax</FONT> effect of extraordinary, <FONT STYLE="white-space:nowrap">non-recurring</FONT> or unusual losses, charges
or premiums including, but not limited to, any expenses or charges related to any Equity Offering, incurrence of Indebtedness permitted to be incurred under the indenture, acquisition, restructuring, integration (including, without limitation, the
sale, closure or consolidation of facilities and <FONT STYLE="white-space:nowrap">start-up</FONT> costs related to new facilities), transition, executive recruiting, severance (including, but not limited to, any severance payments related to
management employment contracts), relocation costs and curtailments or modifications to pension and post-retirement employee benefit plans, recapitalization or the amendment, modification or refinancing of Indebtedness (including a refinancing
thereof) (whether or not successful) (for the avoidance of doubt, the losses, charges and premiums identified in this clause include, without limitation, those related to the refinancing transactions undertaken by Teleflex in January 2017, the
Transaction Costs, any future losses, charges or premiums associated with the prepayment and the related prepayment make-whole amounts of any other refinancings undertaken in the future and any amounts paid or charges incurred in connection
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-65 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
with the termination of interest rate swaps entered into in the future in connection with the Credit Facilities), will be excluded; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all extraordinary losses and expenses and all gains and losses realized in connection with any asset sale (without regard to the dollar limitation in the definition thereof) or
other disposition, disposition of securities or early extinguishment of Indebtedness, together with any related provision for taxes on any such gain, will be excluded; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the net income and loss of any Person that is accounted for by the equity method of accounting will be included only to the extent of the amount of dividends or similar
distributions paid in cash (or to the extent converted into cash or Cash Equivalents) to the specified Person or a Subsidiary of the Person; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the cumulative effect of a change in accounting principles will be excluded; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">non-cash</FONT> gains and losses attributable to movement in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> valuation of (a)&nbsp;Hedging Obligations pursuant to FASB Accounting Standards Codification Topic 815&#151;Derivatives and Hedging, (b)&nbsp;Permitted
Convertible Indebtedness (as such term is defined in the indenture governing the 2026 Senior Notes), (c) any Permitted Convertible Indebtedness Call Transaction (as such term is defined in the indenture governing the 2026 Senior Notes) and
(d)&nbsp;foreign currencies or derivative instruments pursuant to GAAP, will be excluded; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any net unrealized gains or losses (after any offset) with respect to Hedging Obligations will be excluded; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(i) any <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation charges and expenses recorded from grants of stock appreciation or similar rights, phantom equity, stock
options, restricted stock, units or other rights to officers, directors, managers or employees and <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-cash</FONT> income (loss) attributable to deferred compensation plans or trusts, shall be excluded;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any impairment charge, asset <FONT STYLE="white-space:nowrap">write-off</FONT> or write-down, including impairment charges or asset write-offs or write-downs related to
intangible assets, long-lived assets, investments in debt and equity securities or as a result of a change in law or regulation, in each case, pursuant to GAAP and the amortization of intangibles arising pursuant to GAAP shall be excluded;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any amortization of deferred charges or debt discount resulting from the application of FASB Accounting Standards Codification Topic
<FONT STYLE="white-space:nowrap">470-20&#151;Debt&#151;Debt</FONT> with Conversion and Other Options (formerly FASB Staff Position No. APB <FONT STYLE="white-space:nowrap">14-1&#151;Accounting</FONT> for Convertible Debt Instruments That May Be
Settled in Cash Upon Conversion (Including Partial Cash Settlement)) will be excluded; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">accruals and reserves that are established within twelve months after the date of the indenture that are so required to be established as a result of the Transactions in
accordance with GAAP will be excluded; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to the extent covered by insurance or indemnification and actually reimbursed, or, so long as Teleflex has made a determination that there exists reasonable evidence that such
amount will in fact be reimbursed by the insurer or indemnifying party and only to the extent that such amount is (a)&nbsp;not denied by the applicable carrier or indemnifying party in writing within 180 days and (b)&nbsp;in fact reimbursed within
365 days of the date of such evidence (with a deduction for any amount so added back to the extent not so reimbursed within 365 days), losses and expenses with respect to liability or casualty events or business interruption shall be excluded.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Consolidated Net Secured Leverage Ratio&#148; means, as of any date of determination, the ratio of (1)&nbsp;the Indebtedness of
Teleflex that is outstanding and that is secured by a Lien on the assets of Teleflex or any of its </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-66 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Subsidiaries as of such date minus Cash Equivalents included on the consolidated balance sheet of Teleflex as of the end of the most recent fiscal quarter for which internal financial statements
are available immediately preceding the date of determination and still held by Teleflex as of such date to (2)&nbsp;the Consolidated EBITDA of Teleflex for the then most recently ended four full fiscal quarters for which internal financial
statements are available immediately preceding the date of determination, in each case with such pro forma adjustments as are consistent with the pro forma adjustment provisions set forth in this definition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, for purposes of calculating the Consolidated Net Secured Leverage Ratio: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Investments, acquisitions, dispositions and mergers or consolidations that have been made by the specified Person or any of its Subsidiaries, or any Person or any of its
Subsidiaries acquired by the specified Person or any of its Subsidiaries, and including all related financing transactions and including increases in ownership of Subsidiaries, during the four-quarter reference period or subsequent to such reference
period and on or prior to the date on which the event for which the calculation of the Consolidated Net Secured Leverage Ratio is made (the &#147;Calculation Date&#148;), or that are to be made on the Calculation Date, will be given pro forma effect
(as determined in good faith by a responsible financial or accounting officer of Teleflex) as if they had occurred on the first day of the four-quarter reference period; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Consolidated EBITDA attributable to discontinued operations, as determined in accordance with GAAP, and operations or businesses (and ownership interests therein) disposed of
prior to the Calculation Date, will be excluded; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Fixed Charges attributable to discontinued operations, as determined in accordance with GAAP, and operations or businesses (and ownership interests therein) disposed of prior
to the Calculation Date, will be excluded, but only to the extent that the obligations giving rise to such Fixed Charges will not be obligations of the specified Person or any of its Subsidiaries following the Calculation Date;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">if any Indebtedness bears a floating rate of interest, the interest expense on such Indebtedness will be calculated as if the rate in effect on the Calculation Date had been the
applicable rate for the entire period (taking into account any Hedging Obligation applicable to such Indebtedness if such Hedging Obligation has a remaining term as of the Calculation Date in excess of 12 months). </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of this definition, whenever pro forma effect is to be given to an Investment, acquisition, disposition and merger or consolidation, the pro forma
calculations shall include factually supportable and identifiable pro forma cost savings related to operational efficiencies, expense reductions, strategic initiatives or improvements or other synergies, in each case, projected by Teleflex in good
faith to be realized based upon actions taken, committed to be taken or reasonably expected to be taken within 18 months of the Calculation Date (without duplication of the amount of actual benefit realized during such period from such actions),
which cost savings, improvements and synergies can be reasonably computed, as certified in writing by a responsible financial or accounting officer of Teleflex. Interest on a Capitalized Lease Obligation shall be deemed to accrue at an interest rate
reasonably determined by a responsible financial or accounting officer of Teleflex to be the rate of interest implicit in such Capital Lease Obligation in accordance with GAAP. For purposes of making the computation referred to above, interest on
any Indebtedness under revolving credit facilities computed on a pro forma basis shall be computed based upon the average daily balance of such Indebtedness during the applicable period; or, if lower, the maximum commitments under such revolving
credit facilities as of the applicable Calculation Date. Interest on Indebtedness that may optionally be determined at an interest rate based upon a factor of a prime or similar rate, a eurocurrency interbank offered rate, or other rate, shall be
deemed to have been based upon the rate actually chosen, or, if none, then based upon such optional rate chosen as Teleflex may designate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-67 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;continuing&#148; means, with respect to any Default or Event of Default, that such Default or Event of
Default has not been cured or waived. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Credit Agreement&#148; means that certain Amended and Restated Credit Agreement, dated as of
January&nbsp;20, 2017, by and among Teleflex, the guarantors party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent and Bank of America, N.A. and PNC Bank, National Association, as
<FONT STYLE="white-space:nowrap">Co-Syndication</FONT> Agents, including any related notes, Guarantees, collateral documents, instruments and agreements executed in connection therewith, and, in each case, as amended, restated, modified, renewed,
refunded, replaced in any manner (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Credit Facilities&#148; means, one or more debt facilities (including, without limitation, the Credit Agreement) or other financing arrangements (including,
without limitation, commercial paper facilities or indentures), in each case, providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to
borrow from such lenders against such receivables), letters of credit or other indebtedness, including any notes, mortgages, guarantees, collateral documents, instruments and agreements executed in connection therewith, in each case, as amended,
supplemented, restated, modified, renewed, refunded, replaced in any manner (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities) in whole or in part from time to time, including any such
replacement, refunding or refinancing facility or indenture that increases the amount permitted to be borrowed thereunder or alters the maturity thereof (<I>provided </I>that such increase in borrowings is permitted, to the extent applicable, under
&#147;Certain Covenants&#151;Liens&#148;) or adds Subsidiaries as additional borrowers or guarantors thereunder and whether by the same or any other agent, lender or group of lenders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Default&#148; means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Domestic Subsidiary&#148; means any Subsidiary of Teleflex that is, at the time of determination, organized under the laws of the United States or any state of the United States or the District of Columbia.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Equity Interests&#148; means Capital Stock and all warrants, options or other rights to acquire Capital Stock (but excluding any debt security
that is convertible into, or exchangeable for, Capital Stock). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Equity Offering&#148; means a public or private sale either: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">of Equity Interests of Teleflex by Teleflex (other than to a Subsidiary of Teleflex), or </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">of Equity Interests of a direct or indirect parent entity of Teleflex (other than to Teleflex or a Subsidiary of Teleflex) to the extent that the net proceeds therefrom are
contributed to the common equity capital of Teleflex. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Fair Market Value&#148; means the value that would be paid by a willing buyer
to an unaffiliated willing seller in a transaction not involving distress or necessity of either party, determined in good faith by the Board of Directors of Teleflex (unless otherwise provided in the indenture). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;FASB&#148; means Financial Accounting Standards Board. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Fixed Charges&#148; means, with respect to any specified Person for any period, the sum, without duplication, of: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a) the consolidated interest expense of such Person and its Subsidiaries for such period, to the extent such expense was deducted in computing Consolidated Net
Income, including, without limitation, (a)&nbsp;amortization of debt issuance costs and original issue discount, <FONT STYLE="white-space:nowrap">(b)&nbsp;non-cash</FONT> interest payments, (but
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-68 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
excluding any <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense attributable to the movement in the mark to market valuation of Hedging Obligations or other derivative instruments
pursuant to GAAP), (c) the interest component of any deferred payment obligations, (d)&nbsp;the interest component of all payments associated with Capital Lease Obligations, (e)&nbsp;commissions, discounts and other fees and charges incurred in
respect of letter of credit or bankers&#146; acceptance financings, and excluding, (v)&nbsp;penalties and interest relating to taxes, (w)&nbsp;any expense resulting from the discounting of Indebtedness in connection with the application of
recapitalization or purchase accounting, (x)&nbsp;amortization of deferred financing fees, debt issuance costs, commissions, fees and expenses, and original issue discount with respect to Indebtedness issued in connection with the Transactions or
any intercompany Indebtedness, (y)&nbsp;any expensing of bridge, commitment and other financing fees in connection with any acquisitions after the date of the indenture and (z)&nbsp;commissions, discounts, yield and other fees and charges (including
interest) incurred in connection with any Qualified Securitization Facility or any other transaction pursuant to which Teleflex or any of its Subsidiaries may sell, convey or otherwise transfer or grant a security interest in any accounts
receivable, Securitization Assets or related assets of the type specified in the definition of &#147;Qualified Securitization Facility,&#148; and net of the effect of all payments made or received pursuant to Hedging Obligations in respect of
interest rates (but excluding any <FONT STYLE="white-space:nowrap">one-time</FONT> cash costs associated with breakage); <I>plus</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the consolidated interest expense of such Person and its Subsidiaries that was capitalized during such period; <I>plus</I> </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any interest on Indebtedness of another Person that is guaranteed by such Person or one of its Subsidiaries or secured by a Lien on assets of such Person or one of its
Subsidiaries, whether or not such Guarantee or Lien is called upon; <I>plus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">all dividends, whether paid or accrued and whether or not in cash, on any series of preferred stock of such Person or any of its Subsidiaries, other than dividends on Equity
Interests payable solely in Equity Interests of Teleflex or to Teleflex or a Subsidiary of Teleflex; <I>minus</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(a) interest income of such Person and its Subsidiaries for such period; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any amortization of deferred charges or debt discount resulting from the application of FASB Accounting Standards Codification Topic
<FONT STYLE="white-space:nowrap">470-20&#151;Debt&#151;Debt</FONT> with Conversion and Other Options (formerly FASB Staff Position No. APB <FONT STYLE="white-space:nowrap">14-1&#151;Accounting</FONT> for Convertible Debt Instruments That May Be
Settled in Cash Upon Conversion (Including Partial Cash Settlement)). </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Foreign Subsidiary&#148; means, with respect to any Person,
any Subsidiary of such Person that is not organized or existing under the laws of the United States, any state thereof or the District of Columbia, and any Subsidiary of such Foreign Subsidiary. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;GAAP&#148; means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American
Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession,
which are in effect on the date of the indenture; provided that lease liabilities and associated expenses recorded by Teleflex pursuant to ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases, shall not be treated as Indebtedness and shall
not be included in consolidated interest expense or Fixed Charges, unless the lease liabilities would have been treated as capital lease obligations under GAAP as in effect prior to the adoption of ASU
<FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (in which case such lease liabilities and associated expenses shall be treated as Capital Lease Obligations and included in consolidated interest expense and Fixed Charges under the Indenture).
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Guarantee&#148; of or by any Person means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of
guaranteeing any Indebtedness or other obligation of any other Person (the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-69 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
&#147;primary obligor&#148;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the
purchase of) any security for the payment thereof; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such
Indebtedness or other obligation; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>provided</I>, that the term &#147;Guarantee&#148; will not include endorsements for collection or deposit in the ordinary course of business. In any computation
of the Indebtedness or other liabilities of the obligor under any Guarantee, the Indebtedness or other obligations that are the subject of such Guarantee will be assumed to be direct obligations of such obligor. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Guarantors&#148; means any Subsidiary of Teleflex that executes a Note Guarantee in accordance with the provisions of the indenture, and their respective
successors and assigns, in each case, until the Note Guarantee of such Person has been released in accordance with the provisions of the indenture. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Hedging Obligations&#148; means, with respect to any specified Person, the obligations of such Person under: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">other agreements or arrangements designed to manage interest rates or interest rate risk; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">commodity swap agreement, commodity cap agreement, commodity collar agreement, foreign exchange contract, currency swap agreement or any other agreements or arrangements designed
to protect such Person against fluctuations in, or providing for the transfer or mitigation of risks related to, currency exchange rates or commodity prices, in each case, either generally or under specific contingencies. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Immaterial Subsidiary&#148; means, as of any date, any Subsidiary that is a Wholly-Owned Subsidiary whose total assets do not exceed 2.5% of the consolidated
assets of Teleflex and its Subsidiaries, determined as of the end of the fiscal quarter most recently ended for which financial statements are available; <I>provided </I>that (1)&nbsp;a Subsidiary will not be considered to be an Immaterial
Subsidiary if it, directly or indirectly, guarantees or otherwise provides direct credit support for any other Indebtedness of Teleflex and (2)&nbsp;the aggregate amount of total assets of all Immaterial Subsidiaries shall not at any time exceed
5.0% of the consolidated assets of Teleflex and its Subsidiaries, determined as of the end of the fiscal quarter most recently ended for which financial statements are available. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Indebtedness&#148; means, with respect to any specified Person, any indebtedness of such Person (excluding accrued interest (other than accrued interest or interest paid in kind that has accreted to the
principal amount), accrued expenses and trade payables), whether or not contingent, in respect of borrowed money and evidenced by bonds, notes, debentures or similar instruments or letters of credit (or, without duplication, reimbursement agreements
in respect thereof). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The amount of any Indebtedness outstanding as of any date will be: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the accreted value of the Indebtedness, in the case of any Indebtedness issued with original issue discount; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-70 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the principal amount of the Indebtedness, in the case of any other Indebtedness; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in respect of Indebtedness of another Person secured by a Lien on the assets of the specified Person, the lesser of: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the Fair Market Value of such assets at the date of determination; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the amount of the Indebtedness of the other Person. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Investment Grade&#148; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#146;s and <FONT STYLE="white-space:nowrap">BBB-</FONT> (or
the equivalent) by S&amp;P, or, if either such entity ceases to rate the notes for reasons outside of the control of Teleflex, the equivalent investment grade credit rating from any other &#147;nationally recognized statistical rating
organization&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act selected by Teleflex as a replacement agency. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Investments&#148; means, with respect to any Person, all direct or indirect investments by such Person in other Persons (including Affiliates) in the forms of loans (including Guarantees or other
obligations), advances or capital contributions (excluding commission, travel and similar advances to officers and employees made in the ordinary course of business), purchases or other acquisitions of Indebtedness, Equity Interests or other
securities, together with all items that are or would be classified as investments on a balance sheet prepared in accordance with GAAP. Except as otherwise provided in the indenture, the amount of an Investment will be determined at the time the
Investment is made and without giving effect to subsequent changes in value. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Lien&#148; means, with respect to any asset, any mortgage, lien,
pledge, charge, security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease in the
nature thereof, any option or other agreement to sell or give a security interest in and, except in connection with any Qualified Securitization Facility, any filing of or agreement to give any financing statement under the Uniform Commercial Code
(or equivalent statutes) of any jurisdiction; <I>provided</I>, that in no event shall an operating lease be deemed to constitute a Lien. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Moody&#146;s&#148; means Moody&#146;s Investors Service, Inc., and any successor to its rating agency business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Net Proceeds&#148; from a Sale and Lease Back Transaction means cash payments received therefrom (including any cash payments received by way of deferred
payment of principal pursuant to a note or installment receivable or otherwise and proceeds from the sale or other disposition of any securities received as consideration, all purchase price adjustments, earn-outs and contingency payment obligations
to which a seller may become entitled after the closing of such Sale and Lease Back Transaction and all holdbacks, in each case, only as and when received in cash, but excluding any other consideration received in the form of assumption by the
acquiring Person of Indebtedness or other obligations relating to such properties or assets or received in any other <FONT STYLE="white-space:nowrap">non-cash</FONT> form), in each case net of (without duplication): (1) all legal, accounting, title
and transfer or recording tax expenses, broker&#146;s fees or commissions and other fees and expenses (including, without duplication, any repatriation costs associated with receipt by the applicable taxpayer of such proceeds) incurred, and all
federal, state, provincial, foreign and local taxes (whether on account of income, gains or otherwise) required to be accrued as a liability under GAAP, as a consequence of such Sale and Lease Back Transaction; (2)&nbsp;all payments made on any
Indebtedness which is secured by any assets subject to such Sale and Lease Back Transaction, in accordance with the terms of any Lien upon or other security agreement of any kind with respect to such assets, or which must by its terms, or in order
to obtain a necessary consent to such Sale and Lease Back Transaction, or by applicable law, be repaid out of the proceeds from such Sale and Lease Back Transaction; (3)&nbsp;the deduction of appropriate amounts provided by the seller as a reserve,
in accordance with GAAP, against any liabilities associated with the property or other assets disposed in such Sale and Lease Back </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-71 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Transaction and retained by Teleflex or any Subsidiary after such Sale and Lease Back Transaction; (4)&nbsp;any portion of the purchase price from a Sale and Lease Back Transaction placed in
escrow in connection with that Sale and Lease Back Transaction; provided, that upon the termination of that escrow, Net Proceeds will be increased by any portion of funds in the escrow that are released to Teleflex or any Subsidiary; and
(5)&nbsp;the amount of any purchase price adjustment, contingent or deferred payment obligation that Teleflex and/or any Subsidiary is obligated to pay to another Person in connection with a Sale and Lease Back Transaction. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Note Guarantee&#148; means the Guarantee by each Guarantor of Teleflex&#146;s obligations under the indenture and the notes, in accordance with the provisions
of the indenture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Obligations&#148; means any principal, interest, penalties, fees, indemnifications, reimbursements, damages and other
liabilities payable under the documentation governing any Indebtedness. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Permitted Liens&#148; means: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on assets of Teleflex or any of its Subsidiaries securing Indebtedness and other Obligations under Credit Facilities that were permitted by the terms of the indenture to be
incurred pursuant to this clause (1)&nbsp;not to exceed $1.75&nbsp;billion; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens in favor of Teleflex or the Guarantors; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on property, shares of stock or other assets of a Person existing at the time such Person becomes a Subsidiary of Teleflex or is merged with or into or consolidated with
Teleflex or any Subsidiary of Teleflex; <I>provided </I>that such Liens were not created or incurred in contemplation of such Person becoming a Subsidiary of Teleflex or such merger or consolidation and do not extend to any assets other than those
of the Person that becomes a Subsidiary of Teleflex or is merged with or into or consolidated with Teleflex or any Subsidiary of Teleflex; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on property (including Capital Stock) or other assets existing at the time of acquisition of such property or assets by Teleflex or any Subsidiary of Teleflex; <I>provided
</I>that such Liens were in existence prior to such acquisition and not incurred in contemplation of, such acquisition; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens to secure the performance of statutory obligations, insurance, surety or appeal bonds, workers compensation obligations, performance bonds or other obligations of a like
nature incurred in the ordinary course of business (including Liens to secure letters of credit issued to assure payment of such obligations) and any Liens in favor of, or required by contracts with, governmental entities; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens to secure Indebtedness represented by mortgage financings or purchase money obligations </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens existing on the date of the indenture; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens for taxes, assessments or governmental charges or claims that are not yet overdue for a period of 30 days or that are being contested in good faith by appropriate
proceedings promptly instituted and diligently concluded; <I>provided </I>that any reserve or other appropriate provision as is required in conformity with GAAP has been made therefor; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens imposed by law, such as carriers&#146;, warehousemen&#146;s, landlord&#146;s and mechanics&#146; Liens, in each case, incurred in the ordinary course of business;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">survey exceptions, easements or reservations of, or rights of others for, licenses, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT>
sewers, electric lines, telegraph and telephone lines and other similar purposes, or zoning or other restrictions as to the use of real property that were not incurred in connection with Indebtedness and that do not in the aggregate materially
adversely affect the value of said properties or materially impair their use in the operation of the business of such Person; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-72 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens created for the benefit of (or to secure) the notes (or the Note Guarantees); </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(13)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on insurance policies and proceeds thereof, or other deposits, to secure insurance premium financings; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(14)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">filing of Uniform Commercial Code financing statements as a precautionary measure in connection with operating leases; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(15)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">bankers&#146; Liens, rights of setoff, Liens arising out of judgments or awards not constituting an Event of Default and notices of <I>lis pendens </I>and associated rights
related to litigation being contested in good faith by appropriate proceedings and for which adequate reserves have been made; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(16)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on cash, Cash Equivalents or other property arising in connection with the defeasance, discharge or redemption of Indebtedness; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(17)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on specific items of inventory or other goods (and the proceeds thereof) of any Person securing such Person&#146;s obligations in respect of bankers&#146; acceptances
issued or created in the ordinary course of business for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(18)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(a) leases, subleases, licenses or sublicenses granted to others in the ordinary course of business which do not materially interfere with the ordinary conduct of the business of
Teleflex or any of its Subsidiaries and do not secure any Indebtedness and (b)&nbsp;grants of grants of software and other technology licenses in the ordinary course of business; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(19)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into in the ordinary course of business;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(20)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on assets transferred to a Securitization Subsidiary or on assets of a Securitization Subsidiary, in either case, incurred in connection with a Qualified Securitization
Facility; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(21)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens securing Indebtedness of Foreign Subsidiaries that relate solely to the Equity Interests or assets of Foreign Subsidiaries; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(22)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods in the ordinary
course of business; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(23)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens (a)&nbsp;of a collection bank arising under <FONT STYLE="white-space:nowrap">Section&nbsp;4-210</FONT> of the Uniform Commercial Code on items in the course of collection,
(b)&nbsp;attaching to commodity trading accounts or other brokerage accounts incurred in the ordinary course of business, and (c)&nbsp;in favor of banking institutions arising as a matter of law encumbering deposits (including the right of <FONT
STYLE="white-space:nowrap">set-off);</FONT> </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(24)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(25)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens that are contractual rights of <FONT STYLE="white-space:nowrap">set-off</FONT> (a)&nbsp;relating to pooled deposit or sweep accounts of Teleflex or any of its Subsidiaries
to permit satisfaction of overdraft or similar obligations incurred in the ordinary course of business of Teleflex and its Subsidiaries or (b)&nbsp;relating to purchase orders and other agreements entered into with customers of Teleflex or any of
its Subsidiaries in the ordinary course of business; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(26)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">[reserved]; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-73 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(27)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens on property at the time such Person or any of its Subsidiaries acquires the property, including any acquisition by means of a merger or consolidation with or into such
Person or a Subsidiary of such Person; <I>provided</I>, <I>however</I>, that the Liens may not extend to any other property owned by such Person or any of its Subsidiaries (other than assets and property affixed or appurtenant thereto); and
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(28)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Liens incurred in the ordinary course of business of Teleflex or any Subsidiary of Teleflex with respect to obligations that do not exceed, as of any date of incurrence, the
greater of (a) $350.0&nbsp;million or (b) 5.0% of Total Assets. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining compliance with this definition, (x)&nbsp;a
Lien need not be incurred solely by reference to one category of Permitted Liens described in this definition, but may be incurred under any combination of such categories (including in part under one such category and in part under any other such
category) and (y)&nbsp;in the event that a Lien (or any portion thereof) meets the criteria of one or more of such categories of Permitted Liens, Teleflex shall, in its sole discretion, classify or reclassify such Lien (or any portion thereof) in
any manner that complies with this definition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Person&#148; means any individual, corporation, partnership, joint venture, association,
joint-stock company, trust, unincorporated organization, limited liability company or government or other entity. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Qualified Securitization
Facility&#148; means any Securitization Facility (a)&nbsp;constituting a securitization financing facility that meets the following conditions: (1)&nbsp;the Board of Directors of Teleflex shall have determined in good faith that such Securitization
Facility (including financing terms, covenants, termination events and other provisions) is in the aggregate economically fair and reasonable to Teleflex and the applicable Securitization Subsidiary, (2)&nbsp;all sales and/or contributions of
Securitization Assets and related assets to the applicable Securitization Subsidiary are made at Fair Market Value (as determined in good faith by Teleflex) and (3)&nbsp;the financing terms, covenants, termination events and other provisions thereof
shall be market terms (as determined in good faith by Teleflex) or (b)&nbsp;constituting a receivables financing facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Rating Agencies&#148;
means Moody&#146;s and S&amp;P or if Moody&#146;s or S&amp;P or both shall not make a rating on the notes publicly available, a nationally recognized statistical rating agency or agencies, as the case may be, selected by Teleflex, which shall be
substituted for Moody&#146;s or S&amp;P or both, as the case may be. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Ratings Decline Period&#148; means the period that (i)&nbsp;begins on the
earlier of (a)&nbsp;a Change of Control or (b)&nbsp;the first public notice of the intention by Teleflex to affect a Change of Control and (ii)&nbsp;ends 30 days following the consummation of such Change of Control; <I>provided</I>, that such period
will be extended so long as the rating of the notes is under publicly announced consideration for a possible downgrade by either of the Rating Agencies). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Ratings Event&#148; means (i)&nbsp;a downgrade by one or more gradations (including gradations within ratings categories, as well as between rating
categories) or withdrawal of the rating of the notes within the Ratings Decline Period by each of the Rating Agencies (unless the applicable Rating Agency shall have put forth a written statement to the effect that such downgrade is not attributable
in whole or in part to the applicable Change of Control) and (ii)&nbsp;the notes do not have an Investment Grade rating from any Rating Agency. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;S&amp;P&#148; means Standard&nbsp;&amp; Poor&#146;s Ratings Services, and any successor to its rating agency business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Securitization Assets&#148; means the accounts receivable, royalty or other revenue streams and other rights to payment under a Qualified Securitization
Facility that is a securitization financing facility (and not a receivables financing facility) and the proceeds thereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Securitization
Facility&#148; means any of one or more receivables or securitization financing facilities as amended, supplemented, modified, extended, renewed, restated or refunded from time to time, the Obligations of which are
<FONT STYLE="white-space:nowrap">non-recourse</FONT> (except for customary representations, warranties, covenants and indemnities made in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-74 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
connection with such facilities) to Teleflex or any of its Subsidiaries (other than a Securitization Subsidiary) pursuant to which Teleflex or any of its Subsidiaries sells or grants a security
interest in its accounts receivable or Securitization Assets or assets related thereto to either (a)&nbsp;a Person that is not a Subsidiary or (b)&nbsp;a Securitization Subsidiary that in turn sells its accounts receivable to a Person that is not a
Subsidiary. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Securitization Subsidiary&#148; means any Subsidiary formed for the purpose of engaging in, and that solely engages in, one or more
Qualified Securitization Facilities and other activities reasonably related thereto. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Significant Subsidiary&#148; means any Subsidiary that would
be a &#147;significant subsidiary&#148; as defined in Article 1, Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> promulgated pursuant to the Securities Act, as such Regulation is in effect
on the date of the indenture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Stated Maturity&#148; means, with respect to any installment of interest or principal on any series of Indebtedness,
the date on which the payment of interest or principal was scheduled to be paid in the documentation governing such Indebtedness as of the date of the indenture, and will not include any contingent obligations to repay, redeem or repurchase any such
interest or principal prior to the date originally scheduled for the payment thereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Subsidiary&#148; means, with respect to any specified
Person: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of
any contingency and after giving effect to any voting agreement or stockholders&#146; agreement that effectively transfers voting power) to vote in the election of directors, managers or trustees of the corporation, association or other business
entity is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">any partnership or limited liability company of which (a)&nbsp;more than 50% of the capital accounts, distribution rights, total equity and voting interests or general and
limited partnership interests, as applicable, are owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a combination thereof, whether in the form of membership, general, special or
limited partnership interests or otherwise, and (b)&nbsp;such Person or any Subsidiary of such Person is a controlling general partner or otherwise controls such entity. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">&#147;Total Assets&#148; means the total assets of Teleflex and the Subsidiaries, as shown on the most recent balance sheet of Teleflex for the then most recently ended fiscal quarter for which internal financial
statements are available immediately preceding the date of determination, with such adjustments to Total Assets as are consistent with the pro forma adjustment provisions set forth in the definition of &#147;Consolidated Net Secured Leverage
Ratio.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Transaction Costs&#148; means the costs, fees, expenses and premiums associated with the Transactions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Transactions&#148; means the issuance of the notes offered hereby, the use of the net proceeds therefrom as described under the caption &#147;Use of
Proceeds&#148; and other transactions in connection therewith or incidental thereto. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Treasury Rate&#148; means, as of any redemption date, the
yield to maturity as of the earlier of (a)&nbsp;such redemption date or (b)&nbsp;the date on which such notes are defeased or satisfied and discharged of United States Treasury securities with a constant maturity (as compiled and published in the
most recent Federal Reserve Statistical Release H.15 (519) that has become publicly available at least two business days prior to the redemption date (or, if such Statistical Release is no longer published, any publicly available source of similar
market data)) most nearly equal to the period from the redemption date to November&nbsp;15, 2022; <I>provided</I>, <I>however</I>, that if the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-75 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
period from the redemption date to November&nbsp;15, 2022, is less than one year, the weekly average yield on actually traded United States Treasury securities adjusted to a constant maturity of
one year will be used. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Voting Stock&#148; of any specified Person as of any date means the Capital Stock of such Person that is at the time
entitled to vote in the election of the Board of Directors of such Person. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Wholly-Owned Subsidiary&#148; of any Person means a Subsidiary of such
Person, 100% of the outstanding Capital Stock or other ownership interests of which (other than directors&#146; qualifying shares) shall at the time be owned by such Person or by one or more Wholly-Owned Subsidiaries of such Person. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-76 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_15"></A>Certain United States federal </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>income and estate tax consequences to <FONT STYLE="white-space:nowrap">non-United</FONT> States holders </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following is a summary of certain United States federal income and estate tax consequences of the purchase, ownership and disposition of the notes as of the
date hereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion is limited to <FONT STYLE="white-space:nowrap">non-United</FONT> States holders (as defined below) purchasing the notes for
cash at original issue and at their original &#147;issue price&#148; (i.e., the first price at which a substantial amount of the notes is sold to the public for cash). Except where noted, this summary deals only with notes that are held as capital
assets, and does not represent a detailed description of the United States federal income tax consequences applicable to you if you are subject to special treatment under the United States federal income tax laws, including if you are: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a partnership or other pass-through entity for United States federal income tax purposes; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a &#147;controlled foreign corporation;&#148; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a &#147;passive foreign investment company;&#148; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a United States expatriate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A <FONT
STYLE="white-space:nowrap">&#147;non-United</FONT> States holder&#148; means a beneficial owner of the notes (other than an entity treated as a partnership for United States federal income tax purposes) that is not, for United States federal income
tax purposes, any of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an individual citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation (or any other entity treated as a corporation for United States federal income tax purposes) created or organized in or under the laws of the
United States, any state thereof or the District of Columbia; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate the income of which is subject to United States federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more United States persons have the authority to
control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable United States Treasury regulations to be treated as a United States person. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This summary is based upon provisions of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and United States Treasury regulations,
administrative rulings and judicial decisions as of the date hereof. Those authorities may be changed, perhaps retroactively, so as to result in United States federal income and estate tax consequences different from those summarized below. We have
not and will not seek any rulings from the Internal Revenue Service (&#147;IRS&#148;) regarding the matters discussed below. There can be no assurance that the IRS will not take positions concerning the tax consequences of the purchase, ownership or
disposition of the notes that are different from those discussed below. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any entity classified as a partnership for United States federal income tax
purposes holds notes, the tax treatment of a partner will generally depend upon the status of the partner and the activities of such partnership. If you are a partnership or a partner in a partnership holding notes, you should consult your own tax
advisors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This summary does not represent a detailed description of the United States federal income and estate tax consequences to you in light of your
particular circumstances and does not address the effects of any state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States tax laws. It is not intended to be, and should not be construed to be, legal or tax advice to any particular
purchaser of notes. <B>If you are considering the purchase of notes, you should consult your own tax advisors concerning the particular United States federal income and estate tax consequences</B> <B>to you of the purchase, ownership and disposition
of the notes, as well as the consequences to you arising under the laws of any other taxing jurisdiction.</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-77 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>United States federal withholding tax </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Subject to the discussion of backup withholding and FATCA below, United States federal withholding tax will not apply to any payment of interest on the notes under the &#147;portfolio interest rule,&#148; provided
that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">interest paid on the notes is not effectively connected with your conduct of a trade or business in the United States; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">you do not actually (or constructively) own 10% or more of the total combined voting power of all classes of our voting stock within the meaning of the Code and
applicable United States Treasury regulations; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">you are not a controlled foreign corporation that is related to us actually or constructively through stock ownership; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">you are not a bank whose receipt of interest on the notes is described in Section&nbsp;881(c)(3)(A) of the Code; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">either (a)&nbsp;you provide your name and address on an applicable IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> and certify, under penalties of perjury,
that you are not a United States person as defined under the Code or (b)&nbsp;you hold your notes through certain foreign intermediaries and satisfy the certification requirements of applicable United States Treasury regulations. Special
certification rules apply to <FONT STYLE="white-space:nowrap">non-United</FONT> States holders that are pass-through entities rather than corporations or individuals. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you cannot satisfy the requirements described above, payments of interest made to you will be subject to a 30% United States federal withholding tax, unless you provide the applicable withholding agent with a
properly executed: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or
other applicable form) claiming an exemption from or reduction in withholding under the benefit of an applicable income tax treaty; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or other applicable form) stating that interest paid on the notes is not subject to withholding tax
because it is effectively connected with your conduct of a trade or business in the United States (as discussed below under &#147;&#151;United States federal income tax&#148;). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 30% United States federal withholding tax generally will not apply to any payment of principal or gain that you realize on the sale, exchange, retirement,
redemption or other taxable disposition of a note. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>United States federal income tax </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you are engaged in a trade or business in the United States and interest on the notes is effectively connected with the conduct of that trade or business (and, if required by an applicable income tax treaty, is
attributable to a United States permanent establishment), then you will be subject to United States federal income tax on that interest on a net income basis (although you will be exempt from the 30% United States federal withholding tax, provided
the certification requirements discussed above in &#147;&#151;United States federal withholding tax&#148; are satisfied) generally in the same manner as if you were a United States person as defined under the Code. In addition, if you are a foreign
corporation, you may be subject to a branch profits tax equal to 30% (or lower applicable income tax treaty rate) of your effectively connected earnings and profits, subject to adjustments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Subject to the discussion of backup withholding and FATCA below, any gain realized on the sale, exchange, retirement, redemption or other taxable disposition of a note generally will not be subject to United States
federal income tax unless: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is
attributable to a United States permanent establishment), in which case such gain will generally be subject to United States federal income tax (and possibly branch profits tax) in the same manner as effectively connected interest as described
above; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-78 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">you are an individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met, in
which case, unless an applicable income tax treaty provides otherwise, you will generally be subject to a 30% United States federal income tax on any gain recognized, which may be offset by certain United States source losses.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>United States federal estate tax </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you are an individual and are not a United States citizen or a resident of the United States (as specifically defined for United States federal estate tax purposes), your estate will not be subject to United
States federal estate tax on notes beneficially owned by you at the time of your death, provided that any payment to you of interest on the notes would be eligible for exemption from the 30% United States federal withholding tax under the
&#147;portfolio interest rule&#148; described above under &#147;&#151;United States federal withholding tax,&#148; without regard to the statement requirement described in the fifth bullet point of that section. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Information reporting and backup withholding </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest on
the notes paid to you and the amount of tax, if any, withheld with respect to those payments generally will be reported to the IRS. Copies of the information returns reporting such interest payments and any withholding may also be made available to
the tax authorities in the country in which you reside under the provisions of an applicable income tax treaty. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In general, you will not be subject to
backup withholding with respect to payments on the notes that we make to you provided that the applicable withholding agent does not have actual knowledge or reason to know that you are a United States person as defined under the Code, and such
withholding agent has received from you the required certification described above in the fifth bullet point under &#147;&#151;United States federal withholding tax.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, no information reporting or backup withholding will be required regarding the proceeds of a sale or other taxable disposition (including a retirement or redemption) of a note made within the United
States or conducted through certain United States-related financial intermediaries, if the payor receives the statement described above and does not have actual knowledge or reason to know that you are a United States person as defined under the
Code, or you otherwise establish an exemption. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against
your United States federal income tax liability provided the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional withholding
requirements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under Sections 1471 through 1474 of the Code (such Sections commonly referred to as &#147;FATCA&#148;), a 30% United States federal
withholding tax may apply to any interest income paid on the notes and, for a disposition of a note occurring after December&nbsp;31, 2018, the gross proceeds from such disposition, in each case paid to (i)&nbsp;a &#147;foreign financial
institution&#148; (as specifically defined in the Code) which does not provide sufficient documentation, typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> evidencing either (x)&nbsp;an
exemption from FATCA, or (y)&nbsp;its compliance (or deemed compliance) with FATCA (which may alternatively be in the form of compliance with an intergovernmental agreement with the United States) in a manner which avoids withholding, or (ii)&nbsp;a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specifically defined in the Code) which does not provide sufficient documentation, typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> evidencing either (x)&nbsp;an exemption from FATCA, or (y)&nbsp;adequate information regarding certain substantial United States beneficial owners of such entity (if any). If an interest payment is
both subject to withholding under FATCA and subject to the withholding tax discussed above under &#147;&#151;United&nbsp;States federal withholding tax,&#148; the withholding under FATCA may be credited against, and therefore reduce, such other
withholding tax. You should consult your own tax advisors regarding these rules and whether they may be relevant to your ownership and disposition of the notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-79 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_16"></A>Certain ERISA considerations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following is a summary of certain considerations associated with the acquisition and holding of the notes offered hereby by employee benefit plans that are
subject to Title I of the U.S. Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), plans, individual retirement accounts and other arrangements that are subject to Section&nbsp;4975 of the Code or provisions under any
other federal, state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other laws or regulations that are similar to such provisions of ERISA or the Code (&#147;Similar Laws&#148;), and entities whose underlying assets are considered to
include &#147;plan assets&#148; (within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;2510.3-101</FONT> of Title 29 of the United States Code of Federal Regulations, as modified by Section&nbsp;3(42) of ERISA), account or arrangement
pursuant to ERISA or otherwise (each, a &#147;Plan&#148;). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>General fiduciary matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">ERISA and the Code impose certain duties on persons who are fiduciaries of a Plan subject to Title I of ERISA or Section&nbsp;4975 of the Code (an &#147;ERISA Plan&#148;) and prohibit certain transactions involving
the assets of an ERISA Plan and its fiduciaries or other interested parties. Under ERISA and the Code, any person who exercises any discretionary authority or control over the administration of such an ERISA Plan or the management or disposition of
the assets of such an ERISA Plan, or who renders investment advice for a fee or other compensation to such an ERISA Plan, is generally considered to be a fiduciary of the ERISA Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In considering an investment in the notes with any portion of the assets of any Plan, a fiduciary should determine whether the investment is in accordance with the documents and instruments governing the Plan and
the applicable provisions of ERISA, the Code or any Similar Law relating to a fiduciary&#146;s duties to the Plan including, without limitation, the prudence, diversification, delegation of control and prohibited transaction provisions of ERISA, the
Code and any other applicable Similar Laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each ERISA Plan should consider the fact that none of us, the underwriters, or our or their respective
affiliates (collectively, the &#147;Transaction Parties&#148;) are acting, or will act, as a fiduciary to any ERISA Plan with respect to the decision to purchase or hold the notes. The Transaction Parties are not undertaking to provide impartial
investment advice or advice based on any particular investment need, or to give advice in a fiduciary capacity, with respect to the decision to purchase or hold the notes. All communications, correspondence and materials from the Transaction Parties
with respect to the notes are intended to be general in nature and are not directed at any specific purchaser of the notes, and do not constitute advice regarding the advisability of investment in the notes for any specific purchaser. The decision
to purchase and hold the notes must be made solely by each prospective ERISA Plan purchaser on an arm&#146;s length basis. The Transaction Parties have a financial interest in an ERISA Plan&#146;s purchase and holding of the notes, which interests
may conflict with the interest of such ERISA Plan, as more fully described in this prospectus supplement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Prohibited transaction issues
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Section&nbsp;406 of ERISA and Section&nbsp;4975 of the Code prohibit ERISA Plans from engaging in specified transactions involving plan assets with
persons or entities who are &#147;parties in interest&#148;, within the meaning of Section&nbsp;3(14) of ERISA, or &#147;disqualified persons&#148;, within the meaning of Section&nbsp;4975 of the Code, unless an exemption is available. A party in
interest or disqualified person who engaged in a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction may be subject to excise taxes and other penalties and liabilities under ERISA and/or the Code. In addition, the fiduciary of
the ERISA Plan that engaged in such a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction may be subject to penalties and liabilities under ERISA and the Code. The acquisition and/or holding of the notes by an ERISA Plan with
respect to which we, a subsidiary guarantor or an underwriter is considered a party in interest or a disqualified person may constitute or result in a direct or indirect prohibited transaction under Section&nbsp;406 of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-80 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ERISA and/or Section&nbsp;4975 of the Code, unless the investment is acquired and is held in accordance with an applicable statutory, class or individual prohibited transaction exemption. In this
regard, the U.S. Department of Labor has issued prohibited transaction class exemptions, or &#147;PTCEs,&#148; that may apply to provide exemptive relief for direct or indirect prohibited transactions resulting from the acquisition and/or holding of
the notes. These class exemptions include, without limitation, PTCE <FONT STYLE="white-space:nowrap">84-14</FONT> respecting transactions determined by independent qualified professional asset managers, PTCE
<FONT STYLE="white-space:nowrap">90-1</FONT> respecting insurance company pooled separate accounts, PTCE <FONT STYLE="white-space:nowrap">91-38</FONT> respecting bank collective investment funds, PTCE <FONT STYLE="white-space:nowrap">95-60</FONT>
respecting life insurance company general accounts and PTCE <FONT STYLE="white-space:nowrap">96-23</FONT> respecting transactions determined by <FONT STYLE="white-space:nowrap">in-house</FONT> asset managers. In addition, Section&nbsp;408(b)(17) of
ERISA and Section&nbsp;4975(d)(20) of the Code provide relief from the prohibited transaction provisions of Title I of ERISA and Section&nbsp;4975 of the Code for certain transactions, provided that neither the issuer of the securities nor any of
its affiliates (directly or indirectly) has or exercises any discretionary authority or control or renders any investment advice with respect to the assets of any ERISA Plan involved in the transaction and provided further that the ERISA Plan
receives no less, nor pays no more, than &#147;adequate consideration&#148; (within the meaning of Section&nbsp;408(b)(17) of ERISA and Section&nbsp;4975(d)(20) of the Code) in connection with the transaction. Each of the above-noted exemptions
contains conditions and limitations on its application. Fiduciaries of ERISA Plans considering acquiring and/or holdings the notes in reliance of these or any other exemption should carefully review the exemption to assure it is applicable. There
can be no assurance that all of the conditions of any such exemptions will be satisfied. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Plans that are &#147;governmental plans&#148; (as defined in
Section&nbsp;3(32) of ERISA), certain &#147;church plans&#148; (as defined in Section&nbsp;3(33) of ERISA or Section&nbsp;4975(g)(3) of the Code) and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> plans (as described in Section&nbsp;4(b)(4) of
ERISA) are not subject to the requirements of ERISA or Section&nbsp;4975 of the Code but may be subject to similar prohibitions under other applicable Similar Laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Because of the foregoing, the notes should not be acquired or held by any person investing the assets of any Plan unless such acquisition and holding will not constitute a
<FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under ERISA or Section&nbsp;4975 of the Code or a similar violation of any applicable Similar Laws. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Representation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accordingly, by acceptance of the notes each purchaser and subsequent transferee of the notes
(or any interest therein) will be deemed to have represented and warranted that either (i)&nbsp;no portion of the assets used by such purchaser or transferee to purchase or hold the notes constitutes the assets of any Plan or (ii)&nbsp;the purchase
and holding of the notes by such purchaser or transferee will not constitute a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code or a similar violation under
any applicable Similar Laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, if any purchaser or subsequent transferee of the notes is using assets of any ERISA Plan to acquire or hold
the notes, such purchaser and subsequent transferee will be deemed to represent that (i)&nbsp;none of the Transaction Parties has acted as the ERISA Plan&#146;s fiduciary, or has been relied upon for any advice, with respect to the purchaser or
transferee&#146;s decision to acquire, hold, sell, exchange, vote or provide any consent with respect to the notes and none of the Transaction Parties shall at any time be relied upon as the ERISA Plan&#146;s fiduciary with respect to any decision
to acquire, continue to hold, sell, exchange, vote or provide any consent with respect to the notes and (ii)&nbsp;the decision to invest in the notes has been made at the recommendation or direction of an &#147;independent fiduciary&#148;
(&#147;Independent Fiduciary&#148;) within the meaning of U.S. Code of Federal Regulations 29 C.F.R. <FONT STYLE="white-space:nowrap">Section&nbsp;2510.3-21(c)(1),</FONT> as amended from time to time (the &#147;Fiduciary Rule&#148;), who (a)&nbsp;is
independent of the Transaction Parties; (b)&nbsp;is capable of evaluating investment risks independently, both in general and with respect to particular transactions and investment strategies (within the meaning of the Fiduciary Rule); (c) is a
fiduciary (under ERISA and/or Section&nbsp;4975 of the Code) with respect to the purchaser </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-81 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or transferee&#146;s investment in the notes and is responsible for exercising independent judgment in evaluating the investment in the notes; (d)&nbsp;is either (A)&nbsp;a bank as defined in
Section&nbsp;202 of the Investment Advisers Act of 1940, as amended (the &#147;Advisers Act&#148;), or similar institution that is regulated and supervised and subject to periodic examination by a state or federal agency of the United States;
(B)&nbsp;an insurance carrier which is qualified under the laws of more than one state of the United States to perform the services of managing, acquiring or disposing of assets of such an ERISA Plan; (C)&nbsp;an investment adviser registered under
the Advisers Act or, if not registered as an investment adviser under the Advisers Act by reason of paragraph (1)&nbsp;of Section&nbsp;203A of the Advisers Act, is registered as an investment adviser under the laws of the state (referred to in such
paragraph (1)) in which it maintains its principal office and place of business; (D)&nbsp;a broker dealer registered under the Securities Act of 1934, as amended; and/or (E)&nbsp;an Independent Fiduciary (not described in clauses (A), (B), (C) or
(D)&nbsp;above) that holds or has under management or control total assets of at least $50&nbsp;million, and will at all times that such purchaser or transferee holds the notes hold or have under management or control total assets of at least
$50&nbsp;million; (e)&nbsp;it is not paying the Transaction Parties any fee or other compensation directly for the provision of investment advice (as opposed to other services) in connection with the ERISA Plan&#146;s purchase or holding of the
notes; (f)&nbsp;is not an IRA owner (in the case of an IRA); and (g)&nbsp;is aware of and acknowledges that (I)&nbsp;none of the Transaction Parties are undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity,
in connection with the purchaser&#146;s or transferee&#146;s investment in the notes, and (II)&nbsp;the Transaction Parties have a financial interest in the purchaser&#146;s or transferee&#146;s investment in the notes on account of the fees and
other remuneration we or they expect to receive in connection with transactions contemplated hereunder. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foregoing discussion is general in nature
and is not intended to be <FONT STYLE="white-space:nowrap">all-inclusive.</FONT> Due to the complexity of these rules and the penalties that may be imposed upon persons involved in <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited
transactions, it is particularly important that fiduciaries, or other persons considering acquiring the notes on behalf of, or with the assets of, any Plan, consult with their counsel regarding the potential applicability of ERISA, Section&nbsp;4975
of the Code and any Similar Laws to such investment and whether an exemption would be applicable to the acquisition and holding of the notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-82 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_17"></A>Underwriting (conflicts of interest) </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC is acting as the representative of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting
agreement among us, our guarantors and the underwriters named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the principal amount of notes set forth
opposite its name below. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Underwriters</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Principal&nbsp;amount</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>of
notes</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:5.00em; text-indent:-5.00em"><FONT STYLE="font-family:arial" SIZE="2">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:5.00em; text-indent:-5.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">PNC Capital Markets LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Citizens Capital Markets, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">DNB Markets, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">HSBC Securities (USA) Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">MUFG Securities Americas Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SMBC Nikko Securities America, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Wells Fargo Securities, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital One Securities, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Citigroup Global Markets Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fifth Third Securities, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. Bancorp Investments, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Guggenheim Securities, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not
jointly, to purchase all of the notes sold under the underwriting agreement if any of these notes are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be
increased or the underwriting agreement may be terminated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and our guarantors have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The expenses of the offering, not including the underwriting discount, are estimated at $2.5&nbsp;million and are payable by us. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Commissions and discounts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters propose
initially to offer the notes to the public at the public offering price set forth on the cover page of this prospectus supplement. The underwriters may offer the notes to selected dealers at the public offering price minus a concession of up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount. In addition, the underwriters may allow, and those selected dealers may reallow, a concession of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
principal amount to certain other dealers. After the initial offering, the underwriters may change the public offering price, concession or any other selling term. The underwriters may offer and sell the notes through certain of their affiliates.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-83 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table shows the underwriting discounts and commissions to be paid to the underwriters in connection
with this offering (expressed as a percentage of the principal amount of the notes): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Paid&nbsp;by&nbsp;us</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per note</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have also agreed to reimburse the underwriters for certain of their FINRA-related expenses in an amount not to exceed $10,000.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>New issue of notes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The notes are a new issue of
securities with no established trading market. We do not intend to apply for listing of the notes on any national securities exchange or for inclusion of the notes on any automated dealer quotation system. We have been advised by certain of the
underwriters that they presently intend to make a market in the notes after completion of the offering. However, they are under no obligation to do so and may discontinue any market-making activities at any time without any notice. We cannot assure
the liquidity of the trading market for the notes. If an active trading market for the notes does not develop, the market price and liquidity of the notes may be adversely affected. If the notes are traded, they may trade at a discount from their
initial offering price, depending on prevailing interest rates, the market for similar securities, our operating performance and financial condition, general economic conditions and other factors. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>No sales of similar securities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed that we will
not, for a period of 45 days after the date of this prospectus supplement, without first obtaining the prior written consent of J.P. Morgan Securities LLC, directly or indirectly, issue, sell, offer to contract or grant any option to sell, pledge,
transfer or otherwise dispose of, any debt securities or securities exchangeable for or convertible into debt securities, except for the notes sold to the underwriters pursuant to the underwriting agreement. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Short positions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the offering, the
underwriters may purchase and sell the notes in the open market. These transactions may include short sales and purchases on the open market to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater
principal amount of notes than they are required to purchase in the offering. The underwriters must close out any short position by purchasing notes in the open market. A short position is more likely to be created if the underwriters are concerned
that there may be downward pressure on the price of the notes in the open market after pricing that could adversely affect investors who purchase in the offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of the notes or preventing or retarding a
decline in the market price of the notes. As a result, the price of the notes may be higher than the price that might otherwise exist in the open market. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above
may have on the price of the notes. In addition, neither we nor any of the underwriters make any representation that the underwriters will engage in these transactions or that these transactions, once commenced, will not be discontinued without
notice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-84 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other relationships </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Affiliates of substantially all of the underwriters in this offering serve as agents and/or lenders under our Credit Agreement and will receive a portion of the net proceeds of this offering in connection with the
repayment of a portion of the outstanding indebtedness under our revolving credit facility. See &#147;Use of proceeds.&#148; In addition, some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment
banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities
and/or instruments of ours or our affiliates. Certain of the underwriters or their affiliates that have a lending relationship with us routinely hedge, and certain other of those underwriters or their affiliates may hedge, their credit exposure to
us consistent with their customary risk management policies. Typically, these underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of
short positions in our securities, including potentially the notes offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the notes offered hereby. The underwriters and their affiliates may
also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities
and instruments. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Conflicts of interest </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because
affiliates of each of J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, PNC Capital Markets LLC, Citizens Capital Markets, Inc., DNB Markets, Inc., HSBC Securities (USA) Inc., MUFG Securities Americas Inc.,
SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Capital One Securities, Inc., Citigroup Global Markets Inc., Fifth Third Securities, Inc. and U.S. Bancorp Investments, Inc. are each lenders under our revolving credit facility and
will each receive 5% or more of the net proceeds of this offering due to the repayment of borrowings under our revolving credit facility, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, PNC Capital Markets
LLC, Citizens Capital Markets, Inc., DNB Markets, Inc., HSBC Securities (USA) Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Capital One Securities, Inc., Citigroup Global Markets Inc., Fifth
Third Securities, Inc. and U.S. Bancorp Investments, Inc. are each deemed to have a conflict of interest within the meaning of Rule 5121 of FINRA. Accordingly, this offering will be conducted in accordance with Rule 5121, which requires, among other
things, that a &#147;qualified independent underwriter&#148; participate in the preparation of, and exercise the usual standards of &#147;due diligence&#148; with respect to, the registration statement and this prospectus supplement. Guggenheim
Securities, LLC has agreed to act as a qualified independent underwriter for this offering and to undertake the legal responsibilities and liabilities of an underwriter under the Securities Act, specifically including those inherent in
Section&nbsp;11 thereof. Guggenheim Securities, LLC will not receive any additional fees for serving as a qualified independent underwriter in connection with this offering. We have agreed to indemnify Guggenheim Securities, LLC against liabilities
incurred in connection with acting as a qualified independent underwriter, including liabilities under the Securities Act. Pursuant to Rule 5121, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, PNC Capital
Markets LLC, Citizens Capital Markets, Inc., DNB Markets, Inc., HSBC Securities (USA) Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., Wells Fargo Securities, LLC, Capital One Securities, Inc., Citigroup Global Markets Inc.,
Fifth Third Securities, Inc. and U.S. Bancorp Investments, Inc. will not confirm any sales to any account over which they exercise discretionary authority without the specific written approval of the account holder. See &#147;Use of proceeds&#148;
for additional information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-85 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the European Economic Area </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), each underwriter has represented and agreed that with
effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the &#147;Relevant Implementation Date&#148;) it has not made and will not make an offer of notes which are the subject of the
offering contemplated by this prospectus supplement to the public in that Relevant Member State other than: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the relevant dealer
or dealers nominated by the us for any such offer; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of notes shall require the issuer or any underwriter to publish a
prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes of this provision, the expression an &#147;offer of notes to the public&#148; in relation to any notes in any Relevant Member State means the
communication in any form and by any means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe the notes, as the same may be varied in that Member State by
any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the
Relevant Member State. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Kingdom </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Each underwriter has represented and agreed that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(i) it is a person whose ordinary activities involve it in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of its business and
(ii)&nbsp;it has not offered or sold and will not offer or sell the notes other than to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or as agent) for the purposes of their
businesses or who it is reasonable to expect will acquire, hold, manage or dispose of investments (as principal or agent) for the purposes of their businesses where the issue of the notes would otherwise constitute a contravention of Section&nbsp;19
of the FSMA by the issuer; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within
the meaning of Section&nbsp;21 of the FSMA) received by it in connection with the issue or sale of the notes in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to the issuer or the guarantors; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the notes in, from or otherwise involving the United
Kingdom. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Canada </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The notes may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT>
Prospectus Exemptions or subsection 73.3(1) of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-86 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing
Registrant Obligations. Any resale of the notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT>
jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure
requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Switzerland </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
document is not intended to constitute an offer or solicitation to purchase or invest in the notes described herein. The notes may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be
listed on the SIX Swiss Exchange or on any other exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the notes constitutes a prospectus as such term is understood
pursuant to article 652a or article 1156 of the Swiss Code of Obligations, and neither this document nor any other offering or marketing material relating to the notes may be publicly distributed or otherwise made publicly available in Switzerland.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Japan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
notes have not been and will not be registered under the Financial Instruments and Exchange Act. The underwriters have agreed that they have not, directly or indirectly, offered or sold and will not offer or sell any notes, directly or indirectly,
in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with,
the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective
investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each underwriter represents, warrants and agrees that (i)&nbsp;it has not offered or sold and will not offer or sell in Hong
Kong, by means of any document, any notes other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (the &#147;SFO&#148;) and any rules made under that Ordinance; or
(b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the
public within the meaning of that Ordinance; and (ii)&nbsp;it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any
advertisement, invitation or document relating to the notes, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-87 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
permitted to do so under the securities laws of Hong Kong) other than with respect to the notes which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Singapore
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a
relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable
provision of the SFA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Where the notes are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (a)&nbsp;a corporation (which is
not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an
accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries&#146; rights and interest in that trust
shall not be transferable for 6 months after that corporation or that trust has acquired the shares under Section&nbsp;275 except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person, or any person
pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is given for the transfer; or (3)&nbsp;by operation of law. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Ireland </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No action may be
taken with respect to the notes in Ireland otherwise than in conformity with the provisions of (a)&nbsp;the European Communities (Markets in Financial Instruments) Regulations 2007 (Nos. 1 to 3) (as amended), including, without limitation,
Regulations 7 and 152 thereof or any codes of conduct used in connection therewith and the provisions of the Investor Compensation Act 1998, (b)&nbsp;the Companies Act 2014 (as amended) (the &#147;2014 Act&#148;), the Central Bank Acts 1942 to 2015
(as amended) and any codes of conduct rules made under Section&nbsp;117(1) of the Central Bank Act 1989 and (c)&nbsp;the Prospectus (Directive 2003/71/EC) Regulations 2005 (as amended) and any rules issued under Section&nbsp;1363 of the 2014 Act by
the Central Bank of Ireland. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-88 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_18"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Certain legal matters in connection with the offering and sale of the notes and guarantees will be passed upon for us by Simpson Thacher&nbsp;&amp; Bartlett LLP, New York, New York. Certain matters relating to the
offering and sale of the guarantees will also be passed upon by (i)&nbsp;James J. Leyden, Vice President, General Counsel and Secretary of Teleflex Incorporated, (ii)&nbsp;Ballard Spahr LLP, Philadelphia, Pennsylvania, (iii)&nbsp;Dorsey&nbsp;&amp;
Whitney LLP, Minneapolis, Minnesota and (iv)&nbsp;A&amp;L Goodbody, Dublin, Ireland. The underwriters have been represented by Latham&nbsp;&amp; Watkins LLP, New York, New York. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="supprom483473_19"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The financial statements and management&#146;s assessment of the
effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> of Teleflex Incorporated for the year ended December&nbsp;31, 2016 and the audited historical financial statements of NeoTract, Inc. included on page&nbsp;2 of Teleflex Incorporated&#146;s Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> dated November&nbsp;16, 2017 have been so incorporated in reliance on the reports (of which NeoTract, Inc. contains an explanatory paragraph relating to NeoTract&#146;s liquidity position as described
in Note&nbsp;1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s
Report on Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to the Vascular Solutions, Inc. Annual Report for the year ended December&nbsp;31, 2016 have been so incorporated in reliance on the report
of Baker Tilly Virchow Krause, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">S-89 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Teleflex Incorporated </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Guarantees of Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preference
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase
Contracts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
and sell, from time to time, in one or more offerings, any of the following securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">debt securities, in one or more series, which may be senior debt securities, senior subordinated debt securities or subordinated debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">guarantees, if any, of our obligations under any debt securities, which may be given by one or more of our subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of our preference stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase our debt and common and preferred equity securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase contracts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">units; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of these securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain selling stockholders may, from time
to time, offer and sell shares of our common stock or preference stock, in each case, in amounts, at prices and on terms that will be determined at the time of any such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the New York Stock Exchange under the symbol &#147;TFX.&#148; Each prospectus supplement will indicate if the
securities offered thereby will be listed on a securities exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of these securities.
We will provide the specific terms of the securities, including the names of any selling stockholders, if applicable, in one or more supplements to this prospectus. This prospectus may not be used to offer and sell the securities unless accompanied
by a prospectus supplement. You should read this prospectus and the applicable prospectus supplement, as well as the documents incorporated by reference in this prospectus and in any accompanying prospectus supplement, carefully before you invest.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in these securities involves risks. See the information included and incorporated by reference in this prospectus and the
accompanying prospectus supplement for a discussion of the factors you should carefully consider before deciding to purchase these securities, including the information under &#147;<A HREF="#toc483473_6">Risk Factors</A>&#148; in our most recent
annual report on Form 10-K (as it may be updated in our most recent quarterly report on Form 10-Q) filed with the Securities and Exchange Commission. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>None of the Securities and Exchange Commission, any state securities commission or any other regulatory body has approved or disapproved of
these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is November 16, 2017. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_2">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_3">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_5">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_7">RATIOS OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_10">DESCRIPTION OF GUARANTEES OF CERTAIN DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_11">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_12">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_13">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_14">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_15">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_16">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_17">VALIDITY OF THE SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc483473_18">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) under
the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or
more offerings from time to time. In addition, certain selling stockholders may, from time to time, offer and sell shares of our common stock or preference stock, in each case, in amounts, at prices and on terms that will be determined at the time
of any such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we sell
securities under this shelf registration, to the extent required, we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the names of any selling stockholders, if applicable, and
may also provide you with a free writing prospectus. The prospectus supplement and any free writing prospectus may also add, update or change information contained in this prospectus. We also include in the prospectus supplement or any free writing
prospectus where applicable, information about material United States federal income tax considerations relating to the securities. Therefore, if there is any inconsistency between the information in this prospectus and the prospectus supplement and
any free writing prospectus, you should rely on the information in the prospectus supplement and any free writing prospectus. You should read both this prospectus and any prospectus supplement and any free writing prospectus together with additional
information described under the heading &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to the registration statement of which this prospectus is a part contain the full text of certain contracts and other important
documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we may offer, you should review the full text of these documents.
The registration statement and the exhibits can be obtained from the SEC as indicated under the heading &#147;Where You Can Find More Information&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in
this prospectus and any applicable prospectus supplement or any related free writing prospectus prepared by us or on our behalf and filed with the SEC. You must not rely upon any information or representation not contained or incorporated by
reference in this prospectus or the accompanying prospectus supplement. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus and the accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any accompanying
prospectus supplement or any free writing prospectus prepared by us is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to
the date of the document incorporated by reference, even though this prospectus, any accompanying prospectus supplement or any free writing prospectus is delivered or securities are sold on a later date. Our business, financial condition, results of
operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus:
(i)&nbsp;&#147;the Company,&#148; &#147;us,&#148; &#147;we,&#148; &#147;our&#148; and &#147;Teleflex&#148; refer to Teleflex Incorporated, a Delaware corporation, and its consolidated subsidiaries and their respective predecessors and
(ii)&nbsp;&#147;this prospectus&#148; refers to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_2"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement under the Securities Act on Form S-3 with respect to the securities covered by this
prospectus. This prospectus, and any document incorporated by reference into this prospectus, filed as a part of the registration statement, does not contain all the information set forth in the registration statement and its exhibits and schedules,
parts of which are omitted in accordance with the rules and regulations of the SEC. For further information about us and the securities covered by this prospectus, reference is made to the registration statement and to its exhibits. Statements in
this prospectus about the contents of any contract, agreement or other document are not necessarily complete and, in each instance, we refer you to the copy of such contract, agreement or document filed as an exhibit to the registration statement,
with each such statement being qualified in all respects by reference to the document to which it refers. Anyone may inspect the registration statement and its exhibits and schedules without charge at the public reference facilities the SEC
maintains at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of these materials from the SEC upon the payment of certain fees prescribed by the SEC. You may obtain further information about the operation of the
SEC&#146;s Public Reference Room by calling the SEC at 1-800-SEC-0330. You may also inspect these reports and other information without charge at a website maintained by the SEC. The address of this site is http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently subject to the information requirements of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
and in accordance therewith file periodic reports, proxy statements and other information with the SEC. You may read and copy (at prescribed rates) any such reports, proxy statements and other information at the SEC&#146;s Public Reference Room as
described above. Our SEC filings will also be available to you on the SEC&#146;s website at www.sec.gov. Our filings with the SEC are also available to the public through the New York Stock Exchange, 20 Broad Street, New York, New York 10005. We
make our filings available on the investors section of our website (www.teleflex.com) as soon as reasonably practicable after such material is electronically filed or furnished with the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act. Our website and the information contained on or accessible through our website are not a part of this prospectus, and you should not rely on any such information in making your decision whether or not to purchase our securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_3"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information about us by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus. This prospectus incorporates by reference the documents and reports
listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2016 (including the portions of our Proxy Statement on Schedule 14A for our 2017 annual meeting of stockholders filed with the SEC on March&nbsp;31,
2017 that are incorporated by reference therein); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2017, July 2, 2017 and October 1, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed on January 5, 2017, January 20, 2017, February 21, 2017, February 23, 2017 (Item 5.02 only), May 11, 2017, September 5, 2017 (Item 1.01 only), October 2, 2017 and November 16, 2017;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K/A filed on May 4, 2017 and November 16, 2017; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock on Form 8-A/A filed on March&nbsp;16, 1994, as it may be amended or supplemented from time to time. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference the information contained in all other documents we file with the SEC pursuant to Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of the offerings to which this prospectus relates. The information contained in any such document will be considered part of this prospectus from the date
the document is filed with the SEC. We do not incorporate by reference any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K in any future filings unless otherwise stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified
or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes that
statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC&#146;s website at
http://www.sec.gov. We will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request of such person, a copy of any or all of the reports and documents
referred to above which have been or may be incorporated by reference into this prospectus. You should direct requests for those documents to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Teleflex Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Jake
Elguicze, Treasurer and Vice President, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">550 E. Swedesford Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Suite 400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wayne, PA 19087 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(610) 225-6800 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any accompanying prospectus supplement, any related free writing prospectus and the documents incorporated by reference
herein and therein may contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. All statements made in this prospectus, other than statements of historical fact, are
forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;guidance,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;project,&#148; &#147;forecast,&#148; &#147;confident,&#148; &#147;prospects,&#148; and similar expressions typically are used to identify forward-looking statements.
Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and
are subject to risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in business relationships with and purchases by or from major customers or suppliers, including delays or cancellations in shipments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demand for and market acceptance of new and existing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with expectations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to effectively execute our restructuring programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to realize savings resulting from restructuring plans and programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of healthcare reform legislation and proposals to amend the legislation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in Medicare, Medicaid and third-party coverage and reimbursements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitive market conditions and resulting effects on revenues and pricing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increases in raw material costs that cannot be recovered in product pricing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">global economic factors, including currency exchange rates, interest rates, sovereign debt issues and the impact of the United Kingdom&#146;s vote to leave the European Union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties entering new markets; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be other factors that may cause our actual results to
differ materially from the forward-looking statements. Our actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking statements. We can give no assurances that any of the events
anticipated by the forward-looking statements will occur or, if any of them does, what impact they will have on our results of operation and financial condition. You should carefully read the factors described in the &#147;Risk Factors&#148; section
of this prospectus, the applicable prospectus supplement and the documents incorporated by reference into this prospectus for a description of certain risks that could, among other things, cause our actual results to differ from these
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All future written and verbal forward-looking statements attributable to us or any person acting on our
behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New risks and
uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You should not place undue reliance on forward-looking statements. Such statements speak only as to the date on which they are
made, and we undertake no obligation to update or revise any forward-looking statement, except as otherwise specifically stated by us or as required by law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_5"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total
procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and
sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. As of October
2, 2017, we manufacture our products at 36 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on achieving consistent, sustainable and profitable growth and improving our financial performance by increasing our market
share and improving our operating efficiencies through: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development of new products and product line extensions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investment in new technologies and broadening their applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the use of our products in existing markets and introduction of our products into new geographic markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achievement of economies of scale as we continue to expand by leveraging our direct sales force and distribution network for new products, as well as increasing efficiencies in our sales and marketing and research and
development structures and our manufacturing and distribution facilities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of our product portfolio through select acquisitions, licensing arrangements and business partnerships that enhance, extend or expedite our development initiatives or our ability to increase our market share.
In year-to-date 2017, we completed several acquisitions of businesses that complement and expand our product portfolio, as well as expand our business into new markets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development capabilities, commitment to engineering excellence and focus on low-cost manufacturing enable us to bring cost
effective, innovative products to market that improve the safety, efficacy and quality of healthcare. Our research and development initiatives focus on developing these products for both existing and new therapeutic applications, as well as
enhancements to, and line extensions of, existing products. We introduced 25 new products and line extensions during 2016, and 20 during year-to-date 2017. Our portfolio of existing products and products under development consists primarily of Class
I and Class II devices, most of which require 510(k) clearance by the United States Food and Drug Administration for sale in the United States, and some of which are exempt from the requirement to obtain 501(k) clearance. We believe that 510(k)
clearance (or 501(k)-exempt status) reduces our research and development costs and risks, and typically results in a shorter timetable for new product introductions as compared to the premarket approval, process that would be required for Class III
devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is publicly traded on the New York Stock Exchange under the symbol &#147;TFX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teleflex Incorporated is a corporation organized under the laws of the State of Delaware. Our principal executive offices are located at 550
East Swedesford Road, Suite 400, Wayne, PA 19087, and our telephone number at this location is (610)&nbsp;225-6800. Our website is www.teleflex.com. Information on our website is not part of this prospectus or any prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to uncertainties and risks. Before deciding whether to purchase any of our securities, you should carefully consider
and evaluate all of the information included and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our most recent annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> as
updated by our quarterly reports on Form 10-Q and other filings we make with the SEC. Our business, financial condition, liquidity, results of operations or prospects could be materially adversely affected by any of these risks and could result in a
partial or complete loss of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_7"></A>RATIOS OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our historical ratios of earnings to fixed charges for the periods indicated. This information should be read
in conjunction with the consolidated financial statements and the accompanying notes incorporated by reference in this prospectus. During the periods indicated, we had no outstanding shares of preference stock, and accordingly, our historical ratio
of earnings to fixed charges is the same as our ratio of earnings to fixed charges and preference dividends in all periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Earnings
available for fixed charges consist of pre-tax earnings from continuing operations before income or loss from equity investees, fixed charges, distributed earnings of equity investees and amortization of capitalized interest, reduced by
non-controlling interest income or loss. Fixed charges consist of interest expense, amortization of debt discount and expenses and the portion of rental expense estimated to be the equivalent of interest. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2016&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2015&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2012&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October 1, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Due to our loss from continuing operations before taxes for the year ended December&nbsp;31, 2012, the ratio coverage was less than 1:1. We would have needed to generate additional earnings of $166.7 million to achieve
a coverage of 1:1. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise state in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities for
general corporate purposes. General corporate purposes may include repayment of debt, additions to working capital, capital expenditures, investments in our subsidiaries, possible acquisitions and the repurchase, redemption or retirement of
securities, including shares of our common stock. The net proceeds may be temporarily invested or applied to repay short-term or revolving debt prior to use. In the case of a sale of our common stock or preference stock by any selling stockholders,
we will not receive any of the proceeds from such a sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the general terms of the debt securities. We will file a prospectus supplement that may contain additional terms
when we issue debt securities. The terms presented here, together with the terms in a related prospectus supplement, will be a description of the material terms of the debt securities. You should also read the indenture between us and Wells Fargo
Bank, National Association, as trustee under which the debt securities will be issued. We have filed the indenture governing debt securities with the SEC as an exhibit to the registration statement of which this prospectus is a part. All capitalized
terms have the meanings specified in the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue, from time to time, debt securities, in one or more series, that will
consist of either our senior debt, our senior subordinated debt or our subordinated debt. We refer to the subordinated debt securities and the senior subordinated debt securities together as the subordinated securities. Debt securities, whether
senior, senior subordinated or subordinated, may be issued as convertible debt securities or exchangeable debt securities. The following is a summary of the material provisions of the indenture filed as an exhibit to the registration statement of
which this prospectus is a part. For each series of debt securities, the applicable prospectus supplement for the series may change and supplement the summary below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Terms of the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for
the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities
protection against changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued
under the indenture as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with
&#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Certain U.S. federal income tax considerations applicable to debt securities
issued with OID will be described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement for a
series of debt securities that we issue will describe, among other things, the following terms of the offered debt securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities will be guaranteed and the terms of any such guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit on the aggregate principal amount of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities rank as senior debt, senior subordinated debt or subordinated debt or any combination thereof, and the terms of any subordination; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which the series of debt securities will be convertible into or exchangeable for other securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether securities issued by us will be secured or unsecured, and if secured, what the collateral will consist of; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date(s); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any currency exchange rate, commodity, commodity index, stock exchange index or financial index)
at which the debt securities will bear interest, the date or dates from which interest will accrue or the method for determining dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular
record date for the interest payable on any interest payment date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the amounts of payment of principal of, premium, if any, or interest, if any, on the series of debt securities will be determined (if such amounts may be determined by reference to an index based on
a currency or currencies or by reference to a currency exchange rate, commodity, commodity index, stock exchange index or financial index); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place or places where principal of, premium, if any, and interest, if any, on the debt securities will be payable and the method of such payment, if by wire transfer, mail or other means; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions related to redemption or early repayment of the debt securities of our option; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our obligation, if any, to redeem or purchase any series of debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder thereof and the period or periods within which, the price or
prices at which and the terms and conditions upon which such debt securities shall be redeemed or purchased, in whole or in part, pursuant to such obligation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the authorized denominations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the form of the debt securities and whether the debt securities will be issued in bearer or fully registered form (and if in fully registered form, whether the debt securities will be issuable, in whole or in part, as
global debt securities); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any depositaries, interest rate calculation agents, bid solicitation agents, conversion or exchange agents, exchange rate calculation agents or other agents with respect to the debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in the trustee for such debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in or additions to the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the Events of Default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to
such securities to be due and payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of denomination of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation of the currency, currencies or currency units in which the purchase price for, the principal of and any premium and any interest on, such securities will be payable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if payments of principal of, premium, if any, or interest, if any, on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated,
the manner in which the exchange rate with respect to these payments will be determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the securities exchange(s) on which the debt securities will be listed, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether any underwriter(s) will act as market maker(s) for the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which a secondary market for the debt securities is expected to develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the debt securities, which may modify, supplement or delete any provision of the indenture as it applies to that series. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will discuss certain U.S. federal income tax considerations for holders of any debt securities, if any,
and the securities exchange or quotation system on which any debt securities are to be listed or quoted, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be convertible into or exchangeable for other securities, including, for example, shares of our equity securities.
The terms and conditions of conversion or exchange will be stated in the applicable prospectus supplement. The terms will include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion or exchange rate and conversion or exchange price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion or exchange period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions regarding the ability of us or the holder to convert or exchange the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">events requiring adjustment to the conversion or exchange rate; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions affecting conversion or exchange in the event of our redemption of the debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
consolidate or merge with or into, or sell, lease, transfer or otherwise dispose of all or substantially all of our assets to, any person, and we cannot permit any other person to consolidate with or merge into us, unless (1)&nbsp;we will be the
continuing entity or (2)&nbsp;the successor person to which our assets are transferred is a corporation, trust, limited liability company, partnership or other entity organized under the laws of any domestic or foreign jurisdiction and it expressly
assumes our obligations under the debt securities and the indenture. In addition, we cannot complete such transaction unless immediately after completing the transaction, no Event of Default (as defined below) under the indenture, and no event
which, after notice or lapse of time or both, would become an Event of Default under the indenture, shall have occurred and be continuing. When the person to whom our assets are transferred has assumed our obligations under the debt securities and
the indenture, we shall be discharged from all our obligations under the debt securities and the indenture except in limited circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This covenant would not apply to any recapitalization transaction, a change of control of us or a highly leveraged transaction, unless the
transaction or change of control were structured to include a merger or consolidation or sale, lease or transfer or other disposition of all or substantially all of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe any modifications of this covenant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Event
of Default,&#148; when used in the indenture with respect to any series of debt securities, unless otherwise indicated in the applicable prospectus supplement, means any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to pay interest for 30 days after the date payment is due and payable; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to pay principal or premium, if any, on any debt security when due, either at maturity, upon any redemption, upon any repurchase, by declaration or otherwise; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to make sinking fund payments, if any, when due in respect of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to perform other covenants (other than a covenant that has been included in the indenture solely for the benefit of a series of debt securities other than that series) for 60 days after receipt of notice that
performance was required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain events in bankruptcy, insolvency or reorganization relating to us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other Event of Default provided in the applicable officers&#146; certificate, resolution of our board of directors or the supplemental indenture under which we issue a series of debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Event of Default for a particular series of debt securities does not necessarily constitute an Event of Default for any other series of
debt securities issued under the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to any series of debt securities occurs and is
continuing, then either the trustee for such series or the holders of a majority in aggregate principal amount of the outstanding debt securities of such series, by notice in writing, may declare the principal amount (or, if the debt securities are
discount securities, that portion of the principal amount as may be specified in the terms of that series) of and interest on all of the debt securities of such series to be due and payable immediately. We refer you to the prospectus supplement
relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of not less than a majority in aggregate principal amount of the outstanding debt securities of each affected series may, after
satisfying certain conditions, rescind and annul any of the above-described declarations and consequences involving such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an
Event of Default relating to certain events in our bankruptcy, insolvency or reorganization occurs and is continuing, then the principal amount (or, if the debt securities are discount securities, that portion of the principal amount as may be
specified in the terms of that series) of all of the debt securities outstanding, and any accrued interest, will automatically become due and payable immediately, without any declaration or other act by the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture imposes limitations on suits brought by holders of debt securities against us. Except for actions for payment of overdue
principal or interest, no holder of debt securities of any series may institute any action against us under the indenture unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder has previously given to the trustee written notice of default and continuance of such default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of not less than a majority in principal amount of the outstanding debt securities of that series have requested in writing that the trustee institute the action; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the requesting holders have offered the trustee indemnity for expenses and liabilities that may be incurred by bringing the action satisfactory to the trustee; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee has not instituted the action within 60 days of the request; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee has not received inconsistent direction by the holders of a majority in principal amount of that series of debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to file annually with the trustee a certificate, signed by one of our officers, stating whether or not the officer knows
of any default by us in the performance, observance or fulfillment of any condition or covenant of the indenture. In addition, we will be required to notify the trustee in writing upon the occurrence of any such default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated in the applicable prospectus supplement, each debt security will be represented by either one or more global securities
registered in the name of The Depository Trust Company, as depositary, or a nominee (we will refer to any debt security represented by a global debt security as a &#147;book-entry debt security&#148;), or a certificate issued in definitive
registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable prospectus supplement. Except as set forth under the subheading &#147;&#151;Global
Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificated
Debt Securities.</I> You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt
securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium, if any, and interest, if any,
on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new
certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Global Debt Securities and Book-Entry System</I>. Each global debt security representing book-entry
debt securities will be deposited with, or on behalf of, the depositary, and registered in the name of the depositary or a nominee of the depositary.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that the depositary will follow the following procedures with respect to book-entry debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in book-entry debt securities will be limited to persons that have accounts with the depositary for the
related global debt security, which we refer to as participants, or persons that may hold interests through participants. Upon the issuance of a global debt security, the depositary will credit, on its book-entry registration and transfer system,
the participants&#146; accounts with the respective principal amounts of the book-entry debt securities represented by such global debt security beneficially owned by such participants. The accounts to be credited will be designated by any dealers,
underwriters or agents participating in the distribution of the book-entry debt securities. Ownership of book-entry debt securities will be shown on, and the transfer of such ownership interests will be effected only through, records maintained by
the depositary for the related global debt security (with respect to interests of participants) and on the records of participants (with respect to interests of persons holding through participants). The laws of some states may require that certain
purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to own, transfer or pledge beneficial interests in book-entry debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depositary for a global debt security, or its nominee, is the registered owner of that global debt security, the depositary or
its nominee, as the case may be, will be considered the sole owner or holder of the book-entry debt securities represented by such global debt security for all purposes under the indenture. Except as described below, beneficial owners of book-entry
debt securities will not be entitled to have securities registered in their names, will not receive or be entitled to receive physical delivery of a certificate in definitive form representing securities and will not be considered the owners or
holders of those securities under the indenture. Accordingly, each person beneficially owning book-entry debt securities must rely on the procedures of the depositary for the related global debt security and, if such person is not a participant, on
the procedures of the participant through which such person owns its interest, to exercise any rights of a holder under the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
understand, however, that under existing industry practice, the depositary will authorize the persons on whose behalf it holds a global debt security to exercise certain rights of holders of debt securities, and the indenture provides that we, the
trustee and our respective agents will treat as the holder of a debt security the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
persons specified in a written statement of the depositary with respect to that global debt security for purposes of obtaining any consents or directions required to be given by holders of the
debt securities pursuant to the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will make payments of principal of, premium, if any, and interest, if any, on book-entry
debt securities to the depositary or its nominee, as the case may be, as the registered holder of the related global debt security. We, the trustee and any other agent of ours or agent of the trustee will not have any responsibility or liability for
any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising or reviewing any records relating to beneficial ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the depositary, upon receipt of any payment of principal of, premium, if any, or interest, if any, on a global debt security,
will immediately credit participants&#146; accounts with payments in amounts proportionate to the respective amounts of book-entry debt securities held by each participant as shown on the records of such depositary. We also expect that payments by
participants to owners of beneficial interests in book-entry debt securities held through those participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of
customers in bearer form or registered in &#147;street name,&#148; and will be the responsibility of those participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue
certificated debt securities in exchange for each global debt security if the depositary is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary
registered as a clearing agency under the Exchange Act is not appointed by us within 90 days. In addition, we may at any time and in our sole discretion determine not to have the book-entry debt securities of any series represented by one or more
global debt securities and, in that event, will issue certificated debt securities in exchange for the global debt securities of that series. Global debt securities will also be exchangeable by the holders for certificated debt securities if an
Event of Default with respect to the book-entry debt securities represented by those global debt securities has occurred and is continuing. Any certificated debt securities issued in exchange for a global debt security will be registered in such
name or names as the depositary shall instruct the trustee. We expect that such instructions will be based upon directions received by the depositary from participants with respect to ownership of book-entry debt securities relating to such global
debt security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained the foregoing information concerning the depositary and the depositary&#146;s book-entry system from
sources we believe to be reliable, but we take no responsibility for the accuracy of this information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge, Defeasance and Covenant Defeasance
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance.</I> The indenture provides that, unless otherwise provided by the terms of the applicable series of debt
securities, which will be described in the applicable prospectus supplement, we may be discharged from any and all obligations in respect of the debt securities of any series (except for certain obligations, including, among others, the obligations
to register the transfer or exchange of debt securities of such series, to replace stolen, lost or mutilated debt securities of such series, and to maintain paying agencies and certain provisions relating to the treatment of funds held by paying
agents). We will be so discharged upon the deposit with the trustee, in trust, of money and/or U.S. government obligations that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient
in the opinion of a nationally recognized investment bank, appraisal firm or firm of independent public accountants to pay and discharge each installment of principal, premium, if any, and interest, if any, on the debt securities of that series on
the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discharge may
occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the
indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and will
be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants.</I> The indenture provides that, unless otherwise provided by the terms of the applicable series of debt
securities, which will be described in the applicable prospectus supplement, upon compliance with certain conditions:<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger or Sale of Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants which
may be set forth in the applicable prospectus supplement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any omission to comply with those covenants will not constitute a default or an Event of Default with respect to the debt securities of that series, or covenant defeasance. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">depositing with the trustee money and/or U.S. government obligations that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a
nationally recognized investment bank, appraisal firm or firm of independent public accountants to pay and discharge each installment of principal of, premium, if any, and interest, if any, on the debt securities of that series on the stated
maturity of those payments in accordance with the terms of the indenture and those debt securities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of
such covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such covenant defeasance had not occurred. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance and Events of Default.</I> In the event we exercise our option to effect covenant defeasance with respect to any series
of debt securities and the debt securities of that series are declared due and payable because of the occurrence of any Event of Default, the amount of money and/or U.S. government obligations or foreign government obligations on deposit with the
trustee will be sufficient to pay amounts due on the debt securities of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the time of the acceleration resulting
from the Event of Default. However, we shall remain liable for those payments.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that we and the trustee may enter into supplemental indentures without the consent of the holders of debt securities to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cure any ambiguity or correct any inconsistency or defect in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for uncertificated securities in addition to or in place of certificated securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence the assumption by a successor person of our obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add any additional Events of Default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for addition of collateral or guarantees for the benefit of debt securities of any series or add an additional guarantor or obligor under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">secure any debt securities and provide the terms and conditions for the release or substitution of the security; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add to, change or eliminate any of the provisions of the indenture in a manner that will become effective only when there is no outstanding debt security which is entitled to the benefit of the provision as to which the
modification would apply; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any change that would provide any additional rights or benefits to the holders of the debt securities or that does not adversely affect the holders&#146; rights thereunder in any material respect or to surrender
any right or power conferred upon us under the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act of 1939, as amended (the &#147;Trust Indenture Act&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for the issuance of and establish the form and terms and conditions of securities of any series as permitted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate any conflict between the terms of the indenture and the Trust Indenture Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence and provide for the acceptance of appointment by a successor trustee and add to or change any of the provisions of the indenture as is necessary for the administration of the trusts by more than one trustee;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conform any provision of the indenture, the securities of any series or any related guarantees or security documents to the description of such securities contained in the applicable prospectus, prospectus supplement,
offering memorandum or similar document with respect to the offering of the securities of such series to the extent that such description was intended to be a verbatim recitation of a provision in the indenture, such securities or any related
guarantees or security documents (as provided for in an Officer&#146;s Certificate to the trustee). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture also
provides that we and the trustee may, with the consent of the holders of not less than a majority in aggregate principal amount of debt securities of each series then outstanding and affected add any provisions to, or change in any manner, eliminate
or modify in any way the provisions of, the indenture or modify in any manner the rights of the holders of the debt securities. We and the trustee may not, however, without the consent of the holder of each outstanding debt security affected
thereby: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the amount of debt securities whose holders must consent to an amendment, supplement or waiver; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal of or premium, if any, on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with
respect to any series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal amount of discount securities payable upon acceleration of maturity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a default in the payment of the principal of, premium, if any, or interest, if any, on any debt security (except a rescission of acceleration of the debt securities of any series by the holders of at least a
majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make the principal of or premium, if any, or interest, if any, on any debt security payable in currency other than that stated in the debt security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any change to certain provisions of the indenture relating to, among other things, the amendment provision, the right of holders of debt securities to receive payment of the principal of, premium, if any, and
interest, if any, on those debt securities and to institute suit for the enforcement of any such payment, and to waivers of past defaults; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a redemption payment with respect to any debt security. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount
of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt
securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of,
premium, if any, or any interest, if any, on any debt security of that series or in respect of a covenant or provision which cannot be modified or amended without the consent of the holder of each outstanding debt security of the series affected;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Individual Liability of Incorporators, Stockholders, Officers or Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that no past, present or future director, officer, stockholder or employee, as such, of ours or any successor
corporation shall have any individual liability for any of our obligations, covenants or agreements under the debt securities or the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by, and construed in accordance with, the laws of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concerning our Relationship with the Trustee
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we and our subsidiaries may maintain ordinary banking and credit relationships with Wells Fargo Bank, National
Association and its affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_10"></A>DESCRIPTION OF GUARANTEES OF CERTAIN DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be fully and unconditionally guaranteed by certain of our domestic subsidiaries, if so provided in the applicable
prospectus supplement. The prospectus supplement will describe the terms of any guarantees, including, among other things, the method for determining the identity of the guarantors and the conditions under which guarantees will be added or released.
Except as otherwise provided in the applicable prospectus supplement, to the extent any series of debt securities is guaranteed, all additional registrants named in the registration statement, to which this prospectus is a part, will guarantee such
debt securities. Any guarantees will be joint and several obligations of the guarantors. The obligations of each guarantor under its guarantee will be limited as necessary to prevent that guarantee from constituting a fraudulent conveyance or
fraudulent transfer under applicable law. Any guarantee will be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_11"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock is a summary. You should keep in mind, however, that it is our Restated Certificate of
Incorporation, including any certificates of designations that are a part of our Restated Certificate of Incorporation, our Amended and Restated Bylaws and the Delaware General Corporation Law (&#147;DGCL&#148;), and not this summary, which define
your rights as a securityholder. There may be other provisions in these documents that are also important to you. You should read these documents for a full description of the terms of our capital stock. Our Restated Certificate of Incorporation,
including any certificates of designations, and our Amended and Restated Bylaws are incorporated by reference as exhibits to the registration statement that includes this prospectus. See &#147;Where You Can Find More Information&#148; for
information on how to obtain copies of these documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200.5&nbsp;million shares, of which
200&nbsp;million shares are designated as common stock, with a par value of $1 per share, and 500,000 shares are designated as preference stock, with a par value of $1 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> Each
holder of our common stock is entitled to one vote per share held of record on all matters as to which stockholders are entitled to vote. There are no cumulative voting rights in the election of directors. The quorum required at any
stockholders&#146; meeting for consideration of any matter is a majority of the issued and outstanding shares of our common stock, represented in person or by proxy. Generally, all matters submitted to a meeting of stockholders will be decided by
the vote of the holders of record of a majority of the issued and outstanding shares of our common stock present at such meeting, represented in person or by proxy.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I> Holders of our common stock are entitled to receive dividends when, as and if declared by the board of directors out
of funds legally available for that purpose, subject to preferences that may be applicable to any outstanding preference stock and any other provisions of our Restated Certificate of Incorporation.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights Upon Liquidation.</I> In the event of any liquidation, dissolution or winding up, the holders of our common stock are entitled,
after payment of all of our obligations, and subject to the rights of holders of shares of any outstanding preference stock, to receive pro rata any assets distributable to stockholders in respect of shares held by them.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Miscellaneous.</I> All of the outstanding shares of our common stock are fully paid and non-assessable. Holders of common stock have no
preemptive or other rights to subscribe for additional shares. No shares of common stock are subject to redemption or a sinking fund.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing.</I> Our common stock is listed on the New York Stock Exchange under the symbol &#147;TFX.&#148; On November 14, 2017 the last
reported sale price of our common stock on the New York Stock Exchange was $256.55 per share.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock Available for
Issuance Under Stock Plans.</I> Our 2014 Stock Incentive Plan (the &#147;2014 plan&#148;) provides for the granting of various types of equity-based awards to directors, officers and key employees. These awards include stock options, stock
appreciation rights, stock awards and other stock-based awards. Under the 2014 plan, we are authorized to issue up to 5,300,000 shares of common stock, but each share underlying any type of award other than a stock option or a stock appreciation
right will be counted as 1.8 shares. The maximum number of shares underlying incentive stock options (within the meaning of Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) that may be granted under the 2014
plan is 3,975,000.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Effect of Authorized but Unissued Capital Stock.</I> As of October&nbsp;30, 2017, we had
approximately 154,950,733 shares of common stock authorized but not issued and outstanding and therefore available for future<I> </I>issuance.<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
</I>We may<I> </I>use these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital, facilitating corporate acquisitions or
paying a dividend on our capital&nbsp;stock.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of unissued and unreserved shares of common stock may enable our board
of directors to issue shares to persons friendly to current management. In addition, if we issue preference stock, such an issuance could render more difficult or discourage a third party&#146;s attempt to obtain control of us by means of a merger,
tender offer, proxy contest or otherwise, thereby protecting the continuity of our management, and could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments
upon liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent.</I> The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp;
Trust Company, LLC.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preference Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by shareholders, to issue up to 500,000 shares of preference stock in one or
more series. The holders of our preference stock do not have the right to vote, except as our board of directors establishes, or as provided in our Restated Certificate of Incorporation or as determined by state law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors has the authority to determine the terms of each series of preference stock, within the limits of our Restated
Certificate of Incorporation, our Amended and Restated Bylaws and the laws of the state of Delaware. These terms include the number of shares in a series, the consideration, dividend rights, liquidation preferences, terms of redemption, conversion
or exchange rights and voting rights, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effects on Our Common Stock if We Issue Preference Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue preference stock, it may negatively affect the holders of our common stock. These possible negative effects include the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diluting the voting power of shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subordinating the liquidation rights of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">affecting the market price of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying or preventing a change in control of Teleflex; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making removal of our present management more difficult; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restricting dividends and other distributions on our common stock. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Specific Provisions of Our Charter and
Bylaws and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate of Incorporation; Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Constitution of Board of Directors.</I> Our Amended and Restated Bylaws provide that the board of directors must consist of not less than 6
and not more than 15 directors.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors; Vacancies; Newly Created Directorships.</I> Our Restated Certificate of
Incorporation provide that no director can be removed except for cause and (i)&nbsp;upon the affirmative vote of the holders of at least 80% of the outstanding shares of the Company entitled to vote generally in the election of directors or
(ii)&nbsp;upon the majority vote of the entire board of directors. Any vacancies on our board of directors or newly created directorships resulting from any increase in the number of directors may be filled by a majority of the directors then in
office, although less than a quorum, or by the sole remaining director or by our stockholders.<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calling of Special Meetings of Stockholders.</I> Our Amended and Restated Bylaws provide that
special meetings of stockholders can be called at any time by the board of directors. In addition, stockholders are not entitled to call a special meeting of the stockholders.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Requirements for Stockholder Proposals and Director Nomination.</I> Our Amended and Restated Bylaws provide that
stockholders seeking to nominate candidates for election as directors or to propose other business to be considered by the stockholders at an annual meeting of stockholders must provide timely notice of their proposal in writing to the corporate
secretary or assistant corporate secretary at our principal executive offices. Generally, to be timely, a stockholder&#146;s notice regarding the nomination of candidates for election of directors or the proposal of other business to be considered
by the stockholders at an annual meeting of stockholders must be delivered to the corporate secretary not less than ninety days nor more than one hundred and twenty days prior to the first anniversary date of the preceding year&#146;s annual
meeting. If the date of the annual meeting is convened more than thirty days before or more than sixty days after such anniversary date, the stockholder&#146;s notice will be timely if it is delivered not earlier than the one hundred and twentieth
day prior to such annual meeting and not later than the close of business on the later of the ninetieth day prior to such annual meeting or the tenth day following the day on which public announcement of such meeting is first made.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#146;s notice regarding the nomination of candidates for election of directors at a special meeting of
stockholders must be delivered to the corporate secretary not earlier than the one hundred and twentieth day prior to such special meeting and not later than the close of business on the later of the ninetieth day prior to such special meeting or
the tenth day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the board of directors to be elected at such meeting. Our Amended and Restated Bylaws also specify
requirements as to the form and content of a stockholder&#146;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment.</I> Pursuant to the Delaware General Corporation
Law, our Restated Certificate of Incorporation may generally be amended by the adoption of a resolution by our board of directors setting forth the proposed amendment, declaring its advisability and submitting the proposed amendment for approval by
the affirmative vote of the holders of a majority of the voting power of the outstanding stock.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Bylaws
may generally be amended by the holders of a majority of the voting power of the outstanding stock. The provisions of our Amended and Restated Bylaws may also be amended by the board of directors by an affirmative vote of a majority of the board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our Restated Certificate of Incorporation provides that certain specified provisions of our Amended and Restated
Bylaws cannot be altered, amended, supplemented or repealed except by the affirmative vote of at least 80% of the outstanding stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitation of Liability; Indemnification.</I> The Delaware General Corporation Law authorizes corporations to limit or eliminate the
personal liability of directors to a corporation or its stockholders for monetary damages for<I> </I>breaches of directors&#146; fiduciary duties, except (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the corporation or its
stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the Delaware General Corporation Law regarding unlawful dividends or stock
repurchases and redemptions, or (iv)&nbsp;for transactions from which the director derived an improper personal benefit.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Restated Certificate of Incorporation provides that no director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as otherwise provided under the Delaware General Corporation
Law. The effect of these provisions is to eliminate the rights of the Company and its stockholders to recover monetary damages against a director for breach of fiduciary duty of care as a director except in certain limited situations. These
provisions do not limit or eliminate rights of us or any stockholder to seek non-monetary relief such as an injunction or rescission in the event of a breach of a director&#146;s fiduciary duty of care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding (a &#147;Proceeding&#148;), whether civil, criminal, administrative, arbitrative, or investigative, or any appeal in such a Proceeding or any inquiry or investigation that could lead
to such a Proceeding, by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was or has agreed to become a director or officer of the Company, or is or was serving or has agreed to serve at the request
of the Company as a director, officer, partner, venturer, proprietor, trustee, employee, agent, or similar functionary of another foreign or domestic corporation, limited liability company, partnership, joint venture, sole proprietorship, trust,
employee benefit plan, or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by him or her or on his or her behalf in connection with such action, suit or proceeding and any appeal therefrom, provided that he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
interests of the Company, and, with respect to any criminal action or proceeding had no reasonable cause to believe his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-Takeover Provisions.</I> Our Restated Certificate of Incorporation requires the approval of the holders of 80% of the outstanding
shares of all classes of capital stock entitled to vote generally in the election of directors voting together as a single class for certain transactions between the Company and a &#147;Related Person&#148; involving securities or other property
having a fair market value greater than $500,000. A &#147;Related Person&#148; is any person (other than the Company or any subsidiary) who is the beneficial owner of 10% or more of the Company&#146;s outstanding shares of capital stock entitled to
vote generally in the election of directors, considered for such purpose as a single class.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions requiring such
supermajority shareholder approval include (i)&nbsp;any merger or consolidation of the Company with or into any other person or any merger of any other person into the Company, (ii)&nbsp;any sale, lease, exchange or other disposition by the Company
of all or any substantial part of its assets to or with any other person, or (iii)&nbsp;the issuance or transfer by the Company or any subsidiary of the Company of any securities of the Company having voting power to any other person in exchange for
securities, cash or other property or a combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 80% shareholder voting requirement does not apply to any such
transactions, if, prior to the time that the Related Person became a Related Person, the Company&#146;s board of directors shall by resolution have approved a memorandum of understanding with such Related Person setting forth, at least generally,
the substance of the terms on which such transaction shall thereafter be consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the above described
provisions of our Restated Certificate of Incorporation is to discourage other persons from attempting to acquire control of the Company through the acquisition of a substantial number of shares of capital stock followed by a forced merger, sale of
assets or similar transaction without negotiating with management. The provisions also may serve to reduce the danger of possible conflicts of interest between a substantial shareholder on the one hand and the Company and its other shareholders on
the other. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested
stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the corporation has elected in its certificate of incorporation not to be governed by Section&nbsp;203, which we have not done; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the time the person became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an
interested stockholder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares
owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the time of or after the person became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the
affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
term &#147;business combination&#148; is defined generally to include, among other things, mergers or consolidations between a Delaware corporation and an &#147;interested stockholder,&#148; transactions with an &#147;interested stockholder&#148;
involving the assets or stock of the corporation or its majority-owned subsidiaries, transactions which increase an interested stockholder&#146;s percentage ownership of stock and the receipt by an interested stockholder of a disproportionate
financial benefit provided by or through the corporation or its majority-owned subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;interested stockholder&#148;
is defined to include any person, other than the corporation and any direct or indirect majority-owned subsidiary of the corporation, that is the owner of 15% or more of the outstanding voting stock of the corporation, or is an affiliate or
associate of the corporation and was the owner of 15% or more of the outstanding voting stock of the corporation, at any time within three years immediately prior to the relevant date, or the affiliates and associates of any such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 makes it more difficult for a person who would be an &#147;interested stockholder&#148; to effect various business
combinations with a corporation for a three-year period. The provisions of Section&nbsp;203 may encourage companies interested in acquiring our company to negotiate in advance with our board of directors, because the stockholder approval requirement
would be avoided if our board of directors approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board
of directors and may make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_12"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the depositary shares and the terms of the deposit agreement is a summary. It summarizes only those aspects of
the depositary shares and those portions of the deposit agreement that we believe will be most important to your decision to invest in our depositary shares. You should keep in mind, however, that it is the deposit agreement, and not this summary,
which defines your rights as a holder of depositary shares. There may be other provisions in the deposit agreement that are also important to you. You should read the deposit agreement for a full description of the terms of the depositary shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The particular terms of the depositary shares offered by any prospectus supplement and the extent to which the general provisions
described below may apply to such depositary shares will be outlined in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to offer from time to time fractional interests in our debt securities and shares of our common stock or preference stock. If we
do so, we will issue fractional interests in our debt securities, common stock or preference stock, as the case may be, in the form of depositary shares. Each depositary share would represent a fractional interest in a security of a particular
series of debt securities, a fraction of a share of common stock, a fraction of a share of a particular series of preference stock, as the case may be, and would be evidenced by a depositary receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will deposit the debt securities, and shares of common stock and preference stock represented by depositary shares under a deposit
agreement between us and a depositary, which we will name in the applicable prospectus supplement. Subject to the terms of the deposit agreement, as an owner of a depositary share you will be entitled, in proportion to the applicable fraction of a
debt security or share of common stock or preference stock represented by the depositary share, to all the rights and preferences of the debt security, common stock or preference stock, as the case may be, represented by the depositary share,
including, as the case may be, interest, dividend, voting, conversion, redemption, sinking fund, repayment at maturity, subscription and liquidation rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest, Dividends and Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will distribute all payments of interest, cash dividends or other cash distributions received in respect of the debt securities,
common stock or preference stock, as the case may be, in proportion to the numbers of the depositary shares owned by the applicable holders on the relevant record date. The depositary will distribute only an amount, however, that can be distributed
without attributing to any holder of depositary shares a fraction of one cent, and any balance not so distributed will be added to and treated as part of the next sum received by the depositary for distribution to record holders of depositary
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there is a non-cash distribution, the depositary will distribute property received by it to the record holders of depositary
shares entitled to it, unless the depositary determines that it is not feasible to make the distribution. If this happens, the depositary may, with our approval, sell the property and distribute the net sale proceeds to the holders. The deposit
agreement will also contain provisions relating to the manner in which any subscription or similar rights that we offer to holders of the preference stock will be made available to the holders of depositary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Depositary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
redeem a debt security, common stock or a series of preference stock represented by depositary shares, the depositary shares will be redeemed from the redemption proceeds received by the depositary. The depositary will mail notice of redemption not
less than 30, and not more than 60, days before the date fixed for redemption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the record holders of the depositary shares to be redeemed at their addresses appearing in the depositary&#146;s books. The redemption price for each depositary share will be equal to the
applicable fraction of the redemption price for each debt security or share of common stock or preference stock, as the case may be, payable in relation to the redeemed series of debt securities, common stock or preference stock. Whenever we redeem
debt securities or shares of common stock or preference stock held by the depositary, the depositary will redeem as of the same redemption date the number of depositary shares representing, as the case may be, fractional interests in the debt
securities or shares of common stock or preference stock redeemed. If fewer than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot, proportionately or by any other equitable method as the
depositary may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the date fixed for redemption, the depositary shares called for redemption will no longer be considered
outstanding and all rights of the holders of the depositary shares will cease, except the right to receive the cash, securities or other property payable upon the redemption and any cash, securities or other property to which the holders of the
redeemed depositary shares were entitled upon surrender to the depositary of the depositary receipts evidencing the depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount distributed in any of the foregoing cases will be reduced by any amount required to be withheld by us or the depositary on account
of any taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Rights under the Indentures or Voting the Common Stock or Preference Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting at which you are entitled to vote, or of any request for instructions or directions from you as holder of
fractional interests in debt securities, common stock or preference stock, the depositary will mail to you the information contained in that notice. Each record holder of the depositary shares on the record date will be entitled to instruct the
depositary how to give instructions or directions with respect to the debt securities represented by that holder&#146;s depositary shares or how to vote the amount of the common stock or preference stock represented by that holder&#146;s depositary
shares. The record date for the depositary shares will be the same date as the record date for the debt securities, common stock or preference stock, as the case may be. The depositary will endeavor, to the extent practicable, to give instructions
or directions with respect to the debt securities or to vote the amount of the common stock or preference stock, as the case may be, represented by the depositary shares in accordance with those instructions. We will agree to take all reasonable
action which the depositary may deem necessary to enable the depositary to do so. The depositary will abstain from giving instructions or directions with respect to your fractional interests in the debt securities or voting shares of the common
stock or preference stock, as the case may be, if it does not receive specific instructions from you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit
Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into an agreement with the depositary at any time to amend the form of depositary receipt evidencing the
depositary shares and any provision of the deposit agreement. However, the holders of a majority of the depositary shares must approve any amendment which materially and adversely alters the rights of the existing holders of depositary shares. We or
the depositary may terminate the deposit agreement only if (a)&nbsp;all outstanding depositary shares issued under the agreement have been redeemed or (b)&nbsp;a final distribution in connection with any liquidation, dissolution or winding up has
been made to the holders of the depositary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and Removal of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering to us notice of its election to resign, and we may at any time remove the depositary. Any
resignation or removal will take effect when a successor depositary has been appointed and has accepted the appointment. Appointment must occur within 60 days after delivery of the notice of resignation or removal. The successor depositary must be a
bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miscellaneous </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will forward all reports and communications from us which are delivered to the depositary and which we are required or otherwise
determine to furnish to holders of debt securities or preference stock, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the depositary will not be liable
under the deposit agreement to you other than for our gross negligence, willful misconduct or bad faith. Neither we nor the depositary will be liable if we or the depositary is prevented or delayed by law or any circumstance beyond its control in
performing its obligations under the deposit agreement. Our and the depositary&#146;s obligations under the deposit agreement will be limited to performance in good faith of our respective duties under the agreement. We and the depositary will not
be obligated to prosecute or defend any legal proceedings relating to any depositary shares, debt securities, common stock or preference stock, as the case may be, unless a satisfactory indemnity is furnished. We and the depositary may rely upon
written advice of counsel or accountants, or upon information provided by persons presenting debt securities or shares of common stock or preference stock, as the case may be, for deposit, you or other persons believed to be competent and on
documents which we and the depositary believe to be genuine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_13"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the warrants and terms of the warrant agreement is a summary. It summarizes only those aspects of the warrants
and those portions of the warrant agreement which we believe will be most important to your decision to invest in our warrants. You should keep in mind, however, that it is the warrant agreement and the warrant certificate relating to the warrants,
and not this summary, which defines your rights as a warrantholder. There may be other provisions in the warrant agreement and the warrant certificate relating to the warrants which are also important to you. You should read these documents for a
full description of the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase debt or common or preferred equity securities. We may
issue warrants independently or together with any offered securities. The warrants may be attached to or separate from those offered securities. We will issue the warrants under warrant agreements to be entered into between us and a bank or trust
company, as warrant agent, all as described in the applicable prospectus supplement. The warrant agent will act solely as our agent in connection with the warrants and will not assume any obligation or relationship of agency or trust for or with any
holders or beneficial owners of warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any warrants that we may offer will contain the specific
terms of the warrants. These terms may include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation, amount and terms of the securities for which the warrants are exercisable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each other security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices at which the warrants will be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices at which the securities purchasable upon exercise of the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any mandatory or optional redemption provisions relating to the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any right we have to accelerate the exercise of the warrants upon the occurrence of certain events; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the warrants will be sold with any other securities, and the date, if any, on and after which those warrants and any other securities will be transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the identity of the warrant agent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of the material U.S. federal income tax considerations applicable to the exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the warrants will commence, and the date on which the right will expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maximum or minimum number of warrants which may be exercised at any time; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information with respect to book-entry procedures, if any. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder of warrants to purchase for cash the amount of debt or common or preferred equity securities, at the
exercise price stated or determinable in the prospectus supplement for the warrants. Warrants may be exercised at any time up to the close of business on the expiration date shown in the prospectus supplement relating to the warrants, unless
otherwise specified in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as described in the prospectus supplement relating to the warrants.
When the warrant holder makes the payment and properly completes and signs the warrant certificate at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, we will, as soon as possible, forward
the debt or common or preferred equity securities that the warrant holder has purchased. If the warrant holder exercises the warrant for less than all of the warrants represented by the warrant certificate, we will issue a new warrant certificate
for the remaining warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_14"></A>DESCRIPTION OF PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue from time to time purchase contracts, including contracts obligating holders to purchase from us and obligating us to sell to the
holders, debt securities, shares of common stock or preference stock, or other securities that may be sold under this prospectus at a future date or dates, as the case may be. The consideration payable upon settlement of the purchase contracts, as
well as the principal amount of debt securities or number of shares of common stock, preference stock or other securities deliverable upon settlement, may be fixed at the time the purchase contracts are issued or may be determined by a formula set
forth in the purchase contracts. The purchase contracts may be issued separately or as part of units consisting of a purchase contract and other securities or obligations issued by us or third parties, including U.S. treasury securities, in each
case, securing the holders&#146; obligations to purchase the relevant securities under the purchase contracts. The purchase contracts may require us to make periodic payments to the holders of the purchase contracts or units or vice versa, and such
payments may be unsecured or prefunded on some basis. The purchase contracts may require holders to secure their obligations under the purchase contracts in a specified manner and, in certain circumstances, we may deliver newly issued prepaid
purchase contracts, often known as prepaid securities, upon release to a holder of any collateral securing such holder&#146;s obligations under the original purchase contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will describe the terms of any purchase contracts. The description in the prospectus supplement will not necessarily
be complete and will be qualified in its entirety by reference to the purchase contracts, and, if applicable, collateral arrangements and depositary arrangements, relating to the purchase contracts and, if applicable, the prepaid securities and the
document pursuant to which the prepaid securities will be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_15"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue from time to time units comprised of one or more of the other securities that may be offered under this prospectus, in any
combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement
under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately at any time, or at any time before a specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any applicable prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any material provisions of the governing unit agreement that differ from those described above. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_16"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell any series of debt securities, guarantees of debt securities, common stock, preference stock, depository shares, warrants,
purchase contracts and units described in this prospectus from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to one or more purchasers directly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to underwriters for public offering and sale by them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through brokers or dealers; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through a combination of any of the foregoing methods of sale. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain selling
stockholders may, from time to time, offer and sell shares of our common stock or preference stock, in each case, in amounts, at prices and on terms that will be determined at the time of any such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or one or more selling stockholders may sell the securities directly to institutional investors or others who may be deemed to be
underwriters within the meaning of the Securities Act, with respect to any resale of the securities. To the extent required, a prospectus supplement will describe the terms of any sale of securities we are offering hereunder. Direct sales may be
arranged by a securities broker-dealer or other financial intermediary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the applicable prospectus supplement will
name any underwriter involved in a sale of securities. Underwriters may offer and sell securities at a fixed price or prices, which may be changed, or from time to time at market prices prevailing at the time of sale, at prices related to market
prices, or at negotiated prices. Underwriters may be deemed to have received compensation from us from sales of securities in the form of underwriting discounts or commissions and may also receive commissions from purchasers of securities for whom
they may act as agent. Underwriters may be involved in any at-the-market offering of securities by or on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters may
sell securities to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions (which may be changed from time to time) from the purchasers for whom they
may act as agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, the obligations of any underwriters to purchase
securities will be subject to certain conditions precedent, and the underwriters will be obligated to purchase all the securities if any are purchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the applicable prospectus supplement will set forth whether or not underwriters may over-allot or effect transactions
that stabilize, maintain or otherwise affect the market price of the securities at levels above those that might otherwise prevail in the open market, including, for example, by entering stabilizing bids, effecting syndicate covering transactions or
imposing penalty bids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, we will name any agent involved in a sale of securities, as well as any commissions
payable by us to such agent, in the applicable prospectus supplement. Unless otherwise specified in the applicable prospectus supplement, any such agent will be acting on a best efforts basis for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we utilize a dealer in the sale of the securities being offered pursuant to this prospectus, we and/or one or more selling stockholders
will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents participating in a sale of the securities may be deemed to be
underwriters as defined in the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions, under the Securities Act. We
may have agreements with underwriters, dealers and agents to indemnify them against certain civil liabilities, including liabilities under the Securities Act, and to reimburse them for certain expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters or agents and their affiliates may be customers of, engage in transactions with or perform services for us or our affiliates in
the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some or all of the securities may be new issues of securities with no established trading market. Any
underwriters that purchase the securities for public offering and sale may make a market in such securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We make no assurance
as to the liquidity of or the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the specific plan of distribution, including any
selling stockholders, underwriters, brokers, dealers, agents or direct purchasers and their compensation in the applicable prospectus supplement. In case of any inconsistency between the information in this prospectus and the applicable prospectus
supplement, you should rely on the information in the prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_17"></A>VALIDITY OF THE SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, the validity of the securities will be passed upon for us by our counsel,
Simpson Thacher&nbsp;&amp; Bartlett LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc483473_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included
in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K of Teleflex Incorporated for the year ended December 31, 2016 and the audited historical
financial statements of NeoTract, Inc. included on page 2 of Teleflex Incorporated&#146;s Current Report on Form 8-K dated November 16, 2017 have been so incorporated in reliance on the reports (of which NeoTract, Inc. contains an explanatory
paragraph relating to NeoTract&#146;s liquidity position as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial
reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Vascular Solutions, Inc. Annual Report for the year ended December 31, 2016 have been so
incorporated in reliance on the report of Baker Tilly Virchow Krause, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g483473g40e12.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g483473g12y83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g483473g12y83.jpg
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M 0$! 0$! 0$!_\  $0@ UP(_ P$1  (1 0,1 ?_$ !\  0 !!0$! 0$!
M       )!08'" H$ P$""__$ $40   & @$"! 0"! P%! ,!  $" P0%!@ '
M"!$2"1,4(146,4$B42,R-F$7)#="4G%T=7:RM+4*,V)R@1BAL?$T4\+2_\0
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M.Y.:;C9R457]E7:6I%=A2:PUE"[-F%4IQ@W< 4OPEY)AW/4^AC-&R1/TC@1
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M*+%NRCFRJ4<Q9-4,;E[:.SZ,Z9EK$_OBQ>2 _P#?K0G[EL')T_\ "$_"-_\
M_D!4UWXK_"R-E7</*7RS1SIBX.U=&7U];ET4U4Q[3]#Q\8].<H?F1,W4/H&6
M(X;[/^)^+.'L1Q1@Z<-K$YRA!DL?))<K5II*MEG/$Y\-B2-T3RWQ8_1!\5C%
MCM"X7J6IZEBY/%+7D=%)NG9>T/8=$!T<;]C?F LFU3Q%.%-R432B>0E+9**B
M  %K2GJ,F4P] Z*+W2'@&Z8 (]!.=4$_J/>)0ZYN7.S;CFB"9N'+T@'_ (-U
M?($_!M&>PX_ -W[ERZW'/"=H@19NHPG_ ,2)J8^LVXH /CO2VRK-OJ=TCB3%
M.M%=MD2IT[)2LS<;/1Q^X.XO8]BW+IL;N#W#HJ/4/</;,0M4KE&4PW:EFG,-
M[BM02UY1KH=QS,8\:/CT625[5:VSO:MB"S&?"2O+',SKX>O&YS>OQ5Q9QEOI
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBUUV+Q=T+L:^--KWVK
M.W=ECB4-2370OE]K53LZ>J+6\O>M#;(I$!:H>A;)3UY;W[ZR4X=AUVR%K<HZ
M6=1?I3''/E[V1M<^1S6,8"YSWN#6M:!U+G$@  =22=#Q3>AX].OCY=.OCX=/
M%85WFRX&W4MB;;>L]1E7T_/-K!..8/8]P2M))!EKZ>U0#)K*:[LB-E@(1QKN
MV7&J2%3B'4;79..NUV4D(=T\N-E=2F(W^T#@K&%S;?$V)#V;#XZ]IEV5A'BU
MT5+TB1KOS2T.]W5<=]RO%OFGC'M <'GQ_);S'Q \O)7&ISQXKPZ*#"-N+Q=F
MS12:M4(JE6ENT;MVY"I(H-TG4,P(F@DF0J:1$R F1,I2D "@&8W-VS]GL1(9
ME[$^O.'%Y( _#OJL/Z^"V#DZ8_C"?A&_^MH6+5/%CX4-9-Y%25_LL8X8/'+%
MT=SKVXKHIN&JYVZX :-B7YSE*HF;H8B9NXO02]>N6/PO9MQ;Q!@\/Q%B:,%G
M&YW%8_,XYYO5()I*.4IPWJCY(IY8C%(^O/&7QO(<QQ+7=05BTW:)PM7LSU9[
MD\4M>:6O+NE:<T20O=&_1CC>2T.:=$#J.H66:EXA7"VZJ))0W(:ALSJB $"U
MJRM#+W&Z= .I>(RO)I^X]/QG*'7[YM7.SCCBB"9^&\@\#>_1!#D#T]@H2V2?
MJ!WY+G5N-^%+9U%G*;2?_$F6F/MN1P#[UM? 66N6R.2F*M8(2RQ*_P#R92 E
M6$S'+>P#^B>QR[ELI[" _@5'V$!^@YB%BK9IRF&W7GJS-^E%8AD@E'QCE:UP
M^L+)(;$%E@EKS0V(SX20R,E8?@]CG-/VJMYL+>3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3"*R=C:ZIFVJ38M=;"@TK%3K4R*PFHI1W(1RBI$G"#U
MF[82L0[CYF%EXN1:M)6$G860CYN"EV3&7AY!C),FKI$BPPCJ#C3IJDNZI,+1
MT%6Y;8<5MV>?;*VE:9Z?N&QH"4KLO#VVX778=OEK==Y*->T^IHL4K+.S#1".
MK%>@4&A8:&C8YMU]_+8K%,[W)Y*ACHSU#[URO4:?+H9Y(PX^0 V2>@ZKY?*R
M/K)(QG^,YK>GNV1[UA2D[7X%\>Y>Z2E!M;"-E[R[17L*L6YV9?$E&[.<MEF8
M0,"=Z-CBJI4(JPWNZS4)3:LI"5"&D;7/N8F':*2CH5<*M]K'9]3<6R<1P2N'
ME4JY"XTZ]DM:I+#]L@!\EQ79&HWH9VG7Y+7.^]K2/O54LGB3<5*I&K2TK:K*
M#!!1%)1=O2Y]80,NJ5)/HEZ4BH@)S  B!/8/<0SON ^+\'VD\2UN$^%+$MO,
MVX+=F".S6FI0.BI0/LV"9[#6,:1$QQ:':YCIHZE=;D>),5BZK[EN65L#',:Y
MS(9'NW(X,;ZH&SU(W[ K>AO%:X,RRA$E=O/85100 @3.O=B(I]1^QW+.KOFJ
M0!]SK+ID#^EDX3=D?'L()&&9.!X]SDL:X_4U]N-[O@UI/N721=H_"$IT<F^(
MGP[VE> _\S:[VCXN<![ULE1>6/&?9:J+:D;VU=./W(E!"()<(=A.JB;V*"<#
M*.64R;J(@7V8^QA H]#" 9C.0X0XHQ8<^_@,K!&W?-,:4TE=NO;8B;) /_4Z
M^(Z+OJ?$N OD-J9C'3/=]&+TJ)DQ^$,CF2G_ ,BV" 0$ $! 0$.H"'N @/T$
M!^X#F.+NU^X1,(F$3")A$PB810N\VM[WW7>].3E;U-N2<2OK#PU[O?JUJ^*M
M;25>U2X0=\[5MA4W691=*KWR*HRTK8&#A2%EGTD2,9I%;.XXH,E7N\U] #0_
MQ@/N6#KR_P!JV.M\HS\4^2-TM/'#2L]"RU"V4/)7:>PI%EL:W\:)(O2N[<^8
M[S<]Y0.L]J2VL[XZT%*VBR0ESG[@_IC>,>*-(:DG+7PUL=3XC6M=?9X#8Z>'
M3Q6\_"KDSLC8^T=N:CVM5D8V\14M?;M8"MMA+VY]KMW%7=G26>MK%5?@;"+U
M_"#"_"U]0OH64D&NWZQ7[+ME\QB)RQ2R;DOD^6O9[/UWU\?9X+<C=7('3O'B
MKFMVX;Y"4N*,"I8]%\L=>9G'") .=E7X!D1Q,SCLH&**B,:R<>G(8%G1D&X'
M5+PKV1I8V+OKMB.!G7E#CM\A'BV.-NWR.]H8TZ\3H=5D7#/"/$?&%X8[AS%6
MLE8'*971-#*U5CCH26[<I96JQG1TZ>5G.1RL#G::8#^1'CBVV55?0/&>@M*M
M&]5$$K_L9%"8L:Y/<I7434&;E2 AU"F #HGF7]H372-T7C&BO4I8^R7'<SRZ
M/%UQ$WJ!8L@/D/O9"TF-GNYW2['BT'PMAP?\E['P-BM\;9:2]-ZKG8C#.=7I
MM/B8[&1D8+=@$'3A6AHEKAZL\C>ITOUWR?W-OKYF;;>V7:+M)MGR$LV1E9$R
M<8DU>%\E5*.@&!6D%&H-'+<B@),(YJF4ST.TGM[5W[4+F7NST;5O(7+%69CX
M7UWSR>B1SPN[QCVU@X5XWRLD(VR-NQ#L]?&)/E/]G.*X/L\*Y7AO'1XW#7J=
MC$V:U=TSHF9"C(;,-B9\TDDDEBY5LO89))'R/;0VXDC9R)D2JIZ811Z[(_;R
MU_WT\_SY[S_)^_$GV8?YG8?^CA5YXC_?W+?Y=/\ [Y5DY,*Z57'5KA;:/*HS
MU*M%BJ$VWZ>1,5B:DH&41Z"!@\I_%.6KH@=P /0JH!U#KG&MTJ=^(U[U2M<@
M=]*&W!%8B=\8YF/8?K"WZ]JS4D$U2Q/6E'A+7EDAD'P?&YKA]14FFBO%ZY/Z
MM59QVP7$5N^JHB1-5M;"$B;<DV+TZE87.(:@LLX-[B9U98NRJFZB4#$ "B2+
ML_V-\*Y8/DQS9L#;=LA],F:F7'SDHS.Y0T>3*LM4#QZ]=Y_A^TWB''%K+KH\
MO7&@6V0([(:/R+<3>8N/FZQ'8/P4\?&/Q"^.G* 6<+7;$I3-B."% VN;N9M%
MSCI<"_C+7'Q5E(BTIB)53I(Q3PTP5LF+E]#L"#VA7[BGLXXEX4#Y[-87<:T]
M,G0YI8&-\C9C+1-4/4 NE8(><\L<\A4Q\/\ &V"XAY(H)S5O. W1M\L<SG>8
M@?LQ61XD")YEY1S/B9X+>;,"67IA$PB81,(F$3")A$PB81,(F$3")A%K/RX6
MW4AI5^KHA2<1MI;MJOYF<U$:=\^--0CLRJ!NQWKW^$$#4OYY;:I&W+UL9XJA
M"OB%/%)+3Q8I%0M1KS]_Z.GM\U%#5N0W-]_K[6>[JJ[V'L+4"&X;/5M9/)=Q
MHZ&F=T4M?DY&4RH--M^21JI.N=D:K</J-H>[ZACG,#*6!6$VM?'I:Q(HV]0O
MK3?KU[^G3Z_/QWY>\*1C@OR1D.06LDQLS6;&Z0==U_;9>?DR1"+&W0NWJW\]
MUBQ1$=# 4E4;+-G+Y@G0)47=@I<>PC(V9F)]RH$X_+Y(U^O@1Y?'V_'IT6<-
MX\C-+\<*R-JW%?(>H,52K?"X]=0[RPSZZ( )VM>KK$CB8F%BF,F58S-FHV9@
MH15^X:M^Y8O!O9*EC8N]NV&0MZ\K2=R2$>4<;=O>? 'E:0-CF('59-POP;Q+
MQG=] X<Q-G(RM+>_F8!'3J-<>DERY*65JS2 2T22!\G*6Q,D?II@MVSXW]@L
M-L8UW1U :4VF+R2;%Y>+X",O;5FC@QD"2#"NLUSUV %LH=-PH21=6WSFZ9P%
M-LH?M)%W$W'F3=CKS>'(FU;3()'UK-F..Q,Y[!S@,KNYH&O>&N8T2]^WF<TE
MOB%8>S\F.YC^#<[D;6;=<XJK8JQ<QF-Q<(_!PM56BP:KYK,1L7GV8HY*\)9#
M1;'/+&X]ZUGK8AO&V-E[*<F<WN\62SB93S"MI.4<*1K<W7K_ !.(3,G%L2@;
MW C-F@0!]P+URI.7XDSV>D,F8R]_(;=SB.Q8D=7C=_\ 9K MKP#\V&)C?<J/
M2SS3'YV1[_<XG0^#?HCZ@L>YTBVDPBCFNW[9V[_$\_\ [J[S] 78]^*3LM_T
M<\$?],XQ5SSG[]9C^=,A_2YE;&2,NK5V4Z^WC7DLG.T*XVBE32?;V2U4GI2O
MR  0W<4HNXITU7,F _5,QS$, B!BB B \.[CZ&2A-?(4JEZ [W#<KQ68^O0G
MDF8]H/O VN35N6Z,@FI6K%24?QM::2!_3RYHW-=KW;TI0M$>,1R2ULJRC-I-
MX;=U72%--4\PFC6[L@W+T* -+1#L_1O#E*)CG4GX&8>.3 4II% .I\BK/]B_
M#&3#Y<2Z?!6SL@0%UJBYQZ^O4G?SLWT %>Q!&P;/=.\%(6'[4,]0+8\B(LO7
M&@3*!!;:T=/4L1-Y'>TF:&5[C_&-ZE3S<9^>7'?E(DWCZ1:1@;T9#S7.M[D#
M>&MA1(03KFB4_4+QME;) 4ZAEJ^_?K-VY2K2+6/$X)A7[BCL_P").$RZ2_4]
M(Q_-IF3I%T],[.FB8\K9:KCL -LQQM<[;8GR:VICP'&6#XB#65+/<W"-NH6N
M6*ST\>[',Z.PT:)W ]Y:W1D:PG2W,S"5E281,(F$3")A$PB81,(F$3")A$PB
M810I6#GYR7;;OWOKVK5"H6!I (<H(?3,.CJV\OXNY3>AXVKC#GHFU8:^NX;?
MFP6\LKL-#;/'VF5BK; J3RASU9(]CI"MC*W(OK0UOX??OQ]GEHK+/'_Q!WEN
MV/':QV\R&OO&$Y9]>/;"UUA?*ZVLUNF=YV&A:-L4@QFGKM35<+L'7L=095&(
ML(3*\UL7;1Z8TD*VZU;:F+XM"/9U_P"PZ_?]W7SZ2J86BC-Y1>*GQLXYK2-:
MAI!3<FR6)E6ZM3HKYJ:&B7R74HMK/=3E=1$8HFJ11!TRB4;#-,7!/*?1#8![
MPQ?*\68S&ET3'>FVF[!AKN'(QP\I9^K&:((+6"21IZ.8/%39P-V#\:<9-ANV
M(6\.864->W(96*06;$1\'T<8"RS.""'LDL.IUI6'FBL/\#%LP\4'D'R)^9F!
M)2/U6R9.B*-(/7X.63T\,[(*;<SNSO%G$\N_;K)+$>.8QS#,U?4-Q+&HCV@%
M>>TKC[C!KZK<?D7XG&6HWQNCQP[FP)XW;//> ]*;SQ/;R"&6%I+)"6G0UU7;
MSV6GLPDX<EQ-^]>Q67J6(+5JTV%LC<Q4D[R5K3!&P05[%6>%U6 NED!KVBZ:
M0#U<32$C(2SM>0E7[R3?N3BHX?2#I=X[<''ZG7<N3J+*G'[F4.8?WY 4\\]F
M5\]F:6Q-(>:2:>1\LKS[7R2%SW'WDDJN)<7';B7$^))))^L]5X\VEHL1[P_D
M\D_[9%?Z]'+5?(Q_'UP__,_$O_)K*Q'CC^]VU_+5?^.Q:-Y[/*#4PBV*U#RU
MY'Z)5;?P8;>N5?CFIBB2N+R1IVHF*4?<AZG/EDZ]^(O4@JDCB."D$?*63,!3
M!C>9X/X9SX=^%<-2LR/WNRV+T>X-^8N5S%9\>NC*6D^+2N\QG$N=PY;^#\G:
M@8WP@,G?5C\:TPD@\.FQ&' >!"F3X\>-BT<JL:_R8H:<;WF30-L37"+A=FGU
MZ$!S.4I\Y<O4TR@'G/'L!*O5#&$Q65;*7M3"%.).PQ[&R6>%\@9=;<,;DW-:
M\^?+!>C:V,D_19'8A8 /W2UXE2E@^UEKBR#/TQ'O3?3J(<6CRYIJCW.</:]\
M$CNO1E<#HIQ]<;/U[MZK,KKK*X05VJ\@'1"6@7R;M%-8"E.HS?(AVNHR1;@<
MH.HR20:2#0X^6Z;(G_#D#9/%9+#6WT<K2L4;<?5T-B,L);L@/C=U9+$[1Y)8
MG/C>!MCR%+U#(4<G79;Q]J&W7?X2PO#@#H$L>/I1R-V.:.1K7M\'-!5^9UZY
MB81,(F$3"+^>PG?YG87S.G3O[0[^GY=W3KT_=UZ81?)NU;-$2MVK9!LW(8QB
M(-T4T42&.H98YBI)E*0ICJF,J80* F4,8X]3"(X10^\\/%.H_')U.ZRTBWA+
M]N\>YE8)@P$=4_7[M$HH"E-KM%$U+):F(=4B5YNX(TB%@,6=>)KMCP;O#>(.
M+(<:7U*/)8O#;7N/K05CX$/T1WDP_P $#II_=' CD=8GLH[!LCQBVOGN)38Q
M'#3^66M"T=WDLS'XM=7#VGT2A(/_ -Y(PR3L_N2,L>VU'R\[.VML;<]OD;YM
M*X3=VM<H;^,RTVZ%<Z2(&.=)C'M2 FRB8ML)S%9Q46V9QK,@BFU:HD_#D56K
M=F],ZQ;F?/,_Q>\[T/)K1T:Q@_@L: T>0"O1@\!AN&L=#BL%CJN,H0#U*]:,
M-#G: =+,\[EL3OT#)/.^2:0]7O<>JQ]G&7;K*VE;%\N;#A%%%/+:2QSP;SJ;
MM**<B)2-A,/T J<B1DJ83>P%(;W#]8,9XNH>GX*XT-W+5 NQ=-D&OLR:'B2Z
MNZ9HUUV1X^!A;Y0/"W[*NRWB&**/O+N$C9Q'1 ',X28D/DMAH'5SI,7)?B8U
MO4O>S0/@9&L@5>5"811Z[(_;RU_WT\_SY[S_ "?OQ)]F'^9V'_HX5>>(_P!_
M<M_ET_\ OE63DPKI4PB81?1)55!5)=!51%=%0BJ*R1S)JI*IF Z:J2A! Z:B
M9P Q#E$#%, &*(" #FA <"UP#FN!#FD @@C1!!Z$$="#T(6H)!!!(((((.B"
M.H((Z@@^!4UW"?Q:[?KE>(UOR8>R=ZH F081NR# K(WBH(CVI)C/B '=7.#0
M_"=9PIYMJ9I"LHDO.E(TBTX-XY['J63;-D^%F14,CZTDN,V(Z%UWB?1]D,HS
MN\&M&JCSR@MKDOF,K\)]I5JBZ*AGWR7*/1D=[1?<JC>@9M;=;A;YD[LL&R'3
M -B'2E6K-7KE 1%JJ<U&V*MSS%"3A9R'>(OXR38.2]Z+IF[;G.DLD</81*;J
M0X&3.!3D,4*PVJMFE8FJ7():UJO(Z*>"9CHY8I&'3F/8X M(]XZC1'0@J>J]
MB"W!%9K2QSUYF"2*:)P?'(QW@YKFD@C]!V#U"KF;"WDPB81,(F$3")A$PB81
M,(F$3"*ESD'"6>&E*[9(>+L-?G&#J+FH*<CVDM#2\8^1.W>QTI&/T7#*08/&
MZAT'3-V@JW<(G.DJF<AA*)%_)X&#43A45(:).E6W"+NO)'CF9DX%TWCW42W<
MPI#(B6+<(13Y[&(K,0042CWCID0Q6SA5,Y%"AS'\2+3?$@;CI_B73->N=KS$
M_+3%]G:S7H:+HE7N<F":,W,SB,"W9(WK9*HMD4Y,5U%4&;INBG8I%\[8.:^.
M%<0<6PX\OJ8_DL71MLDA]:"L? @Z/SLS3T+ >5A^F208U9'LI[ \AQ8RMG^*
M_2,5PZ_DEJ4F[BR>9BZ.:]O,-T<?(.HL.:;%B/K5CCCDCN#FMV-LR_[=MLG>
MMF6V;NMMEU.][-3KP[MR*8&.9)HU(/:WCXUKWF(QBX]%K',$>B#-J@B4J819
M9M6+DSI[4TD\S_I/D=L^X >#6CR:T!K1T  5X\-A,3P]CX,5A,?5QF/KC45:
MI$(V;T Z20]7S32:!EGF=)-*[UY9'N)*L;..NT4DVI+3\VT2&?JJ>8_9I?")
M,1'N.+V.*1+S5!_INVPMGIOH "X$ #H&5_XGQOX+S-N!HU#*[TJOTT!#.2[E
M:/R8I!)"/Y/>SXKR9[;^#?V$=H^?QL,7=8V_-^&\0 WE8,?E'/F[F(?X.E;%
MJ@WQ)%4'S62LQ]1*F$4<UV_;.W?XGG_]U=Y^@+L>_%)V6_Z.>"/^F<8JYYS]
M^LQ_.F0_I<RMC)&75IA$PB]+-X[CW;9^P=.6+YDX1=LWK-=5L[:.FZA54'+9
MRB8BR#A!4A5$5DCD434*4Y#%, "'R]C)&.CD8V2-[2Q['M#F/8X:<US7 M<U
MP)!:000=$:7TUSF.:]CG,>QP<U[26N:YIV'-<-$.!Z@@@@]0IS^$GBYS]7<1
M&LN5+YW9:N<R#"(V\"2CNSU\!$J2)+NW0(=>S1)"]OF3[=(]D:]IUI!.PBN*
MS*!..NQVO;;-E.$HV5;8YI)L-L,J6/$N-!SB&U9B=ZKN(JOV&QFL&\KY>X2[
M3)J[HL?Q$]UBN>5D63T76(/("V!UL1^&Y@._;HF03\VV=&T-,Q%BB8V>@)./
MFH289-I*)EXIV@_C9*/>)%7:O6+UJHJW=-7*)R*HKH*'343,!B&$! <K3/!-
M6FEKV(I()X)'130S,='+%(PEKXY(W@.8]K@0YK@""-$*=(I8IXHYH9&2PRL;
M)%+&YKXY&/ <U['M):YK@00X$@CJ%4LVEN)A$PB81,(F$3")A$PB81,(F$6N
MU9XHZ(J&S1VY 4^2:W-.P7RVQA'5\V)+4RMV[:3AV[V3;J;K&7MC_6=)ME[=
M24PYM=EJ-1A9N<<6"S+R#Y=6SV \D6NSX*P]JZIXBZ<C(7>>T(F+J,;J%W(V
M!A/O;3<4&SV<E;G([%(O8(%K/"UVK9S[(EI2[59&WQ=NF8V^RCZR5@K*PO7#
MY3CV[=>E ^S:E;##&-N>X_8UH'5[G>#6-!<X] "5VV"P67XER=;#82C-D,C<
M=RPUX0-@#J^661Q;'!!$WUIIY7LBB8"Z1[0%SL\VO%4VIR,<2]#U0O+:ITLH
M9=FHV9NO27>\LQ$4S*VN78JF-&1;M+J!JK#.O1G1660FI"=(9$C:)LYQ;;R1
M?7IE]2B=M(!U/./;*]O5C2/XIAUHD/=)TU?+LR[!L#P:VOE<^VOG^)6\LC9)
M&=YB\7)X@4*\K0)YXW:U?LQ]Z'-:ZK#4/,7Q-9B"G]9-U#:?E*]P[U57RV#]
M3X/)B(]" TD#$3*JH/V(U=E:NSCT'\"!@ /?,=XIQOX4PMN%K>:>!OI=8 ;)
ME@#B6M'FZ6(RQ-]\@/DHA[<^#?V;=F^>H0Q=[DL;$,[B &\TANXMDDKX8@!L
MR7*3K=)@Z>O8:3X*2/(!7DZF$6(]X?R>2?\ ;(K_ %Z.6J^1C^/KA_\ F?B7
M_DUE8CQQ_>[:_EJO_'8M&\]GE!J81,(F$6:-'<@]N<<[>A=-27"0K4EW(EDX
M\IQ<U^QLD3B;X;9(-8182[(P'4!,'"7JF1U!=1KED]*DY3Z//<.8?B6FZCF*
M4=J+3C%(1RV:SW#7>U9V_.0R#0WRGD> &RLD82T]KB,WD\':%O&6GUY.G>,^
ME#.P']SGA=MDK.I YAS,V71N8_3AU0<(_$3UORS8MZI,ILZ!NQFS,K(4I=V(
MQMF(U2\QW+T5ZY-YK]N5,AW3N!<F/-Q")5C&&4CVJDPI4WCKLVR?"$CK<!?D
M<$]^H[S6?.U2XZ9#D&-&HW$D-988!!,=?N,CQ +%<)<<4.)6"M*&TLLQNWU'
M.^;L!HVZ6F]W5[0 7.A=\]$-_NK&F4R,9&JSE,(F$3")A% SXH?B6.-='F^-
M_'R=\J^&35CMG;$BG "I2DUB"1Q4*P[2$?+N"B9A)-S")@/54S^@8G+93.%Z
M[@'%7$YK&3&8Z35CJVU98>L&QUAB</";\MX_<AZK?G=F*UG89V*LS+:O&?%U
M7FQ/,V;!X>PSU<H6G;,C>C=XXX.&ZM=PU?([Z4&CR-N<RYSG5.=54YE%%#&.
MHH<PG.<YQ$QSG.81,8QC")C&,(B81$1$1'(N)WU/4GJ2?-7; #0&M      T
M !T  '0 #H /!?SA:IA%_::AT5$U4CF342.51,Y1Z&(<A@,0Y1#W Q3  @(?
M00ZYHYH<TM< YK@6N!Z@@C1!'F".A6W+%'/%)!,QLD,T;XI8WC;)(Y&ECV.!
MZ%KFDM</,$A2DT^>)9ZO!3Y!+UDXUNNN!>G:F[ GE/40Z>WZ%XFNE[=/U/H'
MTRN&5I.QN2NT7;U7L2,83XNB)YH7_P"O$YC_ /67C?QUPW)P?QAQ'PU(' 8C
M*VJU=S]\TM(O[['SG?7]L49:\X]T@ZE7)G7K$U'KLC]O+7_?3S_/GO/\G[\2
M?9A_F=A_Z.%7GB/]_<M_ET_^^59.3"NE3")A$PB812/\ ^?EJXG6IO5;4XD+
M'HBQR)1L== QW3NHNW1RD5MM12.;]$Y2]E9F&3$C:=;$,(%3E$VCLD9]H?9Y
M4XOJ.MU&QUN(*T9]&LZ#&7&,!(IW"!U:?""<[?7>?.(O8<[X+XTL\-V6UK+I
M)\-._P"?@^DZJYQ&[58'P</&6(:;,W?02!CAURUFRP%RKT+;*K+L9^MV*-:3
M$'-1BY7+"3C'Z)'#1VU6)['362.4P /0Y!ZD4*10IBA3NU5L4;,].W#)7M5I
M7PSP2M+)(I8W%KV/:>H((^!\02""K+U[$%N"*S6E9-7GC;+#+&>9DD;P'-<T
M^P@_$>! *KF<=;R81,(F$3")A$PB81,(F$3")A%S_>*+XESJI.)[C5QXGQ;V
M5,%XG:NR8=ST7KIC *3RD5)\@;JC8 *)T++.-S@K F$\/'J)SA7Z\-'O%7$Y
MA,F+QTFI1MENRP]8O)T$3A_&>4KQ^Y_0:>?FY+;=A?8I'D&5.->,*@?2/)8P
M&&L,]6YH\T>4R$3AZU3H'TJKQRV^EF9KJIB99YL1$3")C"(B(B(B(]1$1]Q$
M1'W$1'W$1^N1BKI+\PB81;*\;+3\/L<C5G"O1M/-O5,BF'V"3CB'4,0@#T !
M<L!7,<?<3"S0* 9'W:!C>_H09*-NY*4G=S$#J:TY #G'Q/=SA@:/(3/*J3\K
M3@W\*<*XOC*K%S6N&K7H>0<UO5V(RLD<;))".I%3(MKMC'@T7K#SKJMV\B!>
M>J811S7;]L[=_B>?_P!U=Y^@+L>_%)V6_P"CG@C_ *9QBKGG/WZS'\Z9#^ES
M*V,D9=6F$3")A$PBE&\//Q"[!Q@L#+7.QGK^=T'/2 %<MS"L]?ZV?O5NJMCK
MJ0=ZRD,HL<5['74 ,"Y16EXE$)<'+69BGM'[.*_%59^3QK(Z_$->/;7#E9'D
MXXV^K5LNZ 3AHY:MEWT?5AF=W/*^"0N".-IN'IV4;SWS8:9_K-ZO?0>\]9X!
MU)B))=/ T>MLRQCO>9LO61#S$588F,GH*192\+-,&DK$2L<Y2>1\E&OT$W3)
M\R=H&.BY:NVRJ:[==(YDU4CE.0PE$!RH4T,U::6O8B?#/!(^&:&5I9)%+&XL
MDCD8X!S7L<"US2 00059**6.>*.:&1DL4K&R121N#F21O <Q['#8<US2"T@Z
M(.PJEFTMQ,(F$3")A$PB81,(F$3")A%CK;&UJ+I+7UFV?LB;0@*A5(\[Z3?*
M_C66.)BI,XV.:@(*/Y:4=J(L(N/0ZK/'JZ*! #N$P<:W;@HUY;5F01PPMYG.
M/B?(-:/X3W'36M'4N("[C 8#*\3Y>E@\+5=;R-^8101-Z-:-%TDTS_HQ5X(P
MZ6>9WJQQ,<X^&EQC\U>:^Q>8VPE)F;5=5_7$ Z<IZ]UVBZ,=A!LCB*02LKY8
M@C*6N21 II.4.42H%-\.C00CTBD4A3.9RSFK)>\F.K&XBM6!]5C?#G?^5,\?
M3=Y?1;IH7I+V9]F>'[.,0*U9K+>:MQL.8S#F:EM2CUO1Z_-MT%"%W2" $%Y'
M?3\\SB1I9G1J2TPB8126:JM/S=1H6344\Q\@A\,E!$1$_P 0CRE1444$>OXW
M2/D/1]_HZ+]/H%?>)<;^"\S;KM;RPO?Z36Z:'<3[>UK?S8G\\._;&5Y)=L_!
MO[!NT7B#$11=UCK-C\+X<!O+'^#,FYT\447MCI3>D8\'S=4<>OBLB9T*BQ8C
MWA_)Y)_VR*_UZ.6J^1C^/KA_^9^)?^365B/''][MK^6J_P#'8M&\]GE!J81,
M(F$3"*IPTS+UR6C9^ DW\+.0SYM)Q,O%NUV$E&R#-4J[1ZQ>MCIN&KILL0BJ
M*Z*A%$U"E,4P"'7-J>"&S#+7L11SP3QNBFAE8V2*6-X+7QR,<"U['-)#FN!!
M!T5N12RP2QS0R/BFB>V2.6-Q9)&]A!:]CFD.:YI ((((*ZL_#B\0AGR;A$M6
M[0=LX[>U;C15(Y J+-ELR%8IAY\[&-R F@WLC%(OFV2$;$(BHGWSL.B2/&18
M0=2.TSLY?PM.<MBF/EP%F719ZSWXN>0^K7E<=N=5D/JU9W$N!U7F)D[J2Q8W
M@3C9O$$0QV1<QF8@CV':#&9"%@]::-HTUMA@ZSPMT"/GHAW?>,AE:R(U(Z81
M,(HT_$NYG&XMZE"MT>013W5LUH^CZ>8O8JK4H4@>GF+RX1'J!5V@J@PK1%P\
MMS.*"\\IZTA))H?,.&>S[/<<U,RW#6J^-?3J.$%^Y'(^L_(2:,%3<>WM<Z,/
M?).QDWHH[N1\$O/'&_KW<<\*\%9_AVSQ;CKF:Q,F1BER6*QTT,5N3'0DF64=
M]\W)&)>[::KI*YNQB:".W5=NQ%QS/EGKEXY=R*[AT^=N%G3MV[64<.7;EPJ9
M5=TNX5,=5PLNL8ZJJZASJ*J&,<YC&,(C5_B?AC/\)9:QB.),?8Q^1B)>6SCF
M98C<YP%JK8:70VZ\I#N6Q"]['.#FEP>U[6^M' W&W"/'_#M+B#@K+4LKA96-
MBC-343Z,D;&[H7*3FLGQUJNPL#Z=B**1C"QS6F)\;W>3,?68)A$PB81;L<9[
M%ZRN2];64ZK0KXKUJ41]_02@&$Q"!]RI/4'"AQ#Z&>$ ?J'6(>T*AW5^KD&M
M]6W"89"/\-6T 7'VNA?&UH\Q$=>"\^/E<\+>@<5X/BR"/EAX@QKJ%Q[1T.1P
MY8UDDCO)TV/LU8HP?%M%^OHE;,9'JJ,H]=D?MY:_[Z>?Y\]Y_D_?B3[,/\SL
M/_1PJ\\1_O[EO\NG_P!\JR<F%=*F$3")A$PB8138^$IS87US;V7&?9$N8=?W
MJ3,77$D_7ZI5"\2*O4( JBIOT$%<W1_+01(/DL[2J@LFB0L[*NTX,[8.!FY.
MD_BC&0__ *C0BWDXHV];M",=;&FCUK%%@VYQZOJ!P+CZ/"PRQV:\6.H6F8"]
M)^T;DFJ,CW=*MR0](02>D-MQT&CHRR6N#1WTKATWY5I6 3")A$PB81,(F$3"
M)A$PB811;^)_S47XS:N)0M>29&^[-H1[M"#=(J!ZFDU03*,I2YB!>ID9-94%
M8JIB<"%&3(^E2'4" 5:N,KP?9YQ-QMB<W+P_-5IS4H!'6L7>\9#9NO+'&E%*
MP'NIO1B]_?EKV02.K"5K6S=XS9H<=<$\&<6<,R<<U+V2PDEYLV2I8X123QTX
MP\1V;$$CF>D4Q;$0L56/CFM5F6F0N<]G=OX_G)G!W"RCHZJKE50ZJZJQS**K
M*J&$ZBJBAQ,=0ZAS"<RAC&,<PB81$1ZY5K.8/,<.9.UB,]0M8W)U7EMBM;9R
MR;/42,>"YD\,H]>*Q"^2&9A$D4CV$./K=PMQ/PYQA@Z&?X3RM',X.[$#3NX^
M0/@TT .@?'ILE6Q7/S<].Q'#8JR Q3PQR-+1\,ZE9 F$3"*J0<NZ@9B,FF1N
MUU%OFSU'W$ ,9NJ504S]/JFJ4!25+]#)G,40$!$,XURK'=JV*DPW%9ADA?KQ
M D:6\S?SFD\S3Y. /DNFXAPE/B7!9?A_(-YJ>8Q]K'S] 7,99A=$)8]^$L#G
M-FA=T+)6,<"" 5*9$R;6:BXZ79'[VDFR;/FYNH"/E.D2+$ W01 #E _:H7ZE
M.!BCT$!#*WV:\E2S/5F&I:\TD,@\N>-Y8[7M!(V#YC1'BO&S-XBY@,QE,'D&
M=W>Q%^WCK3.NA/3G?!(6$ZYHW.9S1N\'L<UPV""JAFPNK4<UV_;.W?XGG_\
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M:=7)^VV1^C%5ZKPTG8)V3<B)4(^(AV2TA(O%A !'RVS1NLL8"@)A G0H"80
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MH::T=7.TT=2%PZ\C-XV?D;N2[[=M)U$W5GE%#146*PJH5ZML_P"*UZO-!]B
MC%1B:"*RJ9$P>OA=R*I/4O%S&OAPU@:O#6%HX>H 658AWTO+RNLVG^O9LO\
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MO8X!S2"-JB.X\4^JB ")/<3$^HD#\R_<Q0_+W$/KU$.O2B7;)\G:QA/2N)^
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M#^<'VZ_4/;H/3V&&^U#L6X9[2('VW-;A^)HX^6MG*L32Z;D;J.#*P L%ZN
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M;5+]M+9-Y64%96YWZX6I14P]1.:P6&1EA-_Y]7[!] #H >P9Z#XBF,?B<90
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M[,8RSA.LXCI-;NR#W@3&+?VQ$?4I/,BM2"F$3")A$PB81,(J+9(XTQ79Z)(
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MD;M+W'30<NGE'6. !^+L(6Y =7I[%3(*ANA4Q,$L=C%X5.-H("=#)8Z_2&_
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MPV-@V20.9Q<]SG&UV(Q53"X^MC:3.6"NSEV=<\LAZR32D <TDKR7O.@ 3RM
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MK-WLFX;FCE8RXQ[4<#PNV6K7D9ELRWF:*-:0&&M(.G[?LM#F0\IWS5V=Y9)
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M,ZXU9KG4%;;5#6-+KU'KC;H8L97HY!BFX7 @$%Y(+D*+J4D%2E %Y&27=OW
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M$XD.#LS'?F;X08ICKSG^YL\>J0]GKVF>/LWK+,?P!Q5D"TMQCZ<;M;ER#VU
MW?Y4+]VC[?5@=]I&Y6]$>";KRNJLYGD#L"0V$]2%-56FTHCFKU3S"]/,;/Y]
M8PVB9:F]Q*I')U!P ]O43% P&B//]N>2LA\'#N.CQK#L"[>++=O7D^.L!Z)
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E\5;-(U@9K&M"T)V?U\AI9LPM$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g483473g40e12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g483473g40e12.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0EP4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              %0   (@    & &< -  P
M &4 ,0 R     0                         !              "(
M%0                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !M0    !    <    !$
M  %0   64   !K@ &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  1 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MLGUKK_\ ^3?ZO_&G_P ]V+CURJ2DAL?,H+Z3]:/_ !(_5K_B<K_T6M+Z_?\
M)/U=_P#"Q_\ /="\D231O'SDKO\ 1ZEWT3\"NA^NW_*'1_\ TW8G_5N7FJ2>
M?F'U1T?H;_&)_P"(_._K8_\ [<8ZY'I__P"3'J/_ (;/_54+R=)0P^0?WPN.
M_P!'JAPKO4O^0>C?\=F_]5CKB$E,>GG^Q:_2WUH_\375?_"=_P#Y[>O,/\7_
M /XLL#_B\C_SVO.$E%C^27U_)<=P_P#_V3A"24T$(0      50    $!
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  5 (@# 1$  A$! Q$!_]T
M!  1_\0 N0   @(" P              " D'"@8+ P0% 0 " @,!
M       $!@,%  $"!Q    8" 0($ P,'#0$      0(#! 4&!P@)$1( $Q05
M%A@*(2(7,2.S)'@9&O!1,K75)E9WE[<X.3HJ$0 ! @,$!04+" 8+       !
M$0(  P0A,1(%05$3% 9A<2(R%?"1H;'!T5(S<S46@9+"(U,T=#;Q<D.SPP="
M8H*RTM,D5"47)__:  P# 0 "$0,1 #\ =:;Z7'0(2F F8-PBG[1[3&OV%C%
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:B*A'\P*CK)9%CE6\;(XQ]1H6_P"3D[A'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g483473g47t88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g483473g47t88.jpg
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M\AMA4O6%-DXZF2HI'MFMZK1R5#5<B9A?7.W6&M:[*6(*YN5S9GA-@>G7;G]
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M8*O8E5S%[$B\A*2 $4Z,9)0GF2/$<EV5:0OAQAJ6,9*[_>4+,@;OX'N+/I$
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M@4<YO>FY[&<YYG:E^=E/V)FX6J8;,@[^OD8-';=DGW^/IMR^WM],D$.$P]<
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M,:V221SY9,7.\AM:Q(YQK2N;4G?ZU9\U:S;U:N)A$PB810VYG_ZF5'^<ZO\
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M?D02.^B'Q"0YOJ. ;M0S'"G281,(F$3")A$PB81,(F$3")A%$SEMRHKG&:D
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MD_>PJ,ZK_P!FQ?WR+]S.M:&3A8]3")A%\E5DT0[4-UWWT'U,;K\@_P"W8]
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M!&!R#(F@;=!L'4432+YU3D3( E*)U#%(4!.8"$#S&$ [,<Q2%#OLQC 4.Q$
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M:[UC+K^S#+K#4OI$NG<AZ!9DS>2FDK6HKF-G+HQ-9>"R2"*9D\)]2>(EL@(
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MS$Q@WDRE&)NW" 9+M1@A;Q3UZT4L5U#AO26.O5F_TB-N\T;1SFC:/C- ZRL
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M-1FT891ZQC)%@\@K#&NXJ:A89XJE*QC=_!2>\S&,C8R.-K61QM:QC&@!K&,
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M+]AQ1O:2 =P,>9W%:4PB81,(F$3")A%9-]A?FT&JLD3S.XWS.T>@[,9(I?\
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M$C@/IVR1;*&2(U$ 4K[%55!?J6=.4(SJ]EW9R<,V/4.=A RLK-Z%*1O/&Q2
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MTKM>6K;JROAL5YV.CEAE8=G,>QP!!!]Q&Q!((*HF<JZR81,(F$3")A$$ $!
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M9NW<.UDVS1!9RX6,!$6[=(ZRRIQ^A$TDRF.<P_@4I1$?P#*%P:"YQ#6CF22
M!\I/(+Z8Q\CFLC8Y[W'9K&-+G./DUK023[ %)C7/"_E/M95 M.T=?5FC@2^G
M,3T0>GP)B&Z[43G;:>$BER$*/F,#9VLIU[%3,<2E&QW=38''@^DY6H'-ZQ12
M"S,#Y&*OWL@W_6:![5,L1V=ZVSA9]S]-Y1T;SZMBU <?5(\7"S>->%P'CP/<
M?  GDMGFD_!6FWYFTER'V.QBX\X 9S2];E&2DW")P#SMG]LFF24='J 'F2<)
M1\%.)*$./H229@ XP3*]IL0#H\/1=(X@@6;WJ1CPW;6B<7O!\"^6(^;".2S;
MI/X/M^"S5R.HLX*4E::*S%4P9+[3)8GB6-QR,\;8H)(GM:?P-:R-^;)FD G<
MWH3C#HCC)7!K.D]<P-+;.$TB2LJW24?6>P'1]R*V&T22CN=F!*H)U$$'C]1F
MR,H<C!LU1$$@QAD<MD,K+WM^U)8()X&$\,4>_411- CC\B6M!=L.(DK:R6>:
M<[RR.>1TWV 'R-: T;^.P&ZSWEN7$K:D*73I:Q0MOE*G6I*V5Q%TWKUHD(*+
M>6*!;OBF(]0A9MPU4DHM%X0YR.DF+E C@IS%5*<#" D7U<U.K/'40^=UJONG
ML!*/YR">.8:.7=0LU*D=)R<O$.%6QEHV4D4WSU-_(,SHNWA'CHKA50KA4#D5
MP81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%39.&AYM#X:9B8V7;!WTWDV
M+5^A][V']Z=)*I^X '?W??\ '/N.62(\44CXW?G1O<P_.T@KAFKU[+>"Q!#.
MS\R:)DK?^E[7#Z%9!M-:?.IZQ]4ZV.MWWZIJ-5S*=_GYQBQ-W[C[]_CG:^Z>
M1VV^Z%W;R]+GVY]>7>;<U;3I[ $\1P>'+OSCC:1/S]SNKNB*U7*^04X&OPD(
M00\HDB(IA&D$O\$2LD$0$/V==9UY)YICO--+*>N\DCWG_P"Q*N%>I4J MJU:
M]9IZBO#'"#\HC:T%5O.)=A,(H0M^"FK%=OW_ &G-F4D8^PQ5D9477C-W=(JG
MZXG-@;!J>X]G[%B&87QZ2.V?>MQT6G;!=W#7:.LCQ4U7&4U&L$[Q(V>[6$J[
MG;;_ -^2MKC=P*A>->U&M_J]Z1>0B&OG]35K+>G%A'SF6FHO53.5,$VVLKJ.
M9:Y93&MI6X4S5S"L-V%)LVR+F>%G"0J[6%3(3O\ ^_E_U6P/"HF$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB814B6K\#/)@C.PD1-(E 0*E+1K*13 !^H 1
MXBL4 '\>@]\Y(YIH3O%+)$3XQO<P_.TA=>>K5M-X;-:O9;^;/#',WG[)&N"L
MT--:?!7U@U3K8%N_-ZH4:K@KW^?J?*_-W^WOO.S]TLCMM]T+NWEZ5/M\W>+H
M?>_@-^+[B8CB_.^YM+?Y^YW5Z14%"02(MX2'BH= >NT(J/:1Z(]?3M-HBB0>
MOP^[[9UI)993O+))(?.1[GGYW$E7""M6K-X*U>"NW\V"*.)O+V1M:/H55SC7
M.F$5B;$UI2MJP"5:O4.I+1K66C)^-69RLU79R"L$*X^)B9^M6>M2,/9:S/1R
MHG^$FJ_+QLF@DLY;D= W<N$E2=%:?^+QI3[%Q.O UU !3(*HV>C1$$!'8-V-
M<NAV*MK217!U\;\UGG,<V?2%E.Y-95I(7<E\W!_(/W+DF_\ JLA4^GUN@UJ)
MJ%1BTX>O0J!T&#%-9TZ. KN%GCQV\?OUW4C)R<D^<.I*6EY-V\E)>4=NY.3>
M.W[MPX5(KEPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*GR,3%S" M9:-C
MY1J/N+:19MWJ _RHN4U4Q_Z<^V221'BCD?&[\YCG,/SM(*XIH(+#>">&*=GY
MDT;)&_\ 2\.'T*QU--Z@55]9756MU5A'S"JI1JP=41^O?J&BQ/WW^/?>=H9+
M(@;"_= \A:G ^;O%;3I_ D\1PF()\SC:1/SF'=79#U>M5THDK]=@X(@AY1)#
MQ+",*)?R$K)N@ A[!["'6=>6>>;G--+*?_RR/D_[B5WJ]*G4&U6I6K#RKP10
MCYHV-"KF<2[*81,(F$3")A$PB81,(F$3")A%&%SS-XQ?8?9.PJ_N6C7RNZAI
MLEL'8@Z[L$7=I*LTJ%24<S%C?Q< [>/21D6S1<O7BP)#Y&K5P<A3F3\@W3(8
M/,XID<F3Q=^A'*XLB?;JS5VR/ XBUCI&-#G!O,@'?;FK?2RV,R3WQX_(4[KX
MVASV5K$4SF-<>$.<(W.(!/($\M^2N!]RAT3#V.>JUBV+ 5:4@-E1.HCFLSQ*
M$8RU_F:GKZXM(*OOGQTF\P)8S:=$9.7S0YH]O8K TK2CH)SSL2VM7'8^7M^L
M>[H>J_:W*7CHW9GD5MT:\(Q+=U];INOM(P,B\O+5&2</*U&G(H8)218MH::=
M2!8[XI)@UA)IR\500B)%1L5-CY+RV;E%INOA5RL;4QN3JUWFBT1E'TR0AIA\
MS=W_ &9(ZABYR205E&7H5R.OL)/P4R^0,Y<MGD!,M&K%Z^8J-,(OK&<K.-DR
MRCI")WAK61:R]U)KB),SM46X6D[VJPB)=&J1[5-<SI[-KP<_"6)!DV1457K4
MJQLB0'@W*4@8G14.?Y>Z,K.U;7I:8LCYML6G2.CXZ5@AA9 17/R#N<=0-?.H
MAUZ0-IAB2T3$,PM3E@HL6HEFH5Q. T1EXXSDJ['D?/?;W=566_+'C,[BDIMG
MO?5CR*<7!CK]F]9W*%=I2%TE(>0L437(P&[I0\G)S%>B92P0Z,>1R$M!1SZ8
MCC.8YHNY3)L?(_-]O,+&=9Y_\7+9;*95HO8T<BEL).Q(TVSRR["&K,_.UW:;
M#3HU6/<R3]M)+6";N<I&MJX@$5\%+)248DD_))RD='.B;'R/+K[/'ZEF^U;V
MUK2]O:JT989M5GL7=#&[OZ#%$8/'#61+0(@D_.-7DFBD=E%/UX4DI)P;*050
M7G6=;M*T85P6O2?PY4VY;_;[?^/,*SZQS#XK72:C:[4^0FHK!-S!5E(J.C+S
M N5Y!%"J/+V9PT$CSTUVJE,C9>SM729S-WD)!6"0:*KMZ_-'8E78^1^;[>87
MJ;\L>.$C'P+Z$W-KJ>/;',VPJ$?%6Z"5DK3)UY&N.9:-A6R[]MZSAFVN-/>N
M%G!VS%M%VRMS3IVA"S3"07*FQ\OM]@?F7DA^6W'Z1A#RK_9],@7T=1:7?[77
M7=KK,Q*TR)OL?4Y"NM)]U4Y>Q0*DD_)>J>FR1A)F70ERVBMOX)S*15B@G\B5
M=CY>SH5G6LV:NW2N0%PJ$Y$V>J6J&C+%6K' OVTK"3\#-,T9&(F8B39*+,Y"
M,DV#A!XQ>M556[ELLFLBH=,Y3"5%7,(F$6.=E[>U9IJ'96';.PZ;K>"DI(D-
M'R]UL,96XY[+*-73Y.-:O)5RV06>G9LGCHK9,YE10:KJ@7R)'$."Q:K56A]F
M>&NQSN!KII&QM+MB>$%Y )V!.PY[ E73$X3,9V>2KA<7?RMB*(SRP8^K-;EC
MA#V1F5[(6/<V,/D8PO(#>)[1ON0K'NW)_2%!K&HKI,WF.>U+>NR*/JG6%CKH
M'L<-9;=L19VA5B(2,0#IJC#O#L7(KSJRI(IDF0%'3E,IRB/)')',QLL3VR1O
M <Q['!S'-/0M<-P0? @[+J6Z5NA:GI7JTU2Y5D=%9K68W0SP2,^-'+%(&O8]
MOBUP!'DO6]Y-\>(V;M];?[JUHSGZ!%3,U=(=S;X9&0K,;7)B)KT^XEFQW0*-
M30LY8:Y$RC8Q?BF+^S5ALY035L<(5_\ :ZVQ\E:=JYG\7JA4[-<Y'=%(>PU1
MUM*;:FP@9=O.OVU%B"R8.93X",,X<%74<PTJP:QJY49%Q(1L@S(V]9@]*W*H
M!/0=>B\]=YH<<IZY;8HKG95;JTWJ!0CJP#<)V K[.5J8:5U7OE[L& 7=2PG6
MI$11MN5\TO*RR4.Y8OHNR*JL/DL:C,O2;'E[?]2-OEY=%59+EOQ];PCZ4@]H
M4JVR*%%NVP6%9@[;6$)F4@Z C;_M"!E9^8A82N*-9&@W2#6<W.7K46PF:G:&
MDK(,/LS8%(TFQ\OM[ED"J;JU;=+9):_K]XK+_8,)!L[#.T9M.13RRP\6[)'"
M=TZ9L'CM)P@Q5EXIK)NHUP^9,'4G&(N')!DF N2HL'TGGCQ?OC!"5B]CM8R+
M-'[:?OY&SM'%::P0Z7V-0]6W".GCRQ6YHN8=6O9U#)4HM<GQERB[1"RM<2D&
M<FP.Y*NQ^KZ>BN"[<U.+- J[RVSV[J"M&-==)[730A)UE/2LA0'3^7AXZR1T
M7%*NGCF.EIV FJ_&.1330=ST5(Q)50>,'B2!-CY>SW_8CYU5]6\J=*[>O]XU
M;4[:Q#8%%EI9B[J<B]BD)R;B(6*I$L^N-=C6TB\>/JHDEL.JMU7SA%D]:.91
MF#^.:-Y"+</R;'R\OIZ+]I<K="!:=W5"2V#$5Z1X\2>M8G:;RS'- 04([VZ4
MB.O_ (6>DP;Q<LC8)KXFI-U8YRN4ERCI.JJ>6;8.69";=/:O-$\PN+4]!SED
MA=^ZLE82M$JQYQ]'V^*=ECAN[^3B*D@JBBN=R=W8)J#G8*,9(HJ/'$_!3D$"
M 2T-)LVI4V/E]AU^9>I[RFTB,S$5RL7^H7RPRDWKJ+4AZE=:.X<Q<?M :LO4
M[&]5E++%,UXF4A[I6+!$M(IS)6*SPTU'.:C!V [M!(Y%](_EAQIE6M5?QN\M
M:/8^\VPM&ILBVM48K&VBU*+UQJVB(*0*N+.34?N[C3VD6X:+JLI5W;*PVC7+
MI>P1";PJ['GRZ=5(/"HF$3"+&MHW)J>DV./J%PV/2ZS:99)DO&5Z<L<7&3#]
M&2=K,(]5I'NW*3E<CUZW7:-C)IF!9PBHDF)CD, 6FYGL)C[45&]EL?3NSMC=
M#5LVX(;$K99'11&.*1[7N$DC',80#Q.:6C<A<;I8F.#'2,:X[;-+@"=SL-@3
MXGD%8;;DYK->Y;2JRPV",AM,OTX'8FSIF*2B-6P-M4AZ78/L<I:G[U R\^2%
MV#57QO1CSQ!QD%F",LK*1TBQ:W9<NWT^'BJI,\F^/-=>*Q\]NK6D.]03O:SI
MO)6^&9J,FFKW=D8;(?O_ %W9 81E$?T^S,+;*/!0CZ^_AW;*3<MG()I'*FQ\
MOL>GSJT4^8_'E===VALNGJ4YA!S\I,7\]NJ#6NP\K7K?1J,XI[R.>3[>XJ6E
MQ9MA5Z$1:L:L[8-[ Z;U.1D65NDX:!DBKL?MX^T+^7OF/Q\HU;OLZ6_PMOD]
M>:J=;HEZ/392&DKN_P!?-8JOS0S<+#/Y.*1>(GC+;4G8G6?-4&B%KK*\@NS1
MGXI1V38_3M[U]=H\OM&:<V%)ZMOMD?1=TC-2EW6>+2A9!VF]H@W :,=>->HI
M"T>S"4V4YU(%);YH,4@\ETFZD>P?KMB;$\_;M[U<4AREXX1(WD)+>&L&1M:2
M;.&OA7%QA4S5>7D+ ZJ+*,E %WVF_<W!B^IR31,%%S6]B^JOD"?9N8Y(J;?;
MZ?J6(7_B%\4HV28MWNS8MG!+W+9E"EKQ(KL8>EU:RZGBF$O;6ECEYE]'K,VZ
M#9\;T9!LR>L4RQTH]D5X^,8J/\*NQ\OM]OMT6>-E[VUIJ2S:CJ-YFU8R<W==
MQU_0FZ+!V^2=3PQCE^FI*N&J2B,+$+O"15:0EY R+)6V6FI5XJOS"P,$U" ;
M[^P;JUPY;\81N:FO WUJL;PE;&]$4JP7.%&9)<75N?Z_1K1F8.O4"7&_1CNB
MG9_YU&Y@VJJP)SSYBP<E38^7VZ_5S7W'E;QJ^#5?EWGK!1HE<6NO@51M\.M\
M1=7S&=E(^ML$TG)U9*3D8ZK6=]&HQY'(2+6MV!9D9=.%DC-B;+QU[E=HN9:,
M/FFP:E4YUW3YG8#FJ3-QIDC,Q%*A'EE:.;-*N:E8K+ (0ZQ*?97;-XE-K).6
M\%-D(/Q<'--8\J['[;K+]%OM+V;5XZ[:^L\+<:G+*22$?/P#Y&0C7#F&E7L%
M-,O70,8$G\-.1DE"S#!8$WD7+Q[Z,?H-WS1P@F5.G(J[L(F$5F7[8M"U76W-
MQV5<JU0ZHR7:-7=CMLRP@85LY?KE:LD%Y*27;M4U7;@Y$&Z9U0,JJ8I" )A
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M;XIXVB89Q5Y5%:)>2B[0TB^;NXY-(KI(A%;>KX01OX[==O#GLJ)IWGEI'?\
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M*RRS=C::S),V,L'85IW_ (?-L6_4>OFJ38/#=+.P-DKL?L^!UW'W?2&X=5[
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M(NR>]N4?(J>NT77 LAEQK\OL+E'86S&AGL)%X.JUJ*AT[B^>.E9=N5"=]AX
M^_H!]0'@LKT/BB2H;C:;JD+V>9L 6'<]GDXME60AH9U*;HK>CX&8(Q(O/S3V
M/80ZVEF[Z-;N'DFX43L*S-T\4-&D>/2;\OF^@$+!K3PX&3.WGNG[O-\D']@M
M<+=M@1LM7:LM"V.PUOF?1^:->/#I1J,3+0<= VR'V+385C,S%P-%UK:#TK%T
M@2O,F+TF_L^VVWR<_'EU"ID_X:,7()QLA#[?EXRT5F6AK!4Y)Q!V!M%LYB+W
M%R3V>X&:0H>R->7"0C)")Y,VNHG:5^^U%\B>%B)X)90JCN%4)OX>'^NW\0"L
MJ5[@I4:]3WU)864D77WNY>/6VF\+7:\XBH6":\?],Z/TU%T6O-W]FFY5E 2L
M3I-B\:.WTY*2T&G-"P,YF5(PLD^(3O\ 3]9/E[5C2:X#;/G]:Z'U3)<FF_V0
MT!$TZL5N)8:PMD-%6.!U;8]+V75LO=8&&WQ'P-DV+!.=0N(R>LS^.5JLE#7B
MP)4_7FO)0B4NH5=^O+KU^G?;ERZ_^ULZPOE,(F$4/=T\*M9[SVW5=QVFQ7J,
MLE195QC'1\ _K[>#72K,Z_L#$SU"1K<F_.HL\D5DG8H2+<IVQ$BHE15 RIX'
MJ#L^Q&H\Y2S]RWDH;=".I'%%5DK-KN;3LRVHS(V6K-(2Z25S7\,K06!H:&NW
M<>I+4CFE9,YSPYG#L 6['A<7#?=I/CSYK%>[^ J.[-I[%V:M=J-0']SUO-T1
M"1H&G%8.^6)9XE3E*RXWS=@V4HUWA7:#*5$CZGUM6JTA_#(/C,&%I:%24<.I
MXNZ';;>S[<O+V]=_<%:=UX.3,'ISDHHWV%%6N][5T;R8JD@9Y6C4ZI)SV]MI
M7_=DY,1Z)WFQ9*%CH*8NKV*@&+DMH?-V4?'NG<F]?@JN)4W_ /U^@;+%VDN%
MMEVG0*CL^0V'$5FS0=HEK;JF8-#678;^77;[\TSOB,MF]'%FMT7.7>T2-XU#
M+U^S1T79HWU:+.Q#6$ML3.0#65*3?G[B.OR]/L5EW9/A^W;<%TOUPV'R-<2Y
MKYJK8VKQC6U$M!&-38;5HNIZ];"4J,F-SSU:K=>:V[5#6Z5V"CJVE))!:;/&
M6VSW.5<,;4R*N_3ET._R[$[?6K\Y4<!:9RFM$G<YRZ2U3LP5_44-4IB)B&KQ
M[4'.L[;M65FGK91=\W"1:[$I.XKGKFP1+@B2#:)??-6RRDFBS,S(';>&_7Z=
MMOF(W5NQWA\-4+=%STCM=R]AZ3L8EVUA#-:6FPD(&)E>6T/S N=<N$XI:I!*
M\.Y:ZU^'JE<L+6&J2E9J+,XR$9:;"_DIQX5-_9X;?01_[7HOO )+8$5MBO26
MUE&4%L0>7(0Z;&D%"6K1.7M%5JEL"2D7%M69V0]4E';Z:KIVL16078*-822(
MNX;*SKLJAW#X>1]X._T_;R5Z<D>%R7(NQ0MI=;CNM#E*-28&#UHC68BM.XZN
MW"#VK2-REN<ZC,LGK^P)+7O4.E91."B9*HKMOW/CIA/K%GE/EQ4!V^WL(^HG
MYU:O^(#"#+?-?W2Y7S?NH/-F^C]FVG7Q+OQ$2>(*,3Y_F_?H$G2_N9 Z\OJ&
MB1^TOH@\_P#2,*O%]0'S-X1]"I>A?#Q@-'/M,.&U[2G0T1=Z]*TZ44@;B>VS
MFO:3HGD7HRB:^O$[;MKWF-<&J\?R-LUD;2-"K>NZN,JW?)LZ!&A8'+AD3BZ^
MWK[R#RZ;<Q[>2^E3X*W36E>V+5=6<AG5.C-IZY:U.S3 4&3/>HNV01KJ%9N%
M'N%?V=55ZFR1;6MDSL,&FPD)E^G"&>U.YT29E%95J5-]]M_#;;[<_MYCDI,<
M9-'.N/&KUM<.[6WN1UMB;;V(,PWA9B$*1WN#9UKVO-Q@(3]ROLRZ;Q=BN<PR
MBWTK9I*46ADHU.6=R,JB]EI$A.YW^3Z!MX;*06%1,(H\<H^-=*Y9Z?F=+; F
M+3!5F;E(*5=2-.=1+*=3<5^21E&9$%YN&GH\J*JZ!".04C53F1$P)*)'$#A<
M\1E9\->COUF0R2QLD8&SA[HR)6%CMQ&^-VX!W'K=>H*YH)WUY!*P-+@" ' D
M>L-CT+3X^:P=6.!U<U;I?1&K=.;"FH6<XU[=F-T:GNFQX-AL!%.TV:N;0I%G
M87.LUMYK$MA@92C;DO\ 7T6T1-U62CUGT7+)2JCF+,F\IELG/F+TM^PR*.69
ML;7,A#VQ@11MB;L)'R.YM8"=W'GOML.233OGE=*\-#GAH(9N!LT #;<N/Y()
MYGFK/UCX>J&I]S4S<L%==<6B>C*:%=N#_8VB&UJN"U@G=U\@M[;*N6H+FTV-
M JZ9?;"MO(^[L7T>2'O#9E Q]<C5591-@Y,]MJXM^6WU'Y.O7?;8*@\4/# I
MG%/8U"V% [0GK0IKVA.M<P<*_KK*-9)5R2@HYU+H)*(2SL6ZDGMJ5VWMER<B
M)A/(;3=09Q42@$)23(3O]OMX;#W+:-A43")A%KQ:>&]J.*V7N/;</==C)7#<
ML/N&+ED))U67];AU-RMYA*;<QT8UK<7**DBE)E92*;N9XYA(BFD[<+F$RHRF
M]JW(7\-!@Y8*;*M>*I$R6-DXL%M-C61ESG3NCW<& OVC )WX0U8WPO9A@\'J
MV[K*K=RTN2O6,G9EKV):;J+7Y6:2:P(XXZ44X:QTA$(=8>6M #W2'<G#\[X6
M$=;=-:YU)+[,I-'/JBOV2MTBRZ!T4AIP[-"SR6D7,M99")_=+N";N^S$7J6:
MK]BM+-]&$FXO8$@!XEHO%%5DXLLE<7/<\_'F=_/V>U7SKCPZF^G]K4[9^O[E
MJMPXJ57G*A'([$X]MKM/52(F=[[XW6*NI[2RV;55M:R?I;WDZ3(.DXRQ(2L/
M6H5PLR2*=RP$J;[C_P _(.?GT69>*?#ACQ3D[*ZA-LWK84=;==ZDJ,TPO#&M
M%<&M&K4;:Q6OK:0K47! >3N<796+*QIR[.7E')ZS#NE["[4*L4Y"2?I/SJ:&
M%1,(J9-12$[#2T(Z.LDUF(Q_%.5&XD*NFA(-56BQT#*$53*L1-8QDQ434(!P
M*)B'+V4>O;K,N5;-.4N;':KS5I',(#VLGC=$\L+FN:'!KB6ES7 ';=I')=BI
M8?3M5K<8:Z2K8AL1M>"6.?!(V5H>&EKBTN: X-<TD;[$'FH*0?A[Z\J&I-YZ
MDINPMAQD=R!JK"BW2;DSUJ5E6%1$TI'V5C7 :0,*V8R=@J]AL$&E*O4Y(L0Y
M>LY=%BY.P,S>0+079G@^SQV4?A[F5MG+-IML?=*:I*(Q2-HQ=SZ+2J<)=Z5)
MWG&9-^%G#P[.XI]KSM-SG:$W%MS%/%51B77'5_N;#<B,ANBJ)>^]*NV^(-]%
MC[O@[O;B?Q<6XX:% < GE2M57FJWO";1:UC>=QW"VG'U:?,]K!!;'L-+OVR]
M1)W*B7BA420UULW9,'<;-?(2X:BN$8_:WQ9. C*U;JY$WHV15CK?ZMOFY#YA
MR"_NB^!4]I78VD[<KON8O59T9K:OZRJ52L-;L!3L:_%: UQI:290:P;.<TZL
M1LO.ZU9[/%"+UY\V"=M5RC)B>GV[Z">UTJEW(C;J?X[_ &^I5MGP(K59I^R$
MJ%?)BK;?V#M[:.RPW(<+:YE8.M[9Y5J\GKEJ*)C8?8-:DZWKZVB6.UUL!MKB
MUZ]D;W$1C6PRKU&>1:J-"IO_ .CTW VW]W4>7SK'M0\.F:IFKMF:;B]X1JE(
MW)I934>PA=ZKD'-D%Q&,M@0U1M%/FUMK*(P/R^"N,4TLT)/1EQ+9']:-*Q<G
M4CSS]LD5=^>^WCO]OF^M7E=?#^B;8NK(M]GR45+M)WD%<*ZY/5FL@RC;=NCD
M]H+E1 /9-A\[9'FH6B7;C]785]!D>Q:ESKTS+('E:XY!!<'M^WA_HJ;[?1]1
M!\/'?W*>59;65I Q;:XR\)/V=)J4LW,5RO/JG!2#[S&%1>*KDE9;B_AV8@)2
MI,G=IG5TP+VI(KF-V!45=PB8181WEH:I[]@X: MLG8HMI!RQYAJK77,:V<*.
M#LUF0IN#2<5*I&1])<Q@*FDDIZ@%'U!+V4;UA<Y:P4\T]2.O*^:(1.%ALCFA
MH>'[M[N6(AV[?$D;>"Z&0QT.1C9',^5@C?Q@Q%@)/"6['C8\;;'P 4;=M\"8
MO:#NB/&NZ-@T\VHJ'K:K:H0C8RJ2+:"L&O-M57<HVRR?'Q0NK %BMNK]-*2D
M+!NZ80S?796ZLDZ;3BS9A;KEJ2];LW)6L;)9FDG>V,.# Z1Q<X,#G.<&@GD"
MYQVZDKMUXFUH8H&<3F0QMC!<07.:UH:.+8 <6V_, <SR"O#4O#&L:SE]J/7]
MLD+;%[9H]KH<]#.(M*(*A$6_?_)7>LD*#YM(.5C* IR1E:H3I-$WPM99RH'(
MXDE6C/K+EW/+V?Z ?P6)H;@%9&9*E+S>]&%AO&KX+C+1=63ZNJ3QT-%Z_P",
MM[D[M#M;Q6V>Q_B+C>+ZI++,KM;(.P4.OE5BX!Y5Z#746LQ'SY5W\-N7/?Y3
M_ ;<OK5%L?AHQ<J6 DHC;\O%VBFN(.2J4BO!V!O%MY>(VUO[9"ZLVA1-D:\N
M#^-D(GD+:*FHRK]]J3Y!2+BITLPH NH94J;^&W+GX^>WL\QO]"EMQSXZ0/'2
M.O,57'S(\5<IG7,HT@HB&<P<!46FN>/>F./T;7ZZT?SUEDPA/E6FV$NQ3E)F
61?L"2PQ+B0E#1X2CTA._V]I/\5__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
